Last updated: Apr 27, 2020 - 02:00 BST
| Adaptive, multicenter, randomized, open, comparative clinical trial of the efficacy and safety of the drug favipiravir in patients hospitalized with COVID-19 |
Coronavirus disease 19 infection |
favipiravir alone |
RNA polymerase inhibitor |
|
Kromis LLC |
|
Russian Federation |
2020-04-23 |
2020-12-31 |
COVID-FPR-01 |
Phase 3 Clinical |
Status not specified |
17 |
8 Months |
390 |
|
2020-04-25 |
| CORONA: A multicenter, randomized, double-blind, placebo-controlled, adaptively designed clinical trial of the efficacy and safety of levilimab (BCD-089) in patients with severe COVID-19 |
Coronavirus disease 19 infection |
BCD-089 alone |
IL-6 receptor antagonist |
|
Biocad Ltd |
|
Russian Federation |
2020-04-22 |
2022-12-30 |
BCD-089-4, CORONA |
Phase 3 Clinical |
Status not specified |
4 |
32 Months |
250 |
|
2020-04-25 |
| A clinical trial of convalescent plasma for the treatment of COVID-19 infection |
Coronavirus disease 19 infection |
onvalescent plasma alone |
|
Healthy volunteers accepted |
Viravaxx AG |
|
|
|
|
|
Phase Not Applicable |
Not yet recruiting |
0 |
|
600 |
|
2020-04-24 |
| RTLS Technology Study |
Coronavirus disease 19 infection |
Real Time Location System alone |
|
|
The Royal Wolverhampton Hospitals Nhs Trust |
Cornell University, La Trobe University |
UK |
2020-01-06 |
2020-12-31 |
2019SUR107, NCT04114110 |
Phase Not Applicable |
No longer recruiting |
1 |
11 Months |
2000 |
|
2020-04-24 |
| CONCOR-1: Convalescent Plasma for Hospitalized Adults With COVID-19 Respiratory Illness |
Coronavirus disease 19 infection |
Convalescent plasma alone |
|
Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Hamilton Health Sciences Corp, Hema-Quebec |
Canadian Blood Services, Universite De Montreal, University of Toronto |
Canada |
2020-04-27 |
2020-12-31 |
CONCOR-1, CONCOR-1, NCT04348656 |
Phase 3 Clinical |
Not yet recruiting |
27 |
8 Months |
1200 |
Andrew Shih, Anne-Sophie Lemay, Arjuna Ponnampalam, Benjamin Rioux-Masse, Brian Berry, Christine Cserti, Danielle Talbot, David Welbourne, Donald M Arnold, MD, Erin B Jamula, MSc., Jacob Pendergrast, Julie Rousseau, Katerina Pavenski, Luigina Mollica, Menaka Pai, Michelle Zeller, Nadine Shehata, Patrice Beauregard, Patricia Pelletier, Shuoyan Ning, Stephen Caplan, Susan Nahirniak, Tony Giulivi, Valerie Arsenault, Vincent Laroche, Yulia Lin, Ziad Solh |
2020-04-24 |
| PRA-001: Plasma Rich Antibodies From Recovered Patients From COVID19 |
Coronavirus disease 19 infection |
Variable regimens including Antibody-Rich Plasma , azithromycin , hydroxychroquine , oseltamivir |
Exo-alpha sialidase inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Ain Shams University |
|
Egypt |
2020-04-20 |
2020-12-31 |
FMASU P15/ 2020, NCT04348877, PRA-001 |
Phase 2 Clinical |
Not yet recruiting |
1 |
8 Months |
20 |
Hossam Fahmy, Professor of Faculty of Medicine |
2020-04-24 |
| WAVES: Airway Pressure Release Ventilation for mechanically ventilated patients with COVID-19 in Western Australian Intensive Care Units: an observational study |
Coronavirus disease 19 infection |
Airway pressure release ventilation alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Sir Charles Gairdner Hospital |
|
Australia |
2020-04-27 |
|
ACTRN12620000474954p, WAVES |
Phase Not Applicable |
Not yet recruiting |
8 |
|
100 |
A/Prof Matthew Anstey |
2020-04-24 |
| COVID RASP: Reducing acute severe respiratory events in health care workers during the Covid-19 pandemic with OM-85 |
Coronavirus disease 19 infection, Respiratory disease |
OM-85 alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University of Queensland |
Australian Government |
Australia |
2020-06-01 |
2020-07-31 |
ACTRN12620000473965p, BV-2020/19, COVID RASP, U1111-1250-2920 |
Phase 3 Clinical |
Not yet recruiting |
3 |
2 Months |
1000 |
Mrs Sharon Brabon, Prof Peter Sly |
2020-04-24 |
| An investigator initiated study to test COVID-19 pneumonia patients with Unyvero HPN panel for bacterial co-infections |
Bacterial infection, Coronavirus disease 19 infection, Viral pneumonia |
Unyvero system alone |
|
|
Karolinska Institutet |
OpGen Inc |
Sweden |
2020-04-21 |
|
|
Phase Not Applicable |
Recruiting |
1 |
|
|
|
2020-04-24 |
| Effectiveness of Measles Vaccine in Health Care Professionals During COVID-19 Outbreak (Randomized Controlled Trial) |
Coronavirus disease 19 infection |
Measles Mumps and Rubella vaccine alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) |
Misr University for Science and Technology |
Kasr Alainy School of Medicine |
Egypt |
2020-04-15 |
|
PACTR202004693933092 |
Phase 2 Clinical |
Not yet recruiting |
1 |
|
200 |
Ahmed Mukhtar, Mahmoud Nassar, Mostafa Alfishawy |
2020-04-24 |
| COVIPOC: Senicapoc in COVID-19 Patients with Severe Respiratory Insufficiency – A Randomized, Open-Label, Phase II Trial |
Coronavirus disease 19 infection, Respiratory insufficiency |
senicapoc alone |
KCNN potassium channel-4 inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Aarhus University |
|
Denmark |
2020-04-14 |
|
0001, 2020-001420-34, COVIPOC |
Phase 2 Clinical |
Recruiting |
1 |
|
|
www.Clinicaltrials.gov |
2020-04-24 |
| A phase I clinical study to assess ABL novel prophylactic COVID-19 vaccine and to analyze biomarker to characterize the immune profile of subjects participating in the study |
Coronavirus disease 19 infection |
ABL novel prophylactic COVID-19 vaccine alone |
|
|
Advanced BioScience Laboratories Inc |
Institut Merieux SA |
|
|
|
|
Phase 1 Clinical |
Planned |
0 |
|
|
|
2020-04-24 |
| Efficacy and safety of IHP Detox Tea (a special blend of Andrographis paniculata, Garcinia kola and Psidium guajava) for treatment of Corona virus disease 2019 (COVID-19): a pilot placebo-controlled randomized trial |
Coronavirus disease 19 infection |
IHP Detox Tea alone, conventional therapy alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) |
Neimeth International Pharmaceuticals Plc |
|
Nigeria |
2020-05-01 |
|
PACTR202004761408382 |
Phase Not Applicable |
Not yet recruiting |
2 |
|
72 |
Charles Esimone, George Eleje, Jude Duru |
2020-04-26 |
| A diagnostic study IgG and/or IgM antibodies to the SARS-CoV-2 (novel 2019 coronavirus) through ZEUS's lateral flow test |
Coronavirus disease 19 infection |
ZEUS's lateral flow test alone |
|
Healthy volunteers accepted |
Zeus Scientific Inc |
|
China, US |
|
|
|
Phase Not Applicable |
Status not specified |
1 |
|
|
|
2020-04-24 |
| A medical records based study for 'Guangdong Pneumonia NO.1' in the Treatment of Novel Coronavirus Pneumonia (COVID-19) |
Coronavirus disease 19 infection, Pneumonia |
Guangdong Pneumonia NO.1 alone, basic treatment alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Guangzhou Hospital |
|
China |
2020-02-11 |
2020-11-30 |
ChiCTR2000031888, ChiMCTR2000003208 |
Phase Not Applicable |
Recruiting |
3 |
9 Months |
300 |
Liansheng Lin, Luping Lin |
2020-04-24 |
| A phase II clinical study of stem cells to treat hospitalized patients with COVID-19 infection |
Coronavirus disease 19 infection |
stem cells alone |
|
|
Personalized Stem Cells Inc |
|
|
|
|
|
Phase 2 Clinical |
Planned |
0 |
|
|
|
2020-04-24 |
| A study of Wondfo SARS-CoV-2A point of care test for the diagnosis of COVID-19 |
Coronavirus disease 19 infection |
Wondfo SARS-CoV-2A point of care test alone |
|
|
Guangzhou Wondfo Biotech Co Ltd |
|
|
|
|
|
Phase Not Applicable |
Status not specified |
0 |
|
|
|
2020-04-24 |
| Phase II, randomized, placebo-controlled, double-blind, single-center clinical trial of HB-adMSCs for the treatment of COVID-19 patients |
Coronavirus disease 19 infection |
Variable regimens including autologous adipose-derived mesenchymal stem cells (iv infusion, rheumatoid arthritis), Hope Biosciences , azithromycin , hydroxychloroquine |
|
|
Hope Biosciences Inc |
Advanced Diagnostics Healthcare (ADH) at River Oaks Hospital and Clinics |
|
|
|
|
Phase 2 Clinical |
Not yet recruiting |
0 |
|
110 |
|
2020-04-24 |
| A validation study of Wondfo SARS-CoV-2A point of care test for the diagnosis of COVID-19 |
Coronavirus disease 19 infection |
Wondfo SARS-CoV-2A point of care test alone |
|
|
National Institute of Virology |
Cellmid Ltd, World Health Organization |
India |
|
2020-04-22 |
|
Phase Not Applicable |
Completed |
1 |
|
36 |
|
2020-04-24 |
| A phase IIa, multicenter clinical trial of Cannabidiol-Steroid formulation for the treatment of COVID-19 infection |
Coronavirus disease 19 infection |
cannabidiol-steroid alone |
|
|
Stero Biotechs Ltd |
|
|
|
|
|
Phase 2a Clinical |
Planned |
0 |
|
40 |
|
2020-04-25 |
| An IP Protected Cliniacl Trial of Cannabidiol- steroid formulation for the treatment of COVID-19 infection |
Coronavirus disease 19 infection |
cannabidiol- steroid alone |
|
|
Stero Biotechs Ltd |
Mor Research Applications Ltd |
Israel |
2020-04-30 |
|
|
Phase Not Applicable |
Planned |
1 |
|
10 |
|
2020-04-25 |
| Prophylaxis of COVID-19 infection with hydroxychloroquine in healthcare personnel with high risk of infection |
Coronavirus disease 19 infection |
hydroxychloroquine alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) |
Mútua Terrassa University Hospital |
|
Spain |
2020-04-18 |
|
2020-001536-98, PREPSARS |
Phase 3 Clinical |
Recruiting |
1 |
|
300 |
HOSPITAL UNIVERSITARI MUTUA TERRASSA, INTERNAL MEDICINE DEPARTMENT |
2020-04-24 |
| Study to investigate the safety and effects of vaccines in healthy adults |
Coronavirus disease 19 infection |
BNT-162 alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) |
BioNTech SE |
Pfizer Inc |
Germany |
2020-04-20 |
|
2020-001038-36, BNT162-01, U1111-1249-4220 |
Phase 1/Phase 2 Clinical |
Recruiting |
1 |
|
196 |
Clinical Study Management |
2020-04-25 |
| A trial to evaluate BNT-162 for the prevention of COVID-19 infection |
Coronavirus disease 19 infection |
BNT-162 alone |
|
|
BioNTech SE |
Pfizer Inc |
US |
|
|
|
Phase Not Applicable |
Planned |
0 |
|
|
|
2020-04-24 |
| CIGB-2020 in contacts and suspects of SARS-CoV-2 infection |
Coronavirus disease 19 infection |
CIGB-2020 alone, conventional treatment alone |
|
Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Center for Genetic Engineering and Biotechnology |
Instituto Pedro Kouri |
Cuba |
2020-03-27 |
2020-06-30 |
CIGB 2020-01, RPCEC00000306 |
Phase 1/Phase 2 Clinical |
Recruiting |
1 |
3 Months |
80 |
Julia Cuesta Diéguez, Zurina Cinza Estévez |
2020-04-24 |
| PrevenCOVID-19: Study for the prevention of COVID-19 infection in healthcare personnel |
Coronavirus disease 19 infection |
hydroxychloroquine (Dolquine) alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) |
Fundación Pública Andaluza Para La Gestión De La Investigación En Salud De Sevilla |
|
Spain |
2020-04-19 |
|
2020-001440-26, PrevenCOVID-19, PrevenCOVID-19 |
Phase 3 Clinical |
Recruiting |
1 |
|
184 |
CTU-HUVR, Clinical trial information |
2020-04-24 |
| COVID-Aging: Efficacy of Hydroxychloroquine, Telmisartan and Azithromycin on Survival in Elderly Hospitalized Patients with VIDOC-19 : A Randomized, Multicenter, Adaptive, Blinded Study |
Coronavirus disease 19 infection |
Variable regimens including azithromycin , curcumin , hydroxychloroquine , telmisartan |
Angiotensin II receptor antagonist |
Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Hopitaux Universitaires de Strasbourg |
|
France |
|
|
2020-001303-16, 7747, COVID-Aging |
Phase 3 Clinical |
Recruiting |
1 |
|
1600 |
Eric DEMONSANT |
2020-04-24 |
| CAPACoV19: Long Term Physical Functional Limitations in Daily Living in SARS-CoV2 Infected Patients Hospitalized in the Acute Phase Then Requiring Rehabilitation |
Coronavirus disease 19 infection |
data record alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Centre Hospitalier Universitaire de Reims |
|
France |
2020-05-01 |
2022-02-01 |
CAPACoV19, NCT04356378, PO20055 |
Phase Not Applicable |
Not yet recruiting |
1 |
21 Months |
300 |
Francois BOYER, François BOYER |
2020-04-24 |
| Efficacy of Tocilizumab on Patients With COVID-19 |
Coronavirus disease 19 infection, Hypoxia, Respiratory failure |
tocilizumab (intravenous), Roche/Chugai alone |
IL-6 receptor antagonist, IL-6 receptor modulator |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Massachusetts General Hospital |
Genentech Inc |
US |
2020-04-27 |
2020-08-30 |
2020P001159, NCT04356937 |
Phase 3 Clinical |
Not yet recruiting |
0 |
4 Months |
300 |
Ana D Fernandes, MA, John H Stone, MD, John H Stone, MD,MPH |
2020-04-23 |
| CORONA-SHIELD: Assessing the System for High-Intensity Evaluation During Radiotherapy During Changes in Response to COVID-19 |
Coronavirus disease 19 infection |
radiation therapy alone, telehealth alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Duke University |
|
US |
2020-04-14 |
2021-04-30 |
CORONA-SHIELD, NCT04357574, PRO00105266 |
Phase Not Applicable |
Recruiting |
0 |
12 Months |
1000 |
Manisha Palta, MD |
2020-04-24 |
| COVID-19: A Pilot Study of Adaptive Immunity and Anti-PD1 |
Coronavirus disease 19 infection, Respiratory failure |
best supportive care alone, nivolumab alone |
Programmed cell death protein 1 inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Queen Mary Hospital |
The University of Hong Kong |
Hong Kong |
2020-04-14 |
2021-08-31 |
NCT04356508, UW20213 |
Phase 2 Clinical |
Not yet recruiting |
1 |
16 Months |
15 |
Gerry Gin Wai Kwok, MBBS |
2020-04-23 |
| A phase II, randomized, double-blind, placebo-controlled clinical study to evaluate the safety and preliminary efficacy of ATYR-1923 in confirmed COVID-19 positive patients with severe respiratory complications |
Coronavirus disease 19 infection |
ATYR-1923 alone |
Neuropilin 2 inhibitor |
|
aTyr Pharma Inc |
|
US |
|
|
|
Phase 2 Clinical |
Not yet recruiting |
0 |
|
30 |
|
2020-04-23 |
| A single-blinded, randomized, placebo-controlled phase II trial of prophylactic treatment with oral azithromycin versus placebo in cancer patients undergoing antineoplastic treatment during the covid-19 pandemic |
Coronavirus disease 19 infection |
azithromycin alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Medical University of Vienna |
|
Austria |
2020-04-14 |
|
2020-001327-13, OnCoVID19Trial |
Phase 2 Clinical |
Recruiting |
1 |
|
200 |
Matthias Preusser |
2020-04-23 |
| A clinical study evaluate the safety and efficacy of combination of chloroquine with azithromycin and interferon beta-1b, to prevent admission to intensive care, mechanical ventilation and/or death to combat COVID-19 |
Coronavirus disease 19 infection |
Variable regimens including azithromycin , chloroquine , interferon beta-1b, Bayer |
Interferon beta ligand |
|
Bayer Inc, Population Health Research Institute |
|
Canada |
|
|
|
Phase Not Applicable |
Planned |
1 |
|
|
|
2020-04-23 |
| MV-COVID19: Measles Vaccine in HCW |
Coronavirus disease 19 infection |
measles, mumps, rubella vaccine alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) |
Kasr El Aini Hospital |
|
Egypt |
2020-05-01 |
2020-11-01 |
MV-COVID19, N-20-2020, NCT04357028 |
Phase 3 Clinical |
Not yet recruiting |
2 |
6 Months |
200 |
Abeer Ahmed, MD, Ahmed M Mukhtar, M.D, Doaa Ghaith, MD, Marwa Rashad, MD, Mostafa Alfishawy, MD |
2020-04-24 |
| A pilot study to assess the effect of beta-nicotinamide mononucleotide (NMN) in the prevention/treatment of patients with Covid-19 |
Coronavirus disease 19 infection |
beta-nicotinamide mononucleotide alone |
|
|
Shinkowa Pharmaceutical Co Ltd |
|
|
|
|
|
Phase Not Applicable |
Planned |
0 |
|
|
|
2020-04-23 |
| Immune Response to Covid-19 in 300 Health Care Workers With Mild Symptoms |
Coronavirus disease 19 infection |
|
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Sciensano |
Jessa Hospital |
Belgium |
2020-04-30 |
2020-07-30 |
JESSA300, NCT04356586 |
Phase Not Applicable |
Recruiting |
2 |
3 Months |
300 |
Maria Goossens, MD, PhD |
2020-04-24 |
| Feasibility, early intervention, chinese herbal treatment, addition to standard of care, COVID-19 |
Coronavirus disease 19 infection |
Chinese herbal treatment alone, standard care alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Sunway TCM Centre |
|
Malaysia |
2020-05-01 |
2020-10-30 |
54625, NMRR-20-759-54625 |
Phase Not Applicable |
Status not specified |
1 |
5 Months |
100 |
Dr LIM REN JYE, Dr Lee Yee Leng |
2020-04-24 |
| PACA: Nebulized Rt-PA for ARDS Due to COVID-19 |
Coronavirus disease 19 infection, Respiratory distress syndrome |
invasive mechanical ventilation alone, nebulized recombinant tissue-plasminogen activator (rt-PA) alone, non-invasive ventilation alone, standard of care alone |
|
Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
University College London |
|
|
2020-04-14 |
2021-01-14 |
132151, NCT04356833, PACA |
Phase 2 Clinical |
Not yet recruiting |
0 |
9 Months |
24 |
Mark Phillips |
2020-04-23 |
| SCout: Risk Stratification With Chest CT to Rule-out Suspected SARS-CoV-2 Infections |
Coronavirus disease 19 infection, Viral pneumonia |
CT-imaging alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Jena University Hospital |
|
Germany |
2020-04-15 |
2020-04-30 |
IDIR-001-2020, NCT04357938, SCout |
Phase Not Applicable |
No longer recruiting |
1 |
|
145 |
Ulf Teichgräber, Prof. Dr. |
2020-04-23 |
| RISC-19-ICU: The Risk Stratification in COVID-19 Patients in the ICU Registry |
Coronavirus disease 19 infection |
standard of care alone |
|
|
University of Zurich |
|
Switzerland |
2020-03-13 |
2022-03-31 |
KEK-ZH-REQ-2020-00322, NCT04357275, RISC-19-ICU |
Phase Not Applicable |
Recruiting |
1 |
24 Months |
10000 |
Dorothea Heuberger, PhD, Jonathan Montomoli, MD, PhD, Matthias P Hilty, MD, Pedro D Wendel Garcia, MSc, Philippe Guerci, MD, Reto A Schüpbach, MD, Theirry Fumeaux, MD |
2020-04-23 |
| MODIF: Myocardial Infarction Rates Overview During COVID-19 Pandemic In France |
Coronavirus disease 19 infection, Myocardial infarction |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Société Française de Cardiologie |
INSERM |
France |
2020-04-27 |
2020-07-31 |
2020-03, MODIF, NCT04357314 |
Phase Not Applicable |
Not yet recruiting |
1 |
3 Months |
80 |
Guillaume BONNET, MD, Guillaume CAYLA, MD, Tessa BERGOT |
2020-04-23 |
| COVIP: Impact of Long-term Protease Inhibitors in Patients Living With HIV on the Incidence of COVID-19 |
Coronavirus disease 19 infection, HIV-1 infection, HIV-2 infection |
antiretroviral therapy alone, protease inhibitor therapy alone, usual care alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Centre Hospitalier Intercommunal Creteil |
Centre Hospitalier Intercommunal Villeneuve Saint Georges, Service des Urgences |
France |
2020-04-30 |
2020-10-31 |
COVIP, COVIP, NCT04357639 |
Phase Not Applicable |
Not yet recruiting |
5 |
6 Months |
794 |
Alice RAFFETIN, MD, GARRAIT Valérie, MD, Gallien Sebastien, MD, Raffetin Alice, MD, SALMON Dominique, MD, Vignier Nicolas, MD |
2020-04-23 |
| Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease |
Coronavirus disease 19 infection, Viral pneumonia |
azithromycin plus hydroxychloroquine (JWT-629) |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Novartis AG |
|
|
2020-04-30 |
2020-07-21 |
CJWT629A12301, NCT04358081 |
Phase 3 Clinical |
Not yet recruiting |
0 |
2 Months |
444 |
Novartis Pharmaceuticals |
2020-04-23 |
| AVoCaDO: Administration of Intravenous Vitamin C in Novel Coronavirus Infection (COVID-19) and Decreased Oxygenation |
Coronavirus disease 19 infection, Hypoxia, Respiratory distress syndrome, Respiratory failure |
ascorbic acid alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Hunter Holmes Mcguire Veteran Affairs Medical Center |
Mcguire Research Institute Inc |
US |
2020-04-16 |
2020-08-01 |
AVoCaDO, DAVIS 001, NCT04357782 |
Phase 1/Phase 2 Clinical |
Recruiting |
0 |
3 Months |
20 |
Brian C Davis, MD |
2020-04-23 |
| COVID-19 Among Egyptian Health Care Providers |
Coronavirus disease 19 infection |
online self-administered questionnaire alone |
|
|
Assiut University |
|
Egypt |
2020-04-30 |
2020-05-31 |
COVIDQ, NCT04357431 |
Phase Not Applicable |
Not yet recruiting |
1 |
1 Month |
600 |
Ahmed Mohamed Abbas |
2020-04-23 |
| WAVE: Wearable-based COVID-19 Markers for Prediction of Clinical Trajectories |
Coronavirus disease 19 infection |
smartwatch alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University Hospital Inselspital, Berne |
ETH Zurich |
Switzerland |
2020-05-01 |
2020-07-31 |
NCT04357834, WAVE, WAVE |
Phase Not Applicable |
Not yet recruiting |
1 |
3 Months |
100 |
Aristomenis Extradaktylos, Prof. MD, David D Srivastava, MD, MBA, David Srivastava, MD, MBA |
2020-04-25 |
| COPLASCOV19: Convalescent Plasma For Ill Patients By COVID-19 |
Coronavirus disease 19 infection, Viral pneumonia |
convalescent plasma alone |
|
Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Instituto De Seguridad Y Servicios Sociales De Los Trabajadores Del Estado |
HOSPITAL CENTRAL NACIONAL PEMEX NORTE, Hospital General de Mexico, SECRETARIA DE SALUD DEL ESTADO DE SONORA |
Mexico |
2020-05-31 |
2020-12-31 |
COPLASCOV19, NCT04356482, TERAPLASCOV2 |
Phase 1/Phase 2 Clinical |
Not yet recruiting |
5 |
7 Months |
90 |
CARLOS BEST, MD, Carlos Martinez-Murillo, MD, Diego Espinoza, MD, FERNANDO PEREZ-JACOBO, MD, LUIS villela, MD, Luis M Villela, MD, Luis Villela, MD,MSc, Melani Otañez, MD |
2020-04-23 |
| Sarilumab treatment in cytokine storm caused by infection with COVID-19 |
Coronavirus disease 19 infection, Respiratory failure |
sarilumab alone |
IL-6 receptor antagonist |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Clinica Universidad de Navarra |
|
Spain |
2020-04-16 |
|
2020-001255-40, STRIKE-SARS-CoV2 |
Phase 2 Clinical |
No longer recruiting |
1 |
|
60 |
UCEC |
2020-04-23 |
| Covid-Thelium: Assessment of Endothelial and Hemostatic Changes During Severe SARS-CoV-2 Infection |
Coronavirus disease 19 infection |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Hospital Boisguillaume |
|
France |
2020-04-09 |
2020-08-31 |
2020/097/OB, Covid-Thelium, NCT04357847 |
Phase Not Applicable |
Recruiting |
1 |
4 Months |
100 |
EBESNIER, emmanuel besnier, MD, thomas clavier, MD, PhD |
2020-04-23 |
| SARICOR: Clinical Trial of Sarilumab in Adults With COVID-19 |
Coronavirus disease 19 infection, Respiratory distress syndrome |
best available treatment alone, sarilumab alone |
IL-6 receptor antagonist |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Maimonides Biomedical Research Institute of Cordoba |
Consejeria de Salud. Junta de Andalucia |
Spain |
2020-04-18 |
2020-07-27 |
2020-001531-27, NCT04357860, SARICOR, SARICOR |
Phase 2 Clinical |
Recruiting |
1 |
3 Months |
120 |
Antonio Luque, José Carlos Garrido Gracia, Julián de la Torre Cisneros, MD, Rafael León López, MD |
2020-04-24 |
| COVID-TGT: Analysis of the Coagulopathy Developed by COVID-19 Infected Patients |
Coronavirus disease 19 infection |
fibrin generation markers assays alone, thrombin generation test assay alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Centre Hospitalier Universitaire de Nimes |
|
France |
2020-04-30 |
2021-01-31 |
COVID-TGT, NCT04356950, PHRC-I/2020/JCG-01 |
Phase Not Applicable |
Not yet recruiting |
4 |
9 Months |
175 |
Albert Sotto, Anissa Megzari, Antonia Perez Martin, Catherine Lechiche, Charles Cazenave, Claire Roger, Claudine Barbuat, Didier Laureillard, Isabelle Quere, Jean-Christophe Gris, Jean-François Faucher, Jean-Marc Mauboussin, Jean-Yves Lefrant, Kada Klouche, Laurent Muller, Paul Loubet, Saber D Barbar, Vincent Le Moing |
2020-04-24 |
| Plasma Adsorption in Patients With Confirmed COVID-19 |
Coronavirus disease 19 infection |
D2000 plasma adsorption cartridge alone, Optia secondary plasma device alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Marker Therapeutics AG |
|
|
2020-04-27 |
2020-12-01 |
MH-007/B, NCT04358003 |
Phase Not Applicable |
Not yet recruiting |
0 |
7 Months |
2000 |
Eeke Romo, MD |
2020-04-25 |
| Registry of Hospitalized Pediatric Patients with SARS-CoV-2 Infection (COVID-19) |
Coronavirus disease 19 infection |
|
|
Newborn Infants (up to 5 months), Infants (6-23 months), Preschool Children (2-5 yrs), Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs) |
University Hospital Carl Gustav Carus |
|
Germany |
2020-03-18 |
|
BO-EK-110032020, DRKS00021506 |
Phase Not Applicable |
Recruiting |
1 |
|
1000 |
Jakob Armann |
2020-04-24 |
| Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19 |
Coronavirus disease 19 infection |
azithromycin plus hydroxychloroquine |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
National Institute of Allergy and Infectious Diseases |
Teva Pharmaceutical Industries Ltd |
|
2020-05-01 |
2021-03-05 |
38720, ACTG A5395, NCT04358068 |
Phase 2b Clinical |
Not yet recruiting |
0 |
10 Months |
2000 |
Davey Smith, MD |
2020-04-24 |
| ICOS: Psychological Outcome of COVID-19 Lockdown on Psychiatric Hospital Staff and Close Relatives |
Anxiety disorder, Coronavirus disease 19 infection, Depression, Psychiatric disorder |
survey alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Centre hospitalier de Ville-Evrard |
|
France |
2020-04-01 |
2020-06-30 |
10477M-ICOS, ICOS, NCT04357418 |
Phase Not Applicable |
No longer recruiting |
1 |
3 Months |
1320 |
Clemence ISAAC, PhD, Dominique JANUEL, Pr |
2020-04-25 |
| Thrombomodulin-modified Thrombin Generation Assay (TGA-TM) in Patients With Critical Infections |
Coronavirus disease 19 infection |
thrombin generation assay alone, thrombomodulin-modified thrombin generation assay alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Medical University of Vienna |
Medizinisch-Wissenschaftlicher Fonds des Burgermeisters der Bundeshauptstadt Wien |
Austria |
2020-04-17 |
2020-12-01 |
NCT04356144, TGA-TM-CRITICAL-2019 |
Phase Not Applicable |
Not yet recruiting |
1 |
7 Months |
60 |
Lukas Infanger, Lukas Infanger, MD, Marion Wiegele, MD |
2020-04-24 |
| Dysosmia and Dysgeusia in COVID-19 patients |
Coronavirus disease 19 infection, Dysgeusia, Dysomia |
smell and taste test alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Kantonsspital Aarau |
|
Switzerland |
2020-04-22 |
|
2020-00666, DRKS00021516 |
Phase Not Applicable |
Not yet recruiting |
1 |
|
100 |
Thirza Singer-Cornelius |
2020-04-24 |
| Evaluation of the efficacy and safety of methylprednisolone pulse therapy in treatment of Covid-19 patients with Acute respiratory distress syndrome |
Coronavirus disease 19 infection |
methylprednisolone pulse therapy alone, hydroxychloroquine plus methylprednisolone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Artesh University of Medical Sciences |
|
Iran |
2020-03-30 |
|
IR.AJAUMS.REC.1399.008, IRCT20200406046963N1 |
Phase 3 Clinical |
Recruiting |
1 |
|
40 |
Ebrahim Hazrati, Ebrahim hazrati, Ramin Hamidi Farahani, Reza Mosaed |
2020-04-24 |
| What’s the STORY?: A pilot, multi-site, UK immunization program to assess novel coronavirus infection (COVID-19) rates in children and teenagers across the UK |
Coronavirus disease 19 infection |
|
|
Newborn Infants (up to 5 months), Infants (6-23 months), Preschool Children (2-5 yrs), Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs) |
University of Oxford |
United Kingdom Research & Innovation |
UK |
|
|
What’s the STORY? |
Phase Not Applicable |
Recruiting |
1 |
|
1200 |
Professor Matthew Snape |
2020-04-23 |
| A compassionate use program of Ruconest in hospitalized patients with confirmed COVID-19 infections suffering from related severe pneumonia who did not improve despite standard treatment, including hydroxychloroquine and lopinavir/ritonavir |
Coronavirus disease 19 infection, Viral pneumonia |
conestat alfa alone |
Complement C1s subcomponent inhibitor, Kallikrein modulator, Mannan-binding lectin serine protease inhibitor |
Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Pharming Group NV |
|
Switzerland |
|
|
|
Phase 2 Clinical |
Status not specified |
1 |
|
5 |
|
2020-04-23 |
| Rapid Salivary Test to Detect SARS-CoV-2 (COVID-19) |
Coronavirus disease 19 infection |
rapid salivary test alone |
|
Healthy volunteers accepted |
Università degli Studi dell'Insubria |
|
Italy |
2020-04-16 |
2020-07-31 |
68/2020, NCT04357327 |
Phase Not Applicable |
Not yet recruiting |
1 |
3 Months |
100 |
Lorenzo Azzi, Lorenzo Azzi, DDS |
2020-04-24 |
| Comparison of New Coronavirus (Covid-19) Awareness in Individuals of Different Age Groups: Analysis of Turkey |
Coronavirus disease 19 infection |
|
|
Healthy volunteers accepted, Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Istanbul University-Cerrahpasa |
|
Turkey |
2020-05-31 |
2020-06-30 |
60350273-605.99-, NCT04357886 |
Phase Not Applicable |
Not yet recruiting |
1 |
1 Month |
1000 |
Aysenur Erekdag, Student, Ipek Yeldan, PhD, Saliha Gurdal Karakelle, MSc |
2020-04-24 |
| CoVS: COVID-19 Survey Study on Dietary Intake, Physical Activity and Overall Well-being |
Coronavirus disease 19 infection |
staying home alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Illinois Institute of Technology |
|
US |
2020-04-17 |
2021-04-30 |
CoVS, IRB-2020-91, NCT04357041 |
Phase Not Applicable |
Recruiting |
0 |
12 Months |
500 |
Britt Burton-Freeman, Ph.D, Di Xiao, MAS, Indika Edirisinghe, Ph.D |
2020-04-23 |
| PSYCHIC: Psychiatric Disorders and Covid-19 |
Coronavirus disease 19 infection, Post traumatic stress disorder, Psychiatric disorder |
|
|
Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
CHU De Nantes |
|
France |
2020-04-25 |
2023-01-01 |
NCT04358042, PSYCHIC, RC20-0165 |
Phase Not Applicable |
Not yet recruiting |
1 |
32 Months |
250 |
Gaelle CHALLET, Marie GRALL-BRONNEC |
2020-04-24 |
| A prospective, multicenter, randomized, placebo-controlled, double-blind, phase II clinical study to assess the efficacy, safety and tolerability of IMU-838 in the treatment of patients with COVID-19 infection |
Coronavirus disease 19 infection |
standard-of-care antiviral therapy alone, vidofludimus alone |
Dihydroorotate dehydrogenase inhibitor, IL-17 antagonist |
|
Immunic Inc |
|
Europe, US |
|
|
|
Phase 2 Clinical |
Planned |
0 |
|
|
|
2020-04-23 |
| A multinational, randomized, controlled, investigator-initiated clinical trial in patients with confirmed COVID-19 infections |
Coronavirus disease 19 infection |
conestat alfa alone |
Complement C1s subcomponent inhibitor, Kallikrein modulator, Mannan-binding lectin serine protease inhibitor |
|
Pharming Group NV |
|
Switzerland |
|
|
|
Phase Not Applicable |
Planned |
1 |
|
150 |
Michael Osthoff |
2020-04-23 |
| A Human Clinical Study to Collect Calibration and Performance Data for the RBA-2 Device |
Coronavirus disease 19 infection |
RBA-2, Kaligia Biosciences alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Kaligia Biosciences LLC |
University of South Florida |
US |
2020-04-30 |
2020-12-31 |
KBS005, NCT04357977 |
Phase Not Applicable |
Not yet recruiting |
0 |
8 Months |
300 |
Asa Oxner, MD, Elsie Medina, MS, Fazal Fazlin, Janice Shirley, MPH MBA PA-C, Jose Tirado, Rachel Karlnoski, PhD |
2020-04-24 |
| Etoposide in Patients With COVID-19 Infection |
Coronavirus disease 19 infection, Respiratory failure |
etoposide phosphate alone |
Topoisomerase II inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Boston Medical Center Corp |
|
US |
2020-04-30 |
2021-12-31 |
H-40102, NCT04356690 |
Phase 2 Clinical |
Not yet recruiting |
0 |
20 Months |
134 |
John Mark Sloan, MD, Sally A Fennessey, BS |
2020-04-24 |
| COVID-19 Surveillance of Patients and Healthcare Workers in a Hospital Department |
Coronavirus disease 19 infection, Upper respiratory tract infection |
COVID-19 test alone, polymerase chain reaction alone |
|
Healthy volunteers accepted |
Rigshospitalet, Denmark |
|
Denmark |
2020-03-23 |
2020-12-31 |
DT P-2020-353, NCT04356560 |
Phase Not Applicable |
Recruiting |
1 |
9 Months |
300 |
Inge J Knudsen, MD, Nikolai S Kirkeby, MSc, Ramon G Jensen, MD |
2020-04-25 |
| Cell therapy in patients with coronavirus19 |
Coronavirus disease 19 infection |
mesenchymal stem cells alone |
|
Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Barakat Pharmaceutical Group, Tehran University of Medical Sciences |
|
Iran |
2020-04-20 |
|
IR.TUMS.VCR.REC.1399.203, IRCT20190717044241N2 |
Phase 1 Clinical |
Recruiting |
1 |
|
10 |
Dr Javad Verdi- Dr Neda Alijani, Dr Mohammad Ali Sahraian, Dr Neda Alijani, Dr. Akbar Borandegi, Mahshid Saleh |
2020-04-24 |
| KONS-COVID-19: Kerecis Oral and Nasal Spray for Treating the Symptoms of COVID-19 |
Coronavirus disease 19 infection |
Kerecis Oral and Nasal Spray device (Kerecis Ehf) alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Kerecis Ehf |
|
Iceland |
2020-04-30 |
2020-07-31 |
KONS-COVID-19, KS-0470, NCT04357990 |
Phase Not Applicable |
Not yet recruiting |
1 |
3 Months |
81 |
|
2020-04-23 |
| TRAPSAH: Long-term Use of Drugs That Could Prevent the Risk of Serious COVID-19 Infections or Make it Worse |
Coronavirus disease 19 infection, Diabetes mellitus, Respiratory failure |
angiotensin receptor blocker (ARB) therapy alone, angiotensin-converting enzyme (ACE) therapy alone, chloroquine alone, hydroxychloroquine alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Assistance Publique Hopitaux de Paris |
GIS EPI-PHARE |
France |
2020-04-30 |
2020-06-30 |
APHP200412, NCT04356417, TRAPSAH |
Phase Not Applicable |
Not yet recruiting |
1 |
2 Months |
6000000 |
Emilie SBIDIAN, Pr, Emilie Sbidian, Pr |
2020-04-26 |
| STARS: Study of Alteplase for Respiratory Failure in SARS-Cov2 (COVID-19) |
Coronavirus disease 19 infection, Respiratory failure |
alteplase plus unfractionated heparin |
Tissue plasminogen activator stimulator |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Denver Health and Hospital Authority |
Beth Israel Deaconess Medical Center, Genentech Inc, Long Island Jewish Med Center, National Jewish Health, University of Colorado, Denver, US |
US |
2020-04-30 |
2020-10-31 |
20-0880, NCT04357730, STARS |
Phase 2a Clinical |
Not yet recruiting |
0 |
6 Months |
60 |
Arsen Ghasabyan, MPH, Ernest "Gene" Moore, MD, Ernest E Moore, MD |
2020-04-26 |
| A new clinical trial to significantly increase the rate of recovery for COVID-19 patients with underlying health conditions and save lives using D'OXYVA (deoxyhemoglobin vasodilator) |
Coronavirus disease 19 infection |
D'OXYVA (deoxyhemoglobin vasodilator) alone |
|
|
Circularity Healthcare LLC |
|
US |
|
|
|
Phase Not Applicable |
Planned |
0 |
|
|
|
2020-04-23 |
| Cardiac Arrhythmias In Patients With Coronavirus Disease (COVID-19) |
Coronavirus disease 19 infection, Heart arrhythmia |
|
|
|
Mount Sinai School of Medicine |
|
US |
2020-04-09 |
2021-12-31 |
GCO 20-0931, NCT04358029 |
Phase Not Applicable |
Recruiting |
0 |
20 Months |
10000 |
Betsy Ellsworth, MSN, Martin Goldman, MD, Stephanie Harcum, MS, Vivek Reddy, MD |
2020-04-23 |
| PsyCOVID: COVID-19 Pandemic Burden in Severe Mental Disease Patients |
Acute stress disorder, Anxiety disorder, Bipolar disorder, Coronavirus disease 19 infection, Major depressive disorder, Psychotic disorder, Schizophrenia |
GAD-7 (7-item Generalized Anxiety Disorder) alone, PHQ-9 (9-item Patient Health Questionnaire) alone, PSS (Perceived Stress Scale) alone, SPEQ (Specific Psychotic Experiences Questionnaire) - Paranoia and Grandiosity Subscales alone, Zaritt Burden Interview alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Universita degli Studi di Napoli Federico II |
|
Italy |
2020-04-10 |
2020-04-25 |
152/20, NCT04357769, PsyCOVID |
Phase Not Applicable |
Recruiting |
1 |
|
400 |
Felice Iasevoli, Felice Iasevoli, M.D., Ph.D. |
2020-04-26 |
| COVeR: COVID-19 Epidemic Response Study |
Coronavirus disease 19 infection |
|
|
Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Centogene Gmbh |
|
Germany |
2020-04-20 |
2020-10-30 |
COVER-2020, COVeR, NCT04357496 |
Phase Not Applicable |
Not yet recruiting |
1 |
6 Months |
400 |
Arndt Rolfs, Prof., Volha Skrahina, PhD |
2020-04-26 |
| The Mental Health Status of the General Population During the COVID-19 Pandemic and Its Association With Adherence to Government-initiated Non-pharmacological Epidemiological Interventions (NPI's) |
Anxiety disorder, Coronavirus disease 19 infection, Depression |
Non-pharmacological interventions alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University of Oslo |
Modum Bad Psychiatric Hospital |
Norway |
2020-03-31 |
2020-04-07 |
NCT04356365, REK125510 |
Phase Not Applicable |
Completed |
1 |
|
10084 |
Asle Hoffart, PhD, Omid V. E Ebrahimi, Double PhD Candidate, Sverre Urnes Johnson, PhD |
2020-04-23 |
| Non-Invasive Monitoring of Respiratory Function in Spontaneously Breathing Patients With COVID-19 Infection |
Coronavirus disease 19 infection, Respiratory failure |
AirGo respiratory monitor alone, non-invasive monitoring alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Massachusetts General Hospital |
|
US |
2020-04-15 |
2020-12-31 |
2020P000881, NCT04356443 |
Phase Not Applicable |
Recruiting |
0 |
8 Months |
500 |
Jeanine Wiener-Kronish, MD, M. Brandon Westover, MD, PhD, Omar Hyder, Omar Hyder, MD, MS |
2020-04-23 |
| Prognosis of Coronavirus Disease 2019 (COVID-19) Patients Receiving Receiving Antihypertensives |
Cardiac failure, Coronary artery disease, Coronavirus disease 19 infection, Diabetes mellitus, Hypertension, Respiratory distress syndrome |
angiotensin II receptor blocker therapy alone, angiotensin-converting enzyme inhibitor therapy alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
King Faisal Specialized Hospital & Research Center |
|
Saudi Arabia |
2020-04-12 |
2020-09-30 |
2210061, NCT04357535 |
Phase Not Applicable |
Recruiting |
1 |
5 Months |
226 |
Abir H Omer, Hakeam A Hakeam, MS Pharm, Hakeam A Hakeam, MSPharm BCPS, Muhannad A Alsemari, MBBS |
2020-04-23 |
| SCHIZOVID-19: COVID-19 and Psychotic Symptoms in France |
Coronavirus disease 19 infection, Hallucination, Paranoia, Psychotic disorder |
survey alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
University Hospital, Montpellier |
Centre référent de réhabilitation psychosociale de Grenoble, Epsylon Laboratory, Universite Grenoble Alpes |
France |
2020-04-01 |
2020-08-01 |
NCT04356885, RECHMPL20_0225, SCHIZOVID-19 |
Phase Not Applicable |
Recruiting |
1 |
4 Months |
600 |
Stephane Raffard, PhD, Stéphane RAFFARD, PhD |
2020-04-24 |
| COPLA: Treatment of Severe Forms of Coronavirus Infection With Convalescent Plasma |
Coronavirus disease 19 infection |
convalescent plasma alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Centro de Hematologia y Medicina Interna |
Laboratorios Clinicos de Puebla, Laboratorios Ruiz |
Mexico |
2020-04-13 |
2020-08-31 |
CHMI-030420-01, COPLA, NCT04357106 |
Phase 2 Clinical |
Recruiting |
1 |
4 Months |
10 |
Guillermo J Ruiz-Arguelles, MD, FRCP, MACP, DSc, Guillermo J. RUIZ-ARGÜELLES, José Manuel Priesca-Marin, MD, Juan Carlos Olivares-Gazca, MD, MPH, Juan Carlos Olivares-Gazca, MD,MPH |
2020-04-23 |
| A prospective, cohort study to follow the health status of medical staff engage in COVID-19 |
Coronavirus disease 19 infection |
medical staff followup alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Yokohama City University |
|
Japan |
2020-04-23 |
|
UMIN000040219 |
Phase Not Applicable |
Not yet recruiting |
1 |
|
30 |
Takuma HIGURASHI |
2020-04-24 |
| IMAGE-19: Imatinib In COVID-19 Disease In Aged Patients |
Coronavirus disease 19 infection |
imatinib alone |
Abl tyrosine kinase inhibitor, Bcr protein inhibitor, Kit tyrosine kinase inhibitor, PDGF receptor antagonist, Signal transduction inhibitor |
Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Versailles University Hospital |
|
France |
2020-05-01 |
2020-12-01 |
IMAGE-19, NCT04357613, P20/05_IMAGE19 |
Phase 2 Clinical |
Not yet recruiting |
2 |
7 Months |
99 |
Laure Morisset, Malvy, Philippe Rousselot |
2020-04-23 |
| LILIADE-COVID: Low Dose of IL-2 In Acute Respiratory Distress Syndrome Related to COVID-19 |
Coronavirus disease 19 infection, Respiratory distress syndrome |
aldesleukin (subcutaneous, autoimmune/inflammatory disorders/allergy/spontaneous abortion), ILTOO Pharma alone |
Interleukin-2 ligand |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Assistance Publique Hopitaux de Paris |
ILTOO Pharma |
France |
2020-04-30 |
2020-07-31 |
2020-001571-32, APHP200406, LILIADE-COVID, NCT04357444 |
Phase 2 Clinical |
Not yet recruiting |
1 |
3 Months |
30 |
Jean-Michel CONSTANTIN, Jean-Michel CONSTANTIN, MD, PhD |
2020-04-24 |
| AIRVM-COVID: Efficacy of Intravenous Almitrine in Reducing the Need for Mechanical Ventilation in Patients With Hypoxemic Acute Respiratory Failure Due to COVID-19-related Pneumonia |
Coronavirus disease 19 infection, Hypoxia, Respiratory failure, Viral pneumonia |
almitrine alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Assistance Publique Hopitaux de Paris |
Centre Hospitalier of Chartres |
France |
2020-04-30 |
2020-07-31 |
2020-001909-22, AIRVM-COVID, APHP200461, NCT04357457 |
Phase 3 Clinical |
Not yet recruiting |
1 |
3 Months |
212 |
Pierre KALFON, PU-PH, Yonathan FREUND, PU-PH, Yonathan Freund, PU-PH |
2020-04-24 |
| Clinical trial of RLS-0071 for inflammatory disorders, such as acute lung injury, caused by an inflammatory response, such as due to COVID-19 infection |
Coronavirus disease 19 infection, Inflammatory disease, Lung injury |
|
|
|
ReAlta Life Sciences Inc |
|
|
|
|
|
Phase Not Applicable |
Planned |
0 |
|
|
|
2020-04-24 |
| TOC-COVID: A prospective, randomized, double-blinded, placebo-controlled trial to evaluate the efficacy and safety of tocilizumab in patients with severe COVID-19 pneumonia |
Coronavirus disease 19 infection, Viral pneumonia |
conventional treatment alone, tocilizumab alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Klinikum der Albert-Ludwigs Universitaet Freiburg |
|
Germany |
2020-04-27 |
|
2020-001408-41, 203/20 (FF-MC), DRKS00021238, TOC-COVID |
Phase 2 Clinical |
Not yet recruiting |
2 |
|
200 |
Mr PD Dr Tobias Wengenmayer |
2020-04-24 |
| Biomarker COVID-19: Local and systemic markers of inflammation and circadian rhythmicity in COVID-19 disease and their role in the prediction of clinical outcome |
Coronavirus disease 19 infection, Respiratory failure |
intensive care therapy alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Klinikum der Albert-Ludwigs Universitaet Freiburg |
|
Germany |
2020-04-21 |
|
225/20, Biomarker COVID-19, DRKS00021522 |
Phase Not Applicable |
Recruiting |
1 |
|
50 |
Nils Schallner |
2020-04-24 |
| COVID-19 BaWu: Prevalence of COVID-19 in children aged 1 to 10 years in Baden-Wurttemberg |
Coronavirus disease 19 infection |
|
|
Infants (6-23 months), Preschool Children (2-5 yrs), Children (6-12 yrs) |
Zentrum für Infektionskrankheiten |
|
Germany |
2020-04-22 |
|
COVID-19 BaWu, DRKS00021521, S-294/2020 |
Phase 0 Clinical |
Recruiting |
5 |
|
2000 |
Georg Friedrich Hoffmann, Hanna Renk, Hans-Georg Kräusslich, Klaus-Michael Debatin, Philipp Henneke |
2020-04-24 |
| COVID-19 Data-bank Project |
Coronavirus disease 19 infection |
|
|
Newborn Infants (up to 5 months), Infants (6-23 months), Preschool Children (2-5 yrs), Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Mahajan Imaging Center |
|
India |
2020-04-17 |
|
CTRI/2020/04/024697 |
Phase Not Applicable |
Not yet recruiting |
3 |
|
100000 |
Dr Anurag Agarwal, Dr Sushila Kataria, VIdur Mahajan |
2020-04-24 |
| A phase II clinical trial to evaluate the safety and efficacy of ArtemiC on patients diagnosed with COVID-19 |
Coronavirus disease 19 infection |
ArtemiC alone |
|
|
MGC Pharma |
Swiss PharmaCan AG |
Israel |
|
|
|
Phase 2 Clinical |
Not yet recruiting |
1 |
|
50 |
|
2020-04-23 |
| A clinical study on side effects of hydroxychloroquine in health care workers |
Coronavirus disease 19 infection |
hydroxychloroquine alone |
|
|
Indian Council of Medical Research |
|
|
|
|
|
Phase Not Applicable |
Status not specified |
0 |
|
|
|
2020-04-24 |
| A clinical trial to evaluate the efficacy of hydroxychloroquine as a preventive medicine for COVID-19 |
Coronavirus disease 19 infection |
hydroxychloroquine alone |
|
|
Indian Council of Medical Research |
|
|
|
|
|
Phase 3 Clinical |
Recruiting |
0 |
|
480 |
|
2020-04-24 |
| Use of UC-MSCs for COVID-19 Patients |
Acute lung injury, Coronavirus disease 19 infection, Respiratory distress syndrome |
standard of care alone, umbilical cord-derived mesenchymal stem cells alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University of Miami |
|
US |
2020-04-17 |
2021-05-01 |
20200370, NCT04355728 |
Phase 1/Phase 2 Clinical |
Recruiting |
0 |
12 Months |
24 |
Camillo Ricordi, MD, David A Baidal, M.D., Khemraj Hirani, MPharm PhD RPH, Rodolfo Alejandro, M.D. |
2020-04-25 |
| Gut Microbiota, 'Spark and Flame' of COVID-19 Disease |
Coronavirus disease 19 infection |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Universidade Nova De Lisboa |
CINTESIS - Centre for Health Technology and Services Research, CUF Academic and Research Medical Center, Centro Hospitalar Lisboa Ocidental, Centro Hospitalar Sao Joao, Centro de Medicina Laboratorial Germano de Sousa, S.A., Hospital CUF Infante Santo, S.A., Nova Medical School |
Portugal |
2020-04-30 |
2020-12-31 |
COVID19_MICROBIOTA, NCT04355741 |
Phase Not Applicable |
Not yet recruiting |
3 |
8 Months |
60 |
André Rosário, PhD, Conceição Calhau, PhD, Cristina Granja, PhD, Gonçalo Marcelino, José Leal, PhD, Maria JR Sousa, PhD, Pedro Póvoa, PhD |
2020-04-24 |
| Convalescent Plasma versus Placebo in Emergency Room Patients With COVID-19 |
Coronavirus disease 19 infection |
convalescent plasma alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Stanford University |
|
US |
2020-05-31 |
2022-12-31 |
56249, NCT04355767 |
Phase 2 Clinical |
Not yet recruiting |
0 |
31 Months |
206 |
Kevin Schulman, MD, Study Team |
2020-04-23 |
| TARUS: The Ariel University Survey on Dietary Changes and Anxiety During the Coronavirus Pandemic |
Anxiety disorder, Coronavirus disease 19 infection |
survey alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Ariel University |
|
Israel |
2020-03-31 |
2020-05-31 |
AU-HEA-VKS-20200329, NCT04353934, TARUS |
Phase Not Applicable |
Recruiting |
1 |
2 Months |
3000 |
Mona Boaz, RD, PhD, Vered Kaufman-Shriqui, RD, PhD |
2020-04-23 |
| URGDENTCOVID: Evaluation of Dental Emergency Treatments During COVID19 Crisis |
Coronavirus disease 19 infection, Tooth disease |
survey alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Assistance Publique Hopitaux de Paris |
|
|
2020-04-13 |
2020-06-20 |
APHP200464, NCT04354272, URGDENTCOVID |
Phase Not Applicable |
Not yet recruiting |
0 |
2 Months |
840 |
Isabelle Rodriguez, Yves Boucher, MD, PhD |
2020-04-23 |
| ENVIROREA: Study of the Dissemination of SARS-COV-2 in the Environment of Infected Patients Admitted to Intensive Care Unit |
Coronavirus disease 19 infection, Lower respiratory tract infection |
Coriolis system alone, RT-PCR alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Assistance Publique Hopitaux de Paris |
|
France |
2020-04-30 |
2020-12-31 |
2020-A00897-32, APHP200411, ENVIROREA, NCT04355481 |
Phase Not Applicable |
Not yet recruiting |
3 |
8 Months |
150 |
Guillaume Voiriot, Dr, Lila Bouadma, Dr, Nacira DARGHAL, Yacine TANDJAOUI-LAMBIOTTE, Dr |
2020-04-22 |
| An investigator-initiated clinical trial of valsartan in patients with COVID-19 infection |
Coronavirus disease 19 infection |
valsartan alone |
Angiotensin I receptor antagonist, Angiotensin II receptor antagonist |
|
Novartis AG |
|
|
|
|
|
Phase Not Applicable |
Planned |
0 |
|
|
|
2020-04-22 |
| Assessment of Seroprevalence and Incidence of SARS-CoV-2 Infection and COVID-19 in Brazil |
Coronavirus disease 19 infection |
IgG/IgM SARS-CoV-2 rapid test alone, blood sampling alone |
|
Healthy volunteers accepted |
Instituto Butantan |
|
Brazil |
2020-05-15 |
2022-05-15 |
COV-01-IB, NCT04355338 |
Phase Not Applicable |
Not yet recruiting |
1 |
24 Months |
4030 |
Ricardo Palacios, MD, PhD |
2020-04-23 |
| An investigator-initiated clinical study of secukinumab for the treatment in patients with COVID-19 infection |
Coronavirus disease 19 infection |
secukinumab alone |
IL-17 antagonist |
|
Novartis AG |
|
|
|
|
|
Phase Not Applicable |
Planned |
0 |
|
|
|
2020-04-22 |
| An investigator-initiated clinical study of imatinib mesylate for the treatment in patients hospitalized with COVID-19 |
Coronavirus disease 19 infection |
imatinib alone |
Abl tyrosine kinase inhibitor, Bcr protein inhibitor, Kit tyrosine kinase inhibitor, PDGF receptor antagonist, Signal transduction inhibitor |
|
Novartis AG |
|
|
|
|
|
Phase Not Applicable |
Planned |
0 |
|
|
|
2020-04-22 |
| A clinical study of canakinumab for the treatment in patients hospitalized with COVID-19 infection |
Coronavirus disease 19 infection |
canakinumab alone |
Immunoglobulin G1 agonist, Interleukin-1 beta ligand inhibitor |
|
Novartis AG |
|
|
|
|
|
Phase Not Applicable |
Planned |
0 |
|
|
|
2020-04-22 |
| Expanded Access Program of Ruxolitinib for the Emergency Treatment of Cytokine Storm From COVID-19 Infection |
Coronavirus disease 19 infection, Respiratory distress syndrome |
ruxolitinib (oral, myeloproliferative disorders), Incyte/Novartis alone |
Jak1 tyrosine kinase inhibitor, Jak2 tyrosine kinase inhibitor |
Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Incyte Corp |
|
US |
|
|
INCB 18424-MA-COVID-19-301, NCT04355793 |
Phase Not Applicable |
Recruiting |
0 |
|
|
Incyte Corporation Call Center (US) |
2020-04-25 |
| CORIA: Coronavirus (COVID-19) Outcomes Registries in Immunocompromised Individuals Australia |
Cancer, Coronavirus disease 19 infection, HIV infection, Immune deficiency |
blood sampling alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
National Centre in HIV Epidemiology and Clinical Research |
Blacktown Hospital, Cancer Council New South Wales, Cancer Institute New South Wales, Garvan Institute of Medical Research, Gilead Sciences Inc, Holdsworth House Medical Practice, Melanoma Institute Australia, Positive Life NSW, Prince of Wales Hospital foundation, Royal North Shore Hospital, St Vincents Hospital Sydney Ltd, Westmead Hospital |
Australia |
2020-04-27 |
2022-04-27 |
2020-04-CORIA, CORIA, NCT04354818 |
Phase Not Applicable |
Not yet recruiting |
1 |
24 Months |
1000 |
Griselda Buckland, Mark Polizzotto, MD |
2020-04-23 |
| COSTA: Open-label Study to Compare Efficacy, Safety and Tolerability of Hydroxychloroquine Combined With Azithromycin Compared to Hydroxychloroquine Combined With Camostat Mesylate and to 'no Treatment' in SARS CoV 2 Virus |
Coronavirus disease 19 infection, Viral pneumonia |
camostat mesylate plus hydroxychloroquine |
Serine protease inhibitor, Trypsin inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Sheba Medical Center |
|
Israel |
2020-04-11 |
2020-12-11 |
7092-20-SMC, COSTA, NCT04355052 |
Phase 3 Clinical |
Recruiting |
1 |
8 Months |
250 |
Irit Avisar, RN, Itsik Levy Dr, Itzchak Levy, MD |
2020-04-22 |
| A randomized, double-blind, placebo-controlled Phase IIa study to evaluate the safety and efficacy of opaganib in adult patients hospitalized with positive SARS-CoV-2 and pneumonia |
Coronavirus disease 19 infection, Viral pneumonia |
opaganib alone |
Dihydroceramide delta 4 desaturase inhibitor, Sphingosine kinase 2 inhibitor |
|
RedHill Biopharma Ltd |
|
US |
|
|
|
Phase 2a Clinical |
Planned |
0 |
|
60 |
|
2020-04-22 |
| A Study Evaluating the Efficacy and Safety of High-Titer Anti-SARS-CoV-2 Plasma in Hospitalized Patients With COVID-19 Infection |
Coronavirus disease 19 infection, SARS coronavirus infection |
anti-SARS-CoV-2 convalescent plasma alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Medical College of Wisconsin |
Froedtert Hospital |
US |
2020-05-01 |
2023-05-01 |
NCT04354831, PRO00037712 |
Phase 2 Clinical |
Not yet recruiting |
0 |
36 Months |
106 |
Mary Beth Graham, Mary Beth Graham, MD, Sonija Parker |
2020-04-22 |
| Soliris (Eculizumab) Treatment of Participants With COVID-19 |
Acute lung injury, Coronavirus disease 19 infection, Respiratory distress syndrome, Viral pneumonia |
eculizumab alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Alexion Pharmaceuticals Inc |
|
France |
|
|
ECU-COV-401, NCT04355494 |
Phase Not Applicable |
Recruiting |
5 |
|
|
Alexion Pharmaceuticals Inc. |
2020-04-26 |
| Effect evaluation of herbal supplementation from the combination of sugarcane, black myrobalan and mastic along with the treatment protocol of the Ministry of Health on the course of coronavirus disease |
Coronavirus disease 19 infection |
Herbal supplement alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Jahrom University of Medical |
|
Iran |
2020-05-04 |
|
IR.JUMS.REC.1399.003, IRCT20200415047082N1 |
Phase 2/Phase 3 Clinical |
Not yet recruiting |
1 |
|
10 |
Alireza hashemi shiri, Esmail Rayat dost, Rahim raufi |
2020-04-23 |
| HyPreC: Effect of Hydroxychloroquine in COVID-19 Positive Pregnant Women |
Coronavirus disease 19 infection |
hydroxychloroquine (Plaquenil) alone |
|
Female, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) |
Sir Mortimer B Davis Jewish General Hospital |
|
|
2020-05-31 |
2020-11-30 |
1, MARCH 30, 2020, HyPreC, NCT04354441 |
Phase 2 Clinical |
Not yet recruiting |
0 |
6 Months |
600 |
Haim Abenhaim |
2020-04-23 |
| Prophylactic Corticosteroid to Prevent COVID-19 Cytokine Storm |
Coronavirus disease 19 infection |
methylprednisolone alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Auxilio Mutuo Cancer Center |
|
Puerto Rico |
2020-04-14 |
2021-04-30 |
CCAM 20-01, NCT04355247 |
Phase 2 Clinical |
Recruiting |
2 |
12 Months |
20 |
Carmelo Santana-López, MD, Fernando Cabanillas, MD, Idalia Liboy, MD, James Bryan, MD, José Abreu-Arbelo, MD, Juan Arraut, MD, Luis Cotto, MD, Margarita Bruno, MD, Mirelis Acosta-Rivera, MD |
2020-04-24 |
| CovidAmiens20: French Single-center Experience of Critically Ill Patients With COVID-19 |
Coronavirus disease 19 infection |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Centre Hospitalier Universitaire D Amiens |
|
France |
2020-04-30 |
2021-04-30 |
CovidAmiens20, NCT04354558, PI2020_843_0026 |
Phase Not Applicable |
Not yet recruiting |
1 |
12 Months |
200 |
Osama Abou Arab, MD |
2020-04-22 |
| COVIPREG: Prevalence and Impact of SARS-COV-2 Infection in Pregnant Women, Fetuses and Newborns |
Coronavirus disease 19 infection |
PCR test alone, serology test alone |
|
Female, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Assistance Publique Hopitaux de Paris |
|
France |
2020-04-16 |
2021-08-31 |
APHP 200448, COVIPREG, NCT04355234 |
Phase Not Applicable |
Not yet recruiting |
1 |
16 Months |
2200 |
Christelle Vauloup Fellous, Vassilis Tsatsaris |
2020-04-23 |
| Evaluation of Activity and Safety of Two Regimens of Low Dose Oral Selinexor in Participants With Moderate or Severe COVID-19 |
Coronavirus disease 19 infection, Cough, Dyspnea, Fever, Headache, Lower respiratory tract infection, Myalgia, Respiratory distress syndrome |
selinexor alone |
Exportin 1 inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Karyopharm Therapeutics Inc |
|
|
2020-04-30 |
2020-08-30 |
NCT04355676, XPORT-COV-1002 |
Phase 2 Clinical |
Not yet recruiting |
0 |
4 Months |
80 |
Dayana Michel, Jatin Shah Chief Medical Officer, Sharon Shacham President and CSO |
2020-04-23 |
| ILIAD: Interferon Lambda for Immediate Antiviral Therapy at Diagnosis |
Coronavirus disease 19 infection |
peginterferon lambda-1a alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
The University Health Network |
|
Canada |
2020-04-21 |
2020-11-30 |
ILIAD, JF-4-2020, NCT04354259 |
Phase 2 Clinical |
Not yet recruiting |
1 |
7 Months |
140 |
Jordan Feld, MD, Josh Booth |
2020-04-23 |
| Study to Evaluate Preventive Effect of Ayurveda and Homeopathy Treatment in COVID-19 |
Coronavirus disease 19 infection |
Variable regimens including Aesenic Album , Khadiradi Vat , Murrchhita Tila Taila , Samshamani Vati , Sudarshan Ghana Vati |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Parul Institute of Ayurved |
|
India |
2020-04-24 |
|
CTRI/2020/04/024731 |
Phase 3 Clinical |
Not yet recruiting |
1 |
|
50 |
Dr Harish Daga, Dr Hemant Toshikhane, Dr Shailesh Deshpande |
2020-04-24 |
| Use of Bromhexine and Hydroxychloroquine for Treatment of COVID-19 Pneumonia |
Coronavirus disease 19 infection, Lung infection, Viral pneumonia |
bromhexine plus hydroxychloroquine |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
General Hospital Celje |
|
Slovenia |
2020-04-10 |
2020-07-31 |
NCT04355026, SBCEBROMHEXINCOVID-19 |
Phase 4 Clinical |
Recruiting |
1 |
3 Months |
90 |
Matej Podbregar, Miha Mežnar, matej Podbregar |
2020-04-24 |
| COVID19@Spain: Characteristics and Outcomes of Hospitalized Patients With COVID-19 in Spain |
Coronavirus disease 19 infection |
chest x-ray alone, oxygen therapy alone, real-time polymerase chain reaction (RT-PCR) alone, systemic corticosteroids therapy alone, tocilizumab alone |
|
|
Fundacion SEIMC-GESIDA |
|
Spain |
2020-03-18 |
2020-04-17 |
COVID-19/SEIMC-FSG, COVID19@Spain, NCT04355871 |
Phase Not Applicable |
No longer recruiting |
6 |
1 Month |
3000 |
Jerónimo Pachón, MD, Jesús Rodriguez Baños, MD, Jordi Carratala, MD, Jose Ramón Arribas, MD, Juan Berenguer, MD, Pablo Ryan, MD |
2020-04-23 |
| DEFEAT COVID-19: A Multicenter, Retrospective Study to Evaluate the Efficacy of Systemic Gluco-corticoid Against COVID-19 |
Coronavirus disease 19 infection |
systemic Gluco-corticoid therapy alone |
|
|
Kanagawa Cardiovascular and Respiratory Center |
|
Japan |
2020-05-01 |
|
DEFEAT COVID-19, UMIN000040211 |
Phase Not Applicable |
Recruiting |
12 |
|
500 |
Satoshi Ikeda, Takashi Ogura |
2020-04-24 |
| Asymptomatic COVID-19 Infection Among Healthcare Workers |
Coronavirus disease 19 infection |
blood sampling alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) |
Kasr El Aini Hospital |
|
Egypt |
2020-04-25 |
2020-07-10 |
N-18-2020, NCT04354792 |
Phase Not Applicable |
Not yet recruiting |
2 |
2 Months |
1000 |
Ahmed M Mukhtar, M.D, Ahmed Mukhtar, Mohamed Elayashy Mohamed Ahmed Hassan, M.D, FCAI |
2020-04-23 |
| A clinical study to assess convalescent plasma in the treatment of patients with COVID-19 |
Coronavirus disease 19 infection |
convalescent plasma alone |
|
|
Froedtert & Medical College of Wisconsin |
|
US |
|
|
|
Phase Not Applicable |
Recruiting |
0 |
|
|
Mary Beth Graham, MD |
2020-04-22 |
| CoVID-19 Plasma in Treatment of COVID-19 Patients |
Coronavirus disease 19 infection |
convalescent COVID 19 plasma alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Christ Hospital |
|
US |
2020-04-30 |
2020-08-31 |
20-23, NCT04355897 |
Phase 0 Clinical |
Not yet recruiting |
0 |
4 Months |
100 |
Dean J Kereiakes, MD |
2020-04-25 |
| A randomized, placebo-controlled study to evaluate the use hydroxychloroquine for the prevention of COVID-19 amongst exposed healthcare workers and household contacts, as well as evaluates the use of hydroxychloroquine for the early treatment of mild cases |
Coronavirus disease 19 infection |
hydroxychloroquine alone |
|
|
St Josephs Healthcare Hamilton |
Mint Pharmaceuticals Inc |
Canada |
|
|
|
Phase Not Applicable |
Status not specified |
1 |
|
|
Dr. Zain Chagla |
2020-04-23 |
| Ruxolitinib to Combat COVID-19 |
Coronavirus disease 19 infection |
ruxolitinib (oral, myeloproliferative disorders), Incyte/Novartis alone |
Jak1 tyrosine kinase inhibitor, Jak2 tyrosine kinase inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Washington University School of Medicine, US |
Incyte Corp |
US |
2020-06-30 |
2021-12-31 |
04-13-20-DUBBERKE, NCT04354714 |
Phase 2 Clinical |
Not yet recruiting |
0 |
18 Months |
25 |
Erik Dubberke, M.D., MSPH, John DiPersio, M.D., Ph.D., Mark Fiala, MSW, Scott Goldsmith, M.D. |
2020-04-23 |
| COVID-19 PrEP HCW HCQ Study |
Coronavirus disease 19 infection |
hydroxychloroquine alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
NYU Langone Health |
|
US |
2020-04-03 |
2020-09-01 |
NCT04354870, S20-00390 |
Phase 2 Clinical |
Recruiting |
0 |
4 Months |
350 |
Emily Beato, Lisa Zhao, Michael Belmont, MD |
2020-04-23 |
| PED-COVID: Immunity Against SARS-CoV2 in Children and Their Parents |
Coronavirus disease 19 infection, Immune disorder |
Classic test (Institut Pasteur) alone, Immunoprotection (neutralizing Ab, Institut Pasteur) alone, Rapid test (NGBiotech / CEA) alone |
|
Newborn Infants (up to 5 months), Infants (6-23 months), Preschool Children (2-5 yrs), Children (6-12 yrs), Adolescents (13-17 yrs) |
Assistance Publique Hopitaux de Paris |
Commissariat a l`Energie Atomique, INSERM, Institut Pasteur, NG Biotech |
France |
2020-04-30 |
2021-07-31 |
2020-A00999-30, APHP200467, NCT04355533, PED-COVID |
Phase Not Applicable |
Not yet recruiting |
3 |
15 Months |
1920 |
Isabelle SERMET-GAUDELUS, MD, PhD, Isabelle SERMET-GAUDELUS, MD,PhD, Nelly BRIAND, PhD |
2020-04-23 |
| COVID-Scan: Combinaison of Chest Scanography and Nasal Viral Detection Test to Detect COVID-19 Positive Patients Before Surgical Intervention in a University Hospital During Coronavirus Pandemia |
Coronavirus disease 19 infection |
RT-PCR Test alone, chest CT scan alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University Hospital, Montpellier |
|
France |
2019-04-01 |
2020-10-20 |
COVID-Scan, NCT04355715, RECHMPL20_0223 |
Phase Not Applicable |
No longer recruiting |
1 |
18 Months |
200 |
Philippe Gaudard, MD |
2020-04-23 |
| A clinical study to evaluate the efficacy of tPA in the treatment of patients with COVID-19 infection |
Coronavirus disease 19 infection, Respiratory failure |
tPA alone |
|
|
Mount Sinai Medical Center |
|
US |
|
|
|
Phase 2 Clinical |
Status not specified |
0 |
|
5 |
|
2020-04-23 |
| CAPTOCOVID: Efficacy of Captopril in Covid-19 Patients With Severe Acute Respiratory Syndrome (SARS) CoV-2 Pneumonia |
Coronavirus disease 19 infection, Respiratory failure, Viral pneumonia |
captopril alone |
ACE inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Assistance Publique Hopitaux de Paris |
|
France |
2020-04-13 |
2020-08-31 |
APHP200410, CAPTOCOVID, NCT04355429 |
Phase 2 Clinical |
Not yet recruiting |
8 |
4 Months |
230 |
Alexandre BLEIBTREU, MD, Anne-Lise LECAPITAINE, MD, Gilles PIALOUX, Pr, Laurent PLANTIER, Pr, Louis BERNARD, MD, Mohammed RAHAOUI, PM, Nunes HILARIO, MD, Olivier BOUCHAUD, Pr, Pascale LONGUET, MD, Sylvain DIAMANTIS, MD, Yacine TANDJAOUI-LAMBIOTTE, MD |
2020-04-24 |
| Inhaled Corticosteroid Treatment of COVID19 Patients With Pneumonia |
Coronavirus disease 19 infection, Viral pneumonia |
Standard of care alone, budesonide alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Fundacion Clinic per a la Recerca Biomédica |
AstraZeneca plc |
Spain |
2020-04-18 |
2020-10-18 |
2020-001616-18, NCT04355637, TACTIC-COVID |
Phase 4 Clinical |
Not yet recruiting |
8 |
6 Months |
300 |
ALVAR AGUSTI, ALVAR AGUSTI, MD, PhD, Alicia Marin, Alvar Agusti, Daniel Ross Monserrate, Jaume Ferrer Sancho, Joaquim Gea Giralt, Jordi Dorca Sargatal, ROSA FANER, Rosa Faner, Salud Santos, Sara Varea, Sergi Pascual, Vicente Plaza, Xavier Muñoz |
2020-04-23 |
| DAS-181 for STOP COVID-19 |
Coronavirus disease 19 infection |
DAS-181 alone, standard local care alone |
Exo-alpha sialidase modulator, Muscarinic receptor antagonist |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Ansun BioPharma Inc |
|
Italy |
2020-04-25 |
2020-07-31 |
2020-001874-30, DAS181-3-02-EU, NCT04354389 |
Phase 2/Phase 3 Clinical |
Not yet recruiting |
2 |
3 Months |
82 |
Andrea Gori, Cristina Mussini, Jennifer Ho, MD, PhD, Liz Dewaghe, Sylvie Lu |
2020-04-23 |
| COVKID: Kidney Involvement in COVID-19 Disease |
Coronavirus disease 19 infection, Renal injury |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Centre Hospitalier Universitaire De Nice |
|
France |
2020-04-15 |
2020-07-30 |
20REAMEDCOVID.05, COVKID, NCT04355624 |
Phase Not Applicable |
Recruiting |
4 |
3 Months |
80 |
Hajar Ouahmi, Philippe DESWARDT, Pierre-Marie BERTRAND, Sonia BOYER-SUAVET, Sonia Boyer-Suavet, Sonia Boyer-Suavet, |
2020-04-23 |
| CCC19: COVID-19 and Cancer Consortium Registry |
Coronavirus disease 19 infection |
web-based REDCap survey alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Vanderbilt-Ingram Cancer Center |
|
US |
2020-03-17 |
2022-12-31 |
CCC19, NCT04354701, VICC MD 2032 |
Phase Not Applicable |
Recruiting |
0 |
33 Months |
1000 |
Jeremy Warner, MD, Teresa Melton, Vanderbilt-Ingram Service for Timely Access |
2020-04-23 |
| COLHEART-19: Colchicine to Reduce Myocardial Injury in COVID-19 |
Coronavirus disease 19 infection, Heart injury |
Current care alone, colchicine (oral, gout/familial Mediterranean fever), Takeda alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University of California Los Angeles |
|
US |
2020-04-25 |
2021-04-25 |
20-000685, COLHEART-19, NCT04355143 |
Phase 2 Clinical |
Not yet recruiting |
0 |
12 Months |
150 |
Amir B Rabbani, MD, Reza Ardehali, MD, PhD |
2020-04-23 |
| A clinical trial of efficacy of BCG vaccine in preventing Covid-19 |
Coronavirus disease 19 infection |
BCG vaccine, ICMR alone |
|
|
Indian Council of Medical Research |
|
|
2020-04-30 |
|
|
Phase Not Applicable |
Planned |
0 |
|
|
|
2020-04-22 |
| Plasma therapy in patient with COVID-19 |
Coronavirus disease 19 infection, Viral pneumonia |
convalescent plasma alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Shahid Beheshti University |
|
Iran |
2020-04-05 |
|
IR.SBMU.RETECH.REC.1399.047, IRCT20200416047099N1 |
Phase 2 Clinical |
Recruiting |
1 |
|
10 |
Abbas hajifathali, Elham Roshandel, Haniyeh Ghaffari-nazari, َAbbas Hajifathali |
2020-04-23 |
| A phase III, randomized, open-label study to assess the safety and efficacy of Ultomiris in adults with COVID-19 – those who are hospitalized with severe pneumonia or acute respiratory distress syndrome (ARDS) |
Coronavirus disease 19 infection, Lung injury, Respiratory distress syndrome, Viral pneumonia |
ravulizumab alone |
Complement C5 factor inhibitor, IgG receptor FcRn large subunit p51 modulator |
|
Alexion Pharmaceuticals Inc |
|
|
2020-05-31 |
|
|
Phase 3 Clinical |
Not yet recruiting |
0 |
|
270 |
|
2020-04-22 |
| Covid-19 in Lupus Patients |
Coronavirus disease 19 infection, Systemic lupus erythematosus |
hydroxychloroquine alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University Hospital, Montpellier |
|
France |
2020-03-01 |
2020-05-30 |
NCT04355702, RECHMPL20_0219 |
Phase Not Applicable |
Recruiting |
1 |
2 Months |
130 |
Christian JORGENSEN, Christian JORGENSEN, PUPH, Christian JORGENSEN, Resident, Jan HOLUBAR |
2020-04-23 |
| Anosmie-COVID: Qualitative and Quantitative Evaluation of Anosmia Over Time in Clinically Symptomatic Patients Tested for COVID-19 Infection |
Coronavirus disease 19 infection, Dysomia |
gustatory test alone, olfactory test alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Centre Hospitalier Universitaire de Nimes |
|
France |
2020-03-27 |
2020-11-30 |
Anosmie-COVID, IRB: 20.04.09, NCT04354857 |
Phase Not Applicable |
Recruiting |
1 |
8 Months |
454 |
Albert Sotto, Anissa Megzari, Benjamin Lallemant, Caroline Alovisetti, Didier Laureillard, Gaelle Regnier, Jean-Philippe Lavigne, Marie-José Carles, Paul Loubet, Robin Stephan |
2020-04-23 |
| Opportunistic Screening for Asymptomatic Left Ventricular Dysfunction in Coronavirus Disease 2019 (COVID-19) Survivors |
Coronavirus disease 19 infection |
cardiac assessment alone, echocardiography alone, standard 12-lead ECG alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
The University of Hong Kong |
|
Hong Kong |
2020-04-20 |
2020-05-01 |
COVID_LVD_SCREEN, NCT04355884 |
Phase Not Applicable |
Not yet recruiting |
1 |
|
100 |
Chung Wah SIU, MD, Venus HO, BSc |
2020-04-23 |
| MOPHYDA: Hydroxychloroquine and Azithromycin as Prophylaxis for Healthcare Workers Dealing With COVID-19 Patients |
Coronavirus disease 19 infection |
azithromycin plus hydroxychloroquine |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
King Hussein Cancer Center |
|
Jordan |
2020-04-15 |
2020-10-15 |
20 KHCC 67, MOPHYDA, NCT04354597 |
Phase 2 Clinical |
Not yet recruiting |
1 |
6 Months |
200 |
Amal Al Omari, PhD, Dalia Al Rimawi, MDS, Hikmat Abdel-Razeq, MD, Iyad Al-Ammouri, MD, Iyad Sultan, Iyad Sultan, MD, Lama Nazer, PharmD, Nedal Al-Rawashdeh, MPH, Osama Abu Ata, MD, Rana Damsees, MPH |
2020-04-23 |
| ANTI-COV-2: COVID-19: Neutralizing Human Monoclonal Antibodies Against SARS-Cov-2 |
Coronavirus disease 19 infection, Viral pneumonia |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Hospices Civils De Lyon |
Eurobio scientific |
France |
2020-04-27 |
2020-07-31 |
2020-A01038-31, 69HCL20_0340, ANTI-COV-2, NCT04354766 |
Phase Not Applicable |
Not yet recruiting |
1 |
3 Months |
10 |
Frédéric COUTANT, MD, Tristan FERRY, MD |
2020-04-23 |
| COVAC-TP: COVID-19 Anticoagulation in Children - Thromboprophlaxis Trial |
Coronavirus disease 19 infection, Thromboembolism |
enoxaparin sodium alone |
Low molecular weight heparin |
Newborn Infants (up to 5 months), Infants (6-23 months), Preschool Children (2-5 yrs), Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs) |
Johns Hopkins All Children's Hospital |
|
US |
2020-05-15 |
2022-10-15 |
COVAC-TP, COVAC-TP, NCT04354155 |
Phase 2 Clinical |
Not yet recruiting |
0 |
29 Months |
38 |
Anthony Sochet, MD, Frances L Hamblin, MSHS, Laurel McDevitt, MS, Neil Goldenberg |
2020-04-23 |
| SevCov: Sevoflurane in COVID-19 ARDS |
Coronavirus disease 19 infection, Lung injury, Respiratory distress syndrome |
sevoflurane alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University of Zurich |
|
|
2020-04-15 |
2021-03-31 |
2020-00719, NCT04355962, SevCov |
Phase 2 Clinical |
Not yet recruiting |
0 |
11 Months |
64 |
Beatrice Beck Schimmer, Prof, Martin Schläpfer, PD |
2020-04-23 |
| STOIC: Computed Tomography for COVID-19 Diagnosis |
Coronavirus disease 19 infection, Viral pneumonia |
chest computed tomography alone, reverse-transcription polymerase chain reaction alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Assistance Publique Hopitaux de Paris |
GE Healthcare, INSERM, TheraPanacea |
France |
2020-04-30 |
2020-07-31 |
APHP200434, NCT04355507, STOIC |
Phase Not Applicable |
Not yet recruiting |
1 |
3 Months |
10000 |
Adèle BELLINO, Marie-Pierre REVEL, MD, PhD, Marie-Pierre REVEL, MD,PhD |
2020-04-23 |
| A phase III large clinical trial of hydroxychloroquine for the treatment in hospitalized patients with COVID-19 disease |
Coronavirus disease 19 infection |
hydroxychloroquine alone, standard of care alone, azithromycin plus hydroxychloroquine |
|
|
Novartis AG |
|
US |
|
|
|
Phase 3 Clinical |
Not yet recruiting |
0 |
|
440 |
|
2020-04-22 |
| Traumax: Evolution of Facial Trauma During COVID Containment Measures |
Bone injury, Coronavirus disease 19 infection |
facial fractures reduction alone, osteosynthesis alone |
|
|
University Hospital, Montpellier |
Amiens (Dr Dapke), Clermont Ferrand (Dr Sesque), Lyon (Dr Bourlet – Croix Rousse), Marseille (Dr Foletti – La conception), Nantes (Pr Corre), Nice (Dr Savoldelli), Perpignan (Dr Llobet), Toulouse (Pr Lauwers - Purpan), Unités de CMF des CHU de Paris |
France |
2020-04-01 |
2020-05-30 |
NCT04355442, RECHMPL20_0228, Traumax |
Phase Not Applicable |
Recruiting |
1 |
1 Month |
300 |
Marie de BOUTRAY, PH |
2020-04-23 |
| Administration of Chloropromazine as a Treatment for COVID-19 |
Coronavirus disease 19 infection, Viral pneumonia |
chlorpromazine (Neurazine) alone, convential treatment alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Cairo University |
|
Egypt |
2020-05-31 |
2020-09-30 |
MEDICAL, NCT04354805 |
Phase 1/Phase 2 Clinical |
Not yet recruiting |
1 |
4 Months |
60 |
Ahmed Nasreldin Rezk, Ahmed Rezk, Noha Rezk |
2020-04-23 |
| Treatment for SARS-CoV-2 in High-Risk Adult Outpatients |
Asthma, Chronic obstructive pulmonary disease, Coronavirus disease 19 infection, Emphysema, Lower respiratory tract infection, Lung disease, Pulmonary hypertension |
Variable regimens including azithromycin , folic acid , hydroxychloroquine sulfate |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University of Washington |
Bill & Melinda Gates Foundation |
US |
2020-04-16 |
2020-10-31 |
NCT04354428, STUDY00009878 |
Phase 2/Phase 3 Clinical |
Recruiting |
0 |
6 Months |
630 |
Christine Johnston, MD, MPH, Hannah Leingang, Kirsten Hauge |
2020-04-23 |
| COV2ICU-DK: Compartmental Inflammation in Mechanically Ventilated Patients With COVID-19 |
Coronavirus disease 19 infection, Respiratory distress syndrome |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
HS Hvidovre Hospital |
|
Denmark |
2020-04-06 |
2021-04-06 |
COV2ICU-DK, COV2ICU-DK, H-20023159, NCT04354584, R349-2020-540 |
Phase Not Applicable |
Recruiting |
1 |
12 Months |
20 |
Ronni R Plovsing, MD, PhD |
2020-04-23 |
| A human trial to assess linear DNA vaccine (COVID-19), Takis Biotech/ LineaRx for COVID-19 |
Coronavirus disease 19 infection |
linear DNA vaccine (COVID-19), Takis Biotech/ LineaRx alone |
|
|
Applied DNA Sciences Inc |
|
|
|
|
|
Phase Not Applicable |
Planned |
0 |
|
|
|
2020-04-22 |
| COVISEP: Epidemiological Characteristics of COVID-19 in Patients With MS or NMO |
Coronavirus disease 19 infection |
|
|
|
Assistance Publique Hopitaux de Paris |
|
France |
2020-04-20 |
2022-04-20 |
APHP200482, COVISEP, NCT04355611 |
Phase Not Applicable |
Not yet recruiting |
1 |
24 Months |
2000 |
Céline LOUAPRE, MD,PhD |
2020-04-23 |
| A randomized, double-blind, placebo-controlled, phase II trial to assess the efficacy and safety of MRx-4DP0004 in patients hospitalized with symptoms indicative of COVID-19 |
Coronavirus disease 19 infection |
MRx-0004 alone |
|
|
4D pharma plc |
|
UK |
|
|
|
Phase 2 Clinical |
Not yet recruiting |
1 |
|
90 |
Dr. Dinesh Saralaya |
2020-04-22 |
| Experimental Use of Convalescent Plasma for Passive Immunization in Current COVID-19 Pandemic in Pakistan in 2020 |
Coronavirus disease 19 infection |
convalescent plasma alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) |
HILTON PHARMA (PVT) LTD |
|
Pakistan |
2020-04-30 |
2021-04-30 |
NCT04352751, PIPK- 0000 /NIBD-0000/2020 |
Phase 4 Clinical |
Not yet recruiting |
1 |
12 Months |
2000 |
Dr. Arshi Naz, PhD,Diplab, Dr. Neeta Maheshwary, Dr. Neeta Maheshwary, MBBS M.Phil, Dr. Tahir Shamsi, FRCP MRCPath, Professor Bikha Ram, Professor Ikram Din Ujjan, Professor Javed Akram, Professor Nadeem Samad Sheikh, Professor Nisar Ahmed, Professor Shahtaj Masood, Saba Fatima |
2020-04-23 |
| UKMSRCV19: The United Kingdom Multiple Sclerosis Register Covid-19 Substudy |
Coronavirus disease 19 infection, Multiple sclerosis |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Swansea University, Wales |
|
UK |
2020-03-14 |
2022-07-14 |
16SW0194, NCT04354519, UKMSRCV19 |
Phase Not Applicable |
Recruiting |
1 |
28 Months |
3000 |
Katie A Tuite-Dalton, BSc, Nikos Evangelou, Richard S Nicholas, Rod M Middleton, MBA |
2020-04-23 |
| Antibody Seroprevalence and Rate of Asymptomatic Infections With SARS-CoV-2 in Austrian Hospital Personnel |
Coronavirus disease 19 infection |
antibody test alone, enzyme-linked immunosorbent assay alone, reverse transcription polymerase chain reaction alone |
|
Healthy volunteers accepted, Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
AUVA-Allgemeine Unfallversicherungsanstalt |
Paracelsus Medical University |
Austria |
2020-04-30 |
2020-10-31 |
AUVA SARS-COV-2 STUDIE, NCT04354779 |
Phase Not Applicable |
Not yet recruiting |
1 |
6 Months |
4000 |
Wolfgang Schaden, MD, Wolfgang Schadenc |
2020-04-24 |
| Effect of ppd on recovery of covid disease 19 |
Coronavirus disease 19 infection |
CT scan alone, Corona testing alone, purified protein derivative skin test alone, chloroquine plus lopinavir + ritonavir |
HIV protease inhibitor |
|
Fasa University of Medical Sciences |
|
Iran |
2020-05-04 |
|
IR.FUMS.REC.1399.004, IRCT20200414047070N1 |
Phase 3 Clinical |
Not yet recruiting |
1 |
|
50 |
Abdolah Azizi, Dr.Jalal Karimi, Dr.Mojtaba Farjam, Dr.jalal karimi |
2020-04-24 |
| AiM COVID for Covid 19 Tracking and Prediction |
Coronavirus disease 19 infection |
AiM COVID alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Aarogyam UK |
Clickmedix, The National Technical University of Ukraine "Igor Sikorsky Kyiv Polytechnic Institute" (NTUU "KPI"), Warwick University |
UK |
2020-03-28 |
2020-04-17 |
AU12, NCT04354753 |
Phase Not Applicable |
Completed |
1 |
|
80 |
Vishwesh Kulkarni |
2020-04-23 |
| Telmisartan for Treatment of COVID-19 Patients |
Coronavirus disease 19 infection, Respiratory distress syndrome |
Bertel, Laboratorio Elea Phoenix alone, Standard care alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Laboratorio Elea |
|
Argentina |
2020-04-01 |
2020-10-01 |
2020-001, NCT04355936 |
Phase 2 Clinical |
Recruiting |
1 |
6 Months |
400 |
Mariano Duarte, MD, Rodolfo P Rothlin, MD |
2020-04-23 |
| A final phase trial to evaluate ChAdOx1 nCoV-19 for the treatment of patients with covid-19 infection |
Coronavirus disease 19 infection |
ChAdOx1 nCoV-19 alone |
|
|
University of Oxford |
|
|
|
|
|
Phase Not Applicable |
Planned |
0 |
|
5000 |
|
2020-04-22 |
| An Expanded Access Program (EAP)to evaluate the efficacy and safety of ruxolitinib in COVID-19 for patients with severe COVID-19 associated cytokine storm |
Coronavirus disease 19 infection |
ruxolitinib (oral, myeloproliferative disorders), Incyte/Novartis alone |
Jak1 tyrosine kinase inhibitor, Jak2 tyrosine kinase inhibitor |
|
Incyte Corp |
|
US |
|
|
|
Phase Not Applicable |
Recruiting |
0 |
|
|
|
2020-04-22 |
| Topical Chloroquine Nasal Drops in Early Stage Covid 19- Impact on Viral load and cure rates |
Coronavirus disease 19 infection |
Chloroquine alone, Standard Treatment alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
All India Institute of Medical Sciences |
|
India |
2020-04-21 |
|
CTRI/2020/04/024729 |
Phase 2 Clinical |
Not yet recruiting |
1 |
|
60 |
Alok Thakar |
2020-04-24 |
| A phase I/IIa, randomized, placebo-controlled study of COV-ENT-1 for the treatment in hospitalized patients with COVID-19 infection |
Coronavirus disease 19 infection, Viral pneumonia |
COV-ENT-1 alone |
|
|
Enterin Inc |
|
US |
2020-07-31 |
|
|
Phase 1/Phase 2 Clinical |
Planned |
0 |
|
80 |
|
2020-04-24 |
| CONFINE: Birth Experience During COVID-19 Confinement |
Coronavirus disease 19 infection, Postnatal depression |
Self-administered questionnaires alone |
|
Female, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Central Hospital, Nancy, France |
|
France |
2020-04-16 |
2021-11-01 |
2020-A00881-38, CONFINE, NCT04348929 |
Phase Not Applicable |
Recruiting |
1 |
18 Months |
600 |
Charline BERTHOLDT |
2020-04-23 |
| VT4COVID: Ultraprotective Ventilation Without Extracorporeal Circulation During COVID-19 Pneumonia |
Coronavirus disease 19 infection, Respiratory distress syndrome, Respiratory failure, Viral pneumonia |
ultraprotective ventilation alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Hospices Civils De Lyon |
|
France |
2020-04-14 |
2022-04-14 |
69HCL20_0322, NCT04349618, VT4COVID |
Phase Not Applicable |
Not yet recruiting |
11 |
24 Months |
200 |
Arnaud FRIGGERI, Dr, Bertrand DELANNOY, Dr, Christian POMMIER, Dr, Claire DUPUIS, Dr, Frédéric AUBRUN, Pr, Guillaume THIERY, Pr, Hodane YONIS, Dr, Jean-Christophe RICHARD, Pr, Laurent ARGAUD, Pr, Loredana BABOI, Michel MULLER, Dr, Nicolas TERZI, Pr, Thomas RIMMELE, Pr |
2020-04-23 |
| COVI-PRONE: Awake Prone Position in Hypoxemic Patients With Coronavirus Disease 19 (COVI-PRONE): A Randomized Clinical Trial |
Coronavirus disease 19 infection, Respiratory failure |
Awake Proning alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
St Josephs Healthcare Hamilton |
|
Canada |
2020-04-20 |
2020-10-31 |
2154, COVI-PRONE, NCT04350723 |
Phase Not Applicable |
Not yet recruiting |
1 |
6 Months |
350 |
Sarah Culgin, Waleed Alhazzani, Zainab Al Duhalib |
2020-04-23 |
| RASCOVID-19: Effects of Discontinuing Renin-angiotensin System Inhibitors in Patients With COVID-19 |
Coronavirus disease 19 infection |
ACEi alone, ARB alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University Hospital Gentofte |
|
Denmark |
2020-04-30 |
2020-12-31 |
2020-001544-26, H-20026205, NCT04351581, RASCOVID-19 |
Phase Not Applicable |
Not yet recruiting |
1 |
8 Months |
215 |
Filip K Knop, MD, PhD |
2020-04-23 |
| Meals MATTER: A Trial of Medically Tailored Meals 2 Weeks vs. 4 Weeks Post Hospital Discharge |
Anxiety disorder, Cancer, Cardiac failure, Chronic obstructive pulmonary disease, Coronavirus disease 19 infection, Depression, Diabetes mellitus, End stage renal disease, Liver cirrhosis, Liver disease |
Medically Tailored Meals alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Kaiser Permanente |
|
US |
2020-04-15 |
2021-07-31 |
IRB-1556587, Meals MATTER, NCT04351880 |
Phase Not Applicable |
Not yet recruiting |
0 |
15 Months |
640 |
John Steiner, MD, MPH, Melanie L Drace, MPH, Rebecca S Boxer, MD, MS |
2020-04-26 |
| Effect of herbal medicine containing Saatar, Hofarigon and Fennel on COVID-19 patients |
Coronavirus disease 19 infection, Lung disease |
Variable regimens including herbal medicine , hydroxychloroquine , lopinavir + ritonavir |
HIV protease inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Mazandaran University of Medical Sciences |
|
Iran |
2020-04-18 |
|
IR.MAZUMS.REC.1398.1457, IRCT20200404046935N1 |
Phase 3 Clinical |
Recruiting |
1 |
|
40 |
Farhang Babamahmoodi |
2020-04-23 |
| HEROES: The COVID-19 Health Care Workers Study |
Coronavirus disease 19 infection, Psychiatric disorder |
|
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University of Chile |
|
Spain, US, Italy, Chile |
2020-04-15 |
2021-04-14 |
HEROES, HEROES COVID-19, NCT04352634 |
Phase Not Applicable |
Not yet recruiting |
3 |
12 Months |
2000 |
Eduardo Fernández-Jiménez, PhD, Eric Tapia, MPH, Francesca Moro, MD, Gonzalo Martínez-Alés, MD, Maria-Fe Bravo-Ortiz, MD, PhD, Mauro Carta, MD, Roberto Mediavilla, PhD, Ruben Alvarado, PhD, Rubén Alvarado, PhD, Sara Schilling, MPH |
2020-04-23 |
| Echocardiographic Manifestation in Patient With Coronavirus Disease 2019 (COVID-19) |
Coronavirus disease 19 infection |
GE Logiq E portable color ultrasound diagnostic machine (GE Healthcare) alone, doppler echocardiography alone, two-dimensional echocardiography alone |
|
|
Renji Hospital |
|
China |
2020-02-19 |
2020-04-06 |
COVID19-ECHOCARDIOGRAPHY, NCT04352842 |
Phase Not Applicable |
Completed |
1 |
1 Month |
55 |
Jun Pu, M.D |
2020-04-24 |
| Assessment of Objective clinical scoring system to rule out COVID-19 with high sensitivity |
Coronavirus disease 19 infection |
Outbreak of Respiratory Tract Infection Score (ORTIS) sytstem alone |
|
Newborn Infants (up to 5 months), Infants (6-23 months), Preschool Children (2-5 yrs), Children (6-12 yrs), Adolescents (13-17 yrs) |
Dr Atul's Child Hospital |
|
India |
2020-05-01 |
|
CTRI/2020/04/024636 |
Phase Not Applicable |
Not yet recruiting |
1 |
|
1000 |
Varnit Shanker |
2020-04-23 |
| PROLIFIC: Chemoprophylaxis Trial (COVID-19) |
Coronavirus disease 19 infection |
hydroxychloroquine alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Cambridge University Hospitals NHS Foundation Trust |
|
UK |
2020-04-30 |
2021-04-30 |
NCT04352933, PROLIFIC, PROLIFIC2020 (A095583) |
Phase 3 Clinical |
Not yet recruiting |
1 |
12 Months |
1000 |
Ella James, PhD, Heike Templin, Joseph Cheriyan, MBCHB, FRCP |
2020-04-21 |
| COVID-19-hematological Malignancies: the Italian Hematology Alliance |
Acute leukemia, Coronavirus disease 19 infection, Lymphoma, Multiple myeloma, Myelodysplastic syndrome, Myeloproliferative disorder |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Ospedale di Circolo - Fondazione Macchi |
|
Italy |
2020-04-07 |
2021-04-30 |
HM-COVID19-ITALY, NCT04352556 |
Phase Not Applicable |
Recruiting |
70 |
12 Months |
250 |
Adriano Venditti, MD, Alberto Bosi, MD, Alessandro Busca, MD, Alessandro Corso, MD, Alessandro Inzoli, MD, Alfredo Molteni, MD, Anna Conconi, MD, Antonio Cuneo, MD, Antonio Pinto, MD, Antonio Spadano, MD, Attilio Guarini, MD, Attilio Olivieri, MD, Atto Billio, MD, Augusto Federici, MD, Benedetto Bruno, MD, Brunangelo Falini, MD, Bruno Martino, MD, Carlo Gambacorti Passerini, MD, Carlo Visco, MD, Carmen Fava, MD, Carmine Selleri, MD, Caterina Musolino, MD, Celestino Ferrandina, MD, Chiara Cattaneo, MD, Corrado Tarella, MD, Daniela Cilloni, MD, Daniele Vallisa, MD, Domenico Russo, MD, Emanuele Angelucci, MD, Fabio Ciceri, MD, Fabrizio Ciambelli, MD, Fabrizio Pane, MD, Felicetto Ferrara, MD, Filippo Gherlinzoni, MD, Francesco Di Raimondo, MD, Francesco Lanza, MD, Francesco Merli, MD, Francesco Passamonti, MD, Francesco Zaja, MD, Giampietro Semenzato, MD, Gianluca Gaidano, MD, Giorgio La Nasa, MD, Giuseppe Avvisati, MD, Giuseppe Visani, MD, Livio Pagano, MD, Luca Arcaini, MD, Luigi Rigacci, MD, Marco Ladetto, MD, Marco Ruggeri, MD, Marco Salvini, MD, Mario Luppi, MD, Massimo Gentile, MD, Massimo Massaia, MD, Matteo Della Porta, MD, Maurizio Martelli, MD, Mauro Krampera, MD, Mauro Turrini, MD, Michele Cavo, MD, Michele Spina, MD, Monica Bocchia, MD, Nicola Di Renzo, MD, Nicola Fracchiolla, MD, Nicola Giuliani, MD, Paolo Corradini, MD, Patrizia Tosi, MD, Patrizio Mazza, MD, Pellegrino Musto, MD, Piero Galieni, MD, Renato Bassan, MD, Renato Fanin, MD, Roberto Cairoli, MD, Roberto Lemoli, MD, Sara Galimberti, MD, Sergio Siragusa, MD, Valerio De Stefano, MD |
2020-04-21 |
| HERO: Health Care Worker Prophylaxis Against COVID-19 |
Coronavirus disease 19 infection |
hydroxychloroquine alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
GeoSentinel Foundation |
|
US |
2020-04-24 |
2020-08-24 |
GFICOVID-19-1, HERO, NCT04352946 |
Phase 3 Clinical |
Not yet recruiting |
0 |
4 Months |
374 |
Bradley A Connor, MD, Kevin Kain, MD, Marina Rogova, RN, Megan Landes, MD, Robert S Brown, Jr, MD, William MacLeod, ScD |
2020-04-23 |
| The effect of PHR spray on patients with coronavirus-19 |
Coronavirus disease 19 infection, Lung disease |
PHR160 Inhaler Spray alone, routine treatment alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Bagheiat-allah University of Medical Sciences |
|
Iran |
2020-03-10 |
2020-03-24 |
IR.BMSU.REC.1398.387, IRCT20160131026298N2 |
Phase 2/Phase 3 Clinical |
Completed |
1 |
|
64 |
Ahmad Reza Sharifi Olounabadi, REZAMOHTASHAMI, AHMAD REZA SHARIFI OLOUNABADI, Reza Mohtashami |
2020-04-22 |
| The effect of herbal drugs (Echinacea and Ginger) on Improvement of clinical symptoms and hospitalizations in suspected COVID-19 outpatient cases |
Coronavirus disease 19 infection |
standard treatment alone, Rucoldup, Ghaem Daru plus Vomigone, Dineh Pharmaceutical Company |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Saveh University of Medical Sciences |
|
Iran |
2020-04-18 |
|
IR.SAVEHUMS.REC.1399.004, IRCT20200415047089N1 |
Phase 3 Clinical |
Recruiting |
1 |
|
100 |
hamidreza koohestani, mehdi mesri |
2020-04-22 |
| The design of an updated iron lung ventilator which can be easily built and used by people with minimal training in situations such as COVID-19 where skilled doctors or normal ventilators are unavailable |
Coronavirus disease 19 infection |
Hudson face mask alone, sedation therapy alone, simplified negative pressure cuirass style ventilator alone, supplemental oxygen therapy alone |
|
Healthy volunteers accepted, Male, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) |
Perth Anaesthetic Group |
St John of God Murdoch Hospital, Australia |
Australia |
2020-04-20 |
2020-04-20 |
ACTRN12620000477921p |
Phase Not Applicable |
Not yet recruiting |
1 |
|
1 |
Dr Michael Soares |
2020-04-22 |
| Phase II, open-label, randomized clinical trial with the primary objective to assess the safety and efficacy of the convalescent plasma to limit complications in Covid-19 patients |
Coronavirus disease 19 infection |
convalescent plasma alone |
|
|
Indian Council of Medical Research |
|
|
|
|
|
Phase 2 Clinical |
Not yet recruiting |
0 |
|
|
|
2020-04-22 |
| Phase II, randomized trial of Brukinsa to treat in later-stage COVID-19 patients |
Coronavirus disease 19 infection |
mechanical ventilation alone, zanubrutinib alone |
Btk tyrosine kinase inhibitor |
|
BeiGene Co Ltd |
|
US |
|
|
|
Phase 2 Clinical |
Planned |
0 |
|
42 |
Treon |
2020-04-22 |
| Thalidomide in COVID19 |
Coronavirus disease 19 infection, Viral pneumonia |
Variable regimens including Talidex. Alan pharmaceuticals , acetaminophen + codeine , azithromycin , ceftriaxone , diphenhydramine , enoxaparin sodium , hydroxychloroquine , methylprednisolone , vancomycin |
Low molecular weight heparin, Peptidoglycan recognition protein inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Isfahan University of medical Sciences |
Deputy minister of technology research |
Iran |
2020-04-15 |
|
IRCT20170207032444N3, http://ethics.research.ac.ir/IR.MUI.MED.REC.1399.027 |
Phase 3 Clinical |
Recruiting |
1 |
|
60 |
Farzane Ashrafi, Mehrzad Salmasi, Ramin Sami, Shaghayegh Haghjooy Javanmard, farzane ashrafi |
2020-04-22 |
| Cord Blood Therapy to prevent progression of COVID-19 related pneumonia |
Coronavirus disease 19 infection, Viral pneumonia |
cord blood therapy alone, standard supportive management alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Monash Health |
|
Australia |
2020-06-01 |
2020-12-31 |
ACTRN12620000478910, CBC-19 |
Phase 2 Clinical |
Not yet recruiting |
1 |
7 Months |
24 |
Dr Atul Malhotra |
2020-04-22 |
| FEELIV COVID: An Online Survey to Understand Feelings Related to COVID-19 Among ILBS Patients With Liver Disease |
Coronavirus disease 19 infection, Liver disease |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Institute of Liver and Biliary Sciences, India |
|
India |
2020-04-22 |
2020-04-30 |
FEELIV COVID, ILBS-COVID-03, NCT04352491 |
Phase Not Applicable |
Recruiting |
1 |
|
1500 |
Dr Mohit Varshney, DM, Dr Mohit Varshney, MD, Dr Shiv Kumar Sarin, DM |
2020-04-23 |
| A clinical trial to investigate the role of Pegylated Interferon alpha-2b for COVID 19 |
Coronavirus disease 19 infection |
peginterferon alfa-2b follow-on-biologic, Zydus-Cadila alone |
Interferon alpha 2 ligand |
|
Zydus-Cadila Group |
|
|
|
|
|
Phase Not Applicable |
Planned |
0 |
|
|
|
2020-04-22 |
| The IMSOMNIA study: Mental health and wellbeing on general population during the COVID-19 outbreak |
Anxiety disorder, Coronavirus disease 19 infection, Depression, Insomnia |
|
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
The George Institute for Global Health |
|
Germany, US, Spain, Italy, China, Australia |
2020-05-01 |
|
ACTRN12620000479909p, The IMSOMNIA study |
Phase Not Applicable |
Not yet recruiting |
5 |
|
3000 |
Dr Amanda Y Wang, Dr Qi Mei |
2020-04-22 |
| BBCovid: COVID-19: Nasal and Salivary Detection of the SARS-CoV-2 Virus After Antiviral Mouthrinses |
Coronavirus disease 19 infection |
Citrox plus beta-cyclodextrin |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Universite Claude Bernard |
Hospices Civils De Lyon, University Hospital, Montpellier, University Hospital, Tours |
France |
2020-04-27 |
2020-06-20 |
BBCOVID, BBCovid, NCT04352959 |
Phase 2 Clinical |
Not yet recruiting |
1 |
1 Month |
178 |
Carrouel Florence |
2020-04-23 |
| SpectrOVID19: Prospective gas chromatographic and spectrometric analysis of the exhalation of healthy test persons and of SARS-CoV2 infected patients as well as of patients suffering from COVID-19 at the Klinikum Dortmund |
Coronavirus disease 19 infection |
gas chromatography alone, ionic motility spectrometry alone |
|
Healthy volunteers accepted, Infants (6-23 months), Preschool Children (2-5 yrs), Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Klinikum Dortmund GgmbH |
|
Germany |
2020-04-12 |
|
176/2020, DRKS00021399, SpectrOVID19 |
Phase Not Applicable |
Recruiting |
1 |
|
450 |
Oliver Müller |
2020-04-23 |
| Efficacy and Safety of MTX-loaded Nanoparticles to Treat Severe COVID-19 Patients |
Coronavirus disease 19 infection, Respiratory distress syndrome |
methotrexate loaded nanoparticle alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Azidus Brasil |
Hospital Santa Marcelina, InCor Heart Institute |
|
2020-05-01 |
2020-11-30 |
LDE-MTX_COVID19, NCT04352465 |
Phase 1/Phase 2 Clinical |
Not yet recruiting |
0 |
7 Months |
42 |
Luciana Ferrara, Rodrido Esper, MD, PhD |
2020-04-23 |
| Stress-reduction Using Probiotics to Promote Ongoing Resilience Throughout COVID-19 for Healthcare Workers (SUPPORT COVID-19 Healthcare Workers) |
Acute stress disorder, Coronavirus disease 19 infection |
Lactobacillus rhamnosus HN001 alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
University of Auckland |
|
New Zealand |
2020-06-01 |
2020-07-16 |
ACTRN12620000480987p |
Phase Not Applicable |
Not yet recruiting |
1 |
1 Month |
507 |
Dr Rebecca Slykerman |
2020-04-23 |
| The RAPID COVID TRIAGE Algorithm |
Coronavirus disease 19 infection |
Spartan Cube point-of-care Covid-19 test alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Ottawa Heart Institute Research Corp |
|
|
2020-04-15 |
2021-02-28 |
20200228-01H, NCT04353154 |
Phase Not Applicable |
Not yet recruiting |
0 |
10 Months |
20 |
Dr. Derek So, Poppy MacPhee |
2020-04-23 |
| RACONA: Efficacy of Nafamostat in Covid-19 Patients |
Coronavirus disease 19 infection |
nafamostat mesylate alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University Hospital Padova |
University of Zurich, Yokohama City University |
Italy |
2020-04-30 |
2021-12-31 |
NCT04352400, RACONA, RACONA NAFAMOSTAT |
Phase 2/Phase 3 Clinical |
Not yet recruiting |
2 |
20 Months |
256 |
Gian Paolo Rossi, Gian Paolo Rossi, Prof. |
2020-04-22 |
| VACAT: COVID-19 and Vaccination Attitudes |
Coronavirus disease 19 infection |
|
|
Healthy volunteers accepted |
Hopitaux Universitaires De Geneve |
University of Lausanne, University of Zurich |
UK |
2020-04-14 |
2020-04-30 |
NCT04352582, VACAT, VACAT |
Phase Not Applicable |
Recruiting |
1 |
|
1000 |
Dominic Rohner, PhD, Geraldine Blanchard-Rohner, Geraldine Blanchard-Rohner, MD-PhD |
2020-04-22 |
| Impact of high intensity interval training and aerobic training on stress, depression symptoms, anxiety and resilience in self-isolated people during the COVID-19 health emergency in Spain |
Acute stress disorder, Anxiety disorder, Coronavirus disease 19 infection, Depression |
high intensity interval training alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Universidad de Extremadura |
|
Spain |
2020-03-17 |
2020-04-26 |
ACTRN12620000482965 |
Phase Not Applicable |
No longer recruiting |
1 |
1 Month |
77 |
Dr Juan Pedro Fuente-García, Mr Santos Villafaina |
2020-04-22 |
| Effects of digital home exercise programs on physical and mental well-being during the COVID-19 pandemic: a multicenter trial |
Coronavirus disease 19 infection |
digital home exercise programs alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Johann Wolfgang Goethe-Universitat Frankfurt am Main |
Foro Italico University of Rome, Spaulding Rehabilitation Network, The University Children’s Hospital Basel, Universidade Cidade de Sao Paulo, Universite Jean Monnet, University of Cadiz |
France, Brazil, US, Spain, Germany, Austria, Switzerland, Chile |
2020-04-22 |
|
2020-25, DRKS00021273 |
Phase Not Applicable |
Not yet recruiting |
7 |
|
544 |
Mr Dr Jan Wilke, Mr Prof Luiz Hespanhol, Mr. Dr Christoph Heidt, Mr. Prof David Jiménez-Pavón, Mr. Prof Pascal Edouard, Ms. Dr Chiara Fossati |
2020-04-22 |
| Effect of Ozone Therapy in Treatment of COVID-19 |
Coronavirus disease 19 infection |
conventional treatment alone, oxygen/ozone alone, ozone major autohemotherapy alone |
|
|
Bagheiat-allah University of Medical Sciences |
|
Iran |
2020-04-23 |
|
IR.BMSU.REC.1399.060, IRCT20191125045492N2 |
Phase 2 Clinical |
Recruiting |
1 |
|
80 |
Ali Sarrafzadeh, Dr. Gholamhosein Alishiri, Morteza Izadi |
2020-04-23 |
| Outcomes of Urological Surgery During Periods of Social COVID-19 Containemnt: is it Reasonable to Limit Access to Surgical Care for All? |
Coronavirus disease 19 infection, Urinary tract tumor |
surgery alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Centre Hospitalier Universitaire De Nice |
|
France |
2020-03-15 |
2020-05-01 |
20UROCOVID.03, NCT04352699 |
Phase Not Applicable |
Recruiting |
1 |
1 Month |
120 |
Aysha SHAIKH, Matthieu DURAND, Matthieu DURAND, MD, PhD |
2020-04-22 |
| AUS-COVID: Australian cardiovascular COVID-19 registry |
Coronavirus disease 19 infection, Heart injury, Myocardial disease, Myocarditis |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Paul Ramsay Foundation |
|
Australia |
2020-04-20 |
2020-08-19 |
ACTRN12620000486921, AUS-COVID |
Phase Not Applicable |
Not yet recruiting |
20 |
4 Months |
865 |
Prof Ravinay Bhindi |
2020-04-22 |
| PATCH 2 and 3: Prevention and Treatment of COVID-19 (Severe Acute Respiratory Syndrome Coronavirus 2) With Hydroxychloroquine |
Coronavirus disease 19 infection |
hydroxychloroquine alone |
|
Healthy volunteers accepted, Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
UnitedHealth Group Inc |
Perelman School of Medicine, Prohealth Care Associates |
US |
2020-04-07 |
2021-06-15 |
2020-0003, NCT04353037, PATCH 2 and 3 |
Phase 2 Clinical |
Recruiting |
0 |
14 Months |
850 |
Daniel Griffin, MD PhD, Daniel Griffin, MD, PhD, Deneen Vojta, MD, Ravi Amaravadi, MD |
2020-04-22 |
| COVID-19 associated brainstem encephalitis - is SARS-CoV-2 a neurotropic agent? |
Ageusia, Coronavirus disease 19 infection, Dysomia, Encephalitis, Taste disorder |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Neurosurgical University Clinic Freiburg |
|
Germany |
2020-04-20 |
|
211/20, DRKS00021439 |
Phase Not Applicable |
Recruiting |
1 |
|
70 |
Jonas Hosp |
2020-04-22 |
| Evaluating the Use of Polymyxin B Cartridge Hemoperfusion for Patients With Septic Shock and COVID 19 |
Coronavirus disease 19 infection, Septic shock |
Toraymyxin PMX-20R cartridge alone, hemoperfusion alone, standard medical care alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Spectral Diagnostics (US) Inc |
|
|
|
|
NCT04352985, SDI-PMX-013 |
Phase Not Applicable |
Recruiting |
0 |
|
|
Debra Foster |
2020-04-22 |
| DolPsyCOVID: Psychological Impact of Quarantine in Chronic Pain Patient During COVID-19 Outbreak |
Anxiety disorder, Coronavirus disease 19 infection, Depression, Pain |
questionnaire assesment alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Centre Hospitalier Regional Universitaire de Lille |
|
France |
2020-04-30 |
2020-12-31 |
2020-A00912-37, DolPsyCOVID, EQ_2020_02, NCT04353011 |
Phase Not Applicable |
Not yet recruiting |
1 |
8 Months |
50 |
Anne BERA, MD |
2020-04-22 |
| Antibody-based Tests for SARS-CoV-2 COVID-19: Evaluation of Patients and Healthcare Providers in the Confines of Healthcare Settings |
Coronavirus disease 19 infection |
CoronaCide COVID-19 IgM/IgG rapid test alone, Premier Biotech COVID-19 IgM/IgG rapid test alone |
|
Healthy volunteers accepted |
Texas Cardiac Arrhythmia |
|
US |
2020-03-27 |
2021-01-31 |
NCT04352764, TCAI_COVID-19 |
Phase Not Applicable |
Recruiting |
0 |
10 Months |
1000 |
Andrea Natale, MD, Andrea Natale, MD FACC FHRS, Deb Cardinal, RN |
2020-04-23 |
| Safety and Immunogenicity Study of 2019-nCoV Vaccine (Inactivated) for Prophylaxis SARS CoV-2 Infection (COVID-19) |
Coronavirus disease 19 infection |
Inactivated vaccine (COVID-19), Sinovac Biotech alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) |
Sinovac Research & Development Co Ltd |
|
China |
2020-04-13 |
2020-12-13 |
NCT04352608, PRO-NCOV-1001 |
Phase 1/Phase 2 Clinical |
Recruiting |
2 |
8 Months |
744 |
Congbing Jiang, Bachelor, Fengcai Zhu, Doctor, Hongxing Pan, Doctor |
2020-04-24 |
| Adipose Mesenchymal Cells for Abatement of SARS CoV-2 Respiratory Compromise in COVID-19 Disease |
Adult respiratory distress syndrome, Coronavirus disease 19 infection, Viral pneumonia |
autologous adipose derived mesenchymal cells alone, conventional treatment alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Regeneris Medical |
|
|
2020-04-30 |
2026-04-30 |
COVID-MSCIV, NCT04352803 |
Phase 1 Clinical |
Not yet recruiting |
0 |
72 Months |
20 |
Ryan Welter, MD PhD |
2020-04-23 |
| Influence Physical Activity Psychological Responses COVID-19 Pandemic |
Acute stress disorder, Anxiety disorder, Coronavirus disease 19 infection, Depression |
Google Forms online survey alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Universidad de Extremadura |
|
Brazil, Uruguay, Chile |
2020-03-16 |
2020-09-30 |
3.954.038, NCT04352517 |
Phase Not Applicable |
Recruiting |
3 |
6 Months |
3500 |
Alba Dr Camacho-Cardenosa, Doctor, Atila Alexandre Trapé, Dr, Eugenio Narciso Merellano Navarro, Javier Dr Brazo-Sayavera, Doctor, Marta Dr Camacho-Cardenosa, Doctor |
2020-04-23 |
| Pirfenidine in SARS-COV2 |
Coronavirus disease 19 infection, Pulmonary fibrosis, Respiratory distress syndrome |
Variable regimens including chloroquine , lopinavir + ritonavir , oseltamivir , pirfenidone , ribavirin |
Exo-alpha sialidase inhibitor, HIV protease inhibitor, PDGF receptor antagonist, TGF beta receptor antagonist, p38 MAP kinase inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Kermanshah University of Medical Sciences |
|
Iran |
2020-04-26 |
|
IR.KUMS.REC.1399.017, IRCT20200314046764N1 |
Phase 3 Clinical |
Not yet recruiting |
1 |
|
40 |
Bahareh Baghchi, Mohammad Nazarian Pirdoosti |
2020-04-24 |
| Atorvastatin effect on COVID-19 |
Coronavirus disease 19 infection |
atorvastatin alone |
HMG CoA reductase inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) |
Mazandaran University of Medical Sciences |
|
Iran |
2020-04-05 |
|
IR.MAZUMS.REC.1399.042, IRCT20190727044343N2 |
Phase 2/Phase 3 Clinical |
No longer recruiting |
1 |
|
100 |
Lotfollah Davoodi |
2020-04-22 |
| ILUSA: International Lung UltraSound Analysis (ILUSA) Study |
Coronavirus disease 19 infection, Cough, Dyspnea, Fever, Respiratory disease, Respiratory tract infection |
Lung ultrasound examination alone |
|
Female |
Katholieke Universiteit Leuven |
|
Belgium, Italy, UK |
2020-04-20 |
2020-12-31 |
COVID-19: ILUSA (S63988), ILUSA, NCT04353141 |
Phase Not Applicable |
Not yet recruiting |
8 |
8 Months |
1850 |
Antonia Testa, PhD, Antonio Lanzone, PhD, Dirk Timmerman, PhD, Federico Prefumo, Francesca Moro, Francesca Moro, MD, Francesco D'Antonio, Giovanni Scambia, PhD, Hannes Van der Merwe, MD, Hannes Van der Merwe, PhD, Irene Cetin, Jan Deprest, PhD, Tiziana Frusca, Tom Bourne, PhD, Wouter Froyman, MD |
2020-04-22 |
| A clinical study to assess antiviral efficacy of DWRX-2003 for the potential treatment of COVID-19 |
Coronavirus disease 19 infection |
repositioned niclosamide (refractory lung disease/COVID-19), Daewoong Pharmaceutical/Institut Pasteur Korea alone |
|
|
Daewoong Pharmaceutical Co Ltd, Institut Pasteur Korea |
|
South Korea |
|
|
|
Phase Not Applicable |
Planned |
1 |
|
|
|
2020-04-23 |
| Evaluation of SinaCurcumin capsule efficacy as an supplement therapy for mild to moderate COVID-19 in Mashhad |
Coronavirus disease 19 infection, Viral pneumonia |
SinaCurcumin alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Mashhad University of Medical Sciences |
|
Iran |
2020-05-19 |
|
IR.MUMS.REC.1399.054, IRCT20200408046990N1 |
Phase 3 Clinical |
Not yet recruiting |
1 |
|
60 |
Mohsen Tafaghodi, Sepideh Elyasi |
2020-04-23 |
| The effect of azithromycin in treatment of COVID19 |
Coronavirus disease 19 infection, Viral pneumonia |
Variable regimens including atazanavir , azithromycin , hydroxychloroquine , lopinavir + ritonavir , oseltamivir |
Exo-alpha sialidase inhibitor, HIV GAG POL polyprotein inhibitor, HIV GAG protein inhibitor, HIV protease inhibitor, HIV-1 protease inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Tehran University of Medical Sciences |
|
Iran |
2020-04-24 |
|
IR.TUMS.VCR.REC.1399.165, IRCT20200415047092N1 |
Phase 3 Clinical |
Not yet recruiting |
1 |
|
110 |
Ehsan Sekhavati Moghadam, Fereshte Ghiasvand, Mohammad Ali Sahraian |
2020-04-23 |
| Treatment of COVID-19-induced cytokine storm by hemoperfusion |
Coronavirus disease 19 infection |
hemodialysis alone, hemoperfusion HA330 filter (JAFRON BIOMEDICAL.CO.LTD, China) alone, heparin alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Tabriz University of Medical Sciences |
|
Iran |
2020-04-20 |
|
IR.TBZMED.REC.1399.024, IRCT20200317046797N5 |
Phase 2 Clinical |
Recruiting |
1 |
|
10 |
Ali Taghizadieh, Dr Bahram Niknafs, Dr Mohammad Samiei, Mohammadreza Ardalan, Sepideh Zununi Vahed |
2020-04-23 |
| The effect of melatonin on the quality of sleep in COVID-19 patients |
Coronavirus disease 19 infection |
Variable regimens including azithromycin , hydroxychloroquine , melatonin |
|
|
Mazandaran University of Medical Sciences |
|
Iran |
2020-04-14 |
|
IR.MAZUMS.REC.1399.056, IRCT20200411047030N1 |
Phase 3 Clinical |
Recruiting |
1 |
|
82 |
Prof. Majid Saeedi, Reza Alizadeh-Navaei, Seyyed Abbas Mousavi |
2020-04-22 |
| COCON: Control of COVID-19 in hospitals |
Coronavirus disease 19 infection |
|
|
|
Universitair Medisch Centrum Utrecht |
The Netherlands Organisation for Health Research and Development |
Netherlands |
2020-04-22 |
2020-08-31 |
COCON, NL8528 |
Phase Not Applicable |
Not yet recruiting |
1 |
4 Months |
2000 |
Marjolein Kluytmans |
2020-04-22 |
| A clinical study of CRISPR-based DETECTR assay for the diagnosis of patients with COVID-19 infection and patients with other viral respiratory infections |
Coronavirus disease 19 infection, Viral respiratory tract infection |
CRISPR-based DETECTR assay alone |
|
|
Mammoth Biosciences |
|
US |
|
|
|
Phase Not Applicable |
Status not specified |
0 |
|
78 |
Dr Charles Chiu, Dr James Broughton, Dr Janice Chen |
2020-04-24 |
| General practice cooperative COVID-19 centre Urmond |
Coronavirus disease 19 infection |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
MCC Omnes |
|
Netherlands |
2020-05-01 |
2022-01-03 |
METCZ20200068, NL8529 |
Phase Not Applicable |
Not yet recruiting |
1 |
20 Months |
2000 |
Luc Gidding |
2020-04-22 |
| An expanded access compassionate use program to assess remestemcel-L in patients with COVID-19 acute respiratory distress syndrome (ARDS) |
Coronavirus disease 19 infection, Respiratory distress syndrome |
remestemcel-L alone |
|
|
Mesoblast Ltd |
|
|
|
|
|
Phase Not Applicable |
Planned |
0 |
|
|
|
2020-04-21 |
| CPAP-Covid: Continuous positive airway pressure in severe Covid-19 pneumonia |
Coronavirus disease 19 infection, Viral pneumonia |
continuous positive airway pressure (CPAP) alone, face mask alone, non-rebreathing mask alone, oxygen alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Academic Medical Center, University of Amsterdam |
Nederlandse Vereniging van Artsen voor Longziekten en Tuberculose |
Netherlands |
2020-04-18 |
2020-07-18 |
CPAP-Covid, NL8521 |
Phase 1 Clinical |
Not yet recruiting |
1 |
3 Months |
13 |
Joost van den Aardweg |
2020-04-22 |
| Effect of Arbidol in treatment of COVID-19 |
Coronavirus disease 19 infection |
arbidol plus hydroxychloroquine |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Iran University of Medical Sciences |
|
Iran |
2020-04-29 |
|
IR.IUMS.REC.1399.090, IRCT20180725040596N2 |
Phase 3 Clinical |
Not yet recruiting |
1 |
|
100 |
Dr Abbas Motevalian, Dr. Marzieh Nojomi, Dr. Mitra ranjbar, ِDr. Mitra Ranjbar |
2020-04-22 |
| SOS COVID: SARS-CoV-2 Observational Study |
Coronavirus disease 19 infection, Respiratory tract infection |
|
|
Infants (6-23 months), Preschool Children (2-5 yrs), Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Universitair Medisch Centrum Utrecht |
European Commission |
Netherlands, Europe |
2020-04-14 |
2022-02-01 |
NL73596.041.20, NL8520, SOS COVID |
Phase Not Applicable |
Not yet recruiting |
1 |
21 Months |
600 |
Alike van der Velden |
2020-04-23 |
| Comparison between the efficacy of intravenous immunoglobulin and convalescent plasma in COVID-19 |
Coronavirus disease 19 infection |
common national protocol alone, convalescent plasma alone, immunoglobulin alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) |
Birjand University of Medical Sciences |
|
Iran |
2020-04-18 |
|
IR.BUMS.REC.1399.008, IRCT20200413047056N1 |
Phase 3 Clinical |
Recruiting |
1 |
|
15 |
Malihe Zangoue, Mohammad Fereidouni, Tooba Kazemi |
2020-04-22 |
| Assessment the Activity Value of Retinoic Acid in the Treatment of COVID-19 (Isotretinoin) |
Coronavirus disease 19 infection |
standard therapy alone, Variable regimens including ascorbic acid , azithromycin , cis-retinoic acid , clarithromycin , cyanocobalamin , hydroxychloroquine , lopinavir , oseltamivir , paracetamol , ritonavir |
Cytochrome P450 3A4 inhibitor, Exo-alpha sialidase inhibitor, HIV protease inhibitor, HIV-1 protease inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Kafrelsheikh University |
|
Egypt |
2020-04-30 |
2020-06-30 |
, PROPOSED BY MAHMOUD ELKAZZAZ, NCT04353180 |
Phase 3 Clinical |
Recruiting |
1 |
2 Months |
45 |
Dr.Tamer Hydara, Doctor of internal medicine, Mahmoud Ramadan mohamed Elkazzaz |
2020-04-24 |
| Convalescent Plasma in ICU Patients With COVID-19-induced Respiratory Failure |
Coronavirus disease 19 infection, Respiratory failure, Viral pneumonia |
anti-SARS-CoV-2 convalescent plasma alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Cedars-Sinai Medical Center |
Johns Hopkins University, University of Pittsburgh Medical Center |
US |
2020-05-31 |
2021-05-31 |
ACUTE CARE CP CONSORTIUM TRIAL, NCT04353206 |
Phase 0 Clinical |
Not yet recruiting |
0 |
12 Months |
90 |
Akil Merchant, MD, Anders Berg, MD PhD, Catherine Le, MD, David Hager, MD PhD, David N Hager, MD PhD, Daving NG, MD, Ellen Klapper, MD, Eric Vail, MD, Jenny Van Eyk, PhD, Jillian Oft, MD, John F McDyer, MD, John McDyer, MD, Justin Darrah, MD, Noah Merin, MD PhD, Peter Chen, MD, Philip Cheng, MD, Rachel Zabner, MD |
2020-04-22 |
| A Phase II trial to evaluate the efficacy of Ryanodex in patients infected with SARS-CoV-2 |
Coronavirus disease 19 infection |
dantrolene sodium (heat stroke/malignant hyperthermia), Eagle Pharmaceuticals alone |
Calcium channel modulator |
|
Eagle Pharmaceuticals Inc |
Hackensack University Medical Center |
|
|
|
|
Phase 2 Clinical |
Planned |
0 |
|
|
|
2020-04-21 |
| PostCOVID19: Study of Biomarkers in the Long-term Impact of Coronavirus Infection in the Cardiorespiratory System |
Coronavirus disease 19 infection, Heart disease, Respiratory disease, Viral pneumonia |
azithromycin plus hydroxychloroquine |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo |
|
Brazil |
2020-06-01 |
2021-09-30 |
NCT04353245, PostCOVID19, UAP107 |
Phase Not Applicable |
Not yet recruiting |
1 |
16 Months |
130 |
Carlos Vicente Serrano |
2020-04-22 |
| Investigate the Aerosol Particle Distribution During Aerosol Generating Procedures |
Coronavirus disease 19 infection |
High-flow nasal cannula alone, Surgical mask alone, bronchoscopy examination alone, intubation alone, nebulization alone, tracheostomy alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Rush University Medical Center |
|
US |
2020-04-20 |
2020-05-30 |
COVID19-AEROSOL, NCT04353531 |
Phase Not Applicable |
Not yet recruiting |
0 |
1 Month |
40 |
Jie Li, PhD |
2020-04-22 |
| Renal Outcome in Patients With COVID-19 |
Coronavirus disease 19 infection, End stage renal disease, Renal injury |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University of Giessen |
|
Germany |
2020-04-30 |
2020-07-31 |
AZ 58/20, NCT04353583 |
Phase Not Applicable |
Not yet recruiting |
1 |
3 Months |
40 |
Faeq Husain-Syed, MD, Horst-Walter Birk, MD, Werner Seeger, MD |
2020-04-25 |
| Stopping ACE-inhibitors in COVID-19 |
Coronavirus disease 19 infection |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Medizinische Universität Innsbruck |
Ludwig-Maximilians University of Munich |
Austria, Germany |
2020-04-15 |
2022-05-15 |
2020-001206-35, ACEI-COVID, NCT04353596 |
Phase 4 Clinical |
Not yet recruiting |
18 |
25 Months |
208 |
Andreas Knez, MD, August Zabernigg, MD, Axel Bauer, MD, Clemens Wendnter, Dominik Wolf, MD, Florian Straube, MD, Gert Mayer, MD, Graziadei Ivo, MD, Hannes Alber, MD, Hannes Gänzer, MD, Herbert Tilg, MD, Heribert Schunkert, MD, Julia Mayerle, MD, Konstantinos Rizas, MD, Lorenz Bott-Flügerl, MD, Martin Reincke, Mathias Pauschinger, MD, Michael Bergwelt von, MD, Michael Joannidis, MD, Michael Schreinlechner, MD, Nikolay Vdovin, MD, Norbert Kaiser, MD, Peter Trenkwalder, MD, Steffen Massberg, MD, Ulrich Kreider-Stempfle, MD, Wöll Ewald, MD |
2020-04-22 |
| covid19 fai2r: Covid-19 in Patients With Chronic Inflammatory Rheumatism, Auto-immune or Auto-inflammatory Rare and Non-rare Diseases |
Autoinflammatory disease, Coronavirus disease 19 infection, Inflammatory disease, Rare immune disease |
|
|
|
Centre Hospitalier Regional Universitaire de Lille |
FAI²R (Auto-immune and auto-inflammatory rare diseases French network) |
France |
2020-04-30 |
2020-12-31 |
NCT04353609, NI_2020_03, covid19 fai2r |
Phase Not Applicable |
Not yet recruiting |
1 |
8 Months |
13770 |
Eric Hachulla, MD,PhD, Samira Plassart |
2020-04-22 |
| Modulation of Hyperinflammation in COVID-19 |
Coronavirus disease 19 infection, Respiratory distress syndrome |
leucocyte modulatory device (L-MOD) alone, slow low-efficiency daily dialysis alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Lawson Health Research Institute |
|
UK |
2020-04-20 |
2021-01-01 |
115785, NCT04353674 |
Phase 1 Clinical |
Not yet recruiting |
1 |
8 Months |
40 |
Christopher W McIntyre, MD, Sandrine Lemoine, MD |
2020-04-23 |
| THICK: Trial of Hydroxychloroquine In Covid-19 Kinetics |
Coronavirus disease 19 infection |
hydroxychloroquine alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University of South Alabama |
|
US |
2020-04-17 |
2020-12-01 |
NCT04353271, THICK, [1582736-1] |
Phase 2/Phase 3 Clinical |
Recruiting |
0 |
7 Months |
58 |
Kate Ledbetter, RN, Wendy Blount, RN, MSN, William O Richards, MD |
2020-04-23 |
| Camostat Mesylate in COVID-19 Outpatients |
Coronavirus disease 19 infection |
camostat mesylate alone |
Serine protease inhibitor, Trypsin inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Yale University |
|
US |
2020-04-30 |
2021-05-31 |
2000027971, NCT04353284 |
Phase 2a Clinical |
Not yet recruiting |
0 |
13 Months |
114 |
Joseph Vinetz, M.D. |
2020-04-22 |
| A phase II, Randomized, Placebo-controlled trial of Vicromax for the treatment of COVID-19 |
Coronavirus disease 19 infection |
merimepodib alone |
Inosine monophosphate dehydrogenase inhibitor |
|
Biosig Technologies Inc |
|
US |
|
|
|
Phase 2 Clinical |
Planned |
0 |
|
|
Andrew D. Badley |
2020-04-23 |
| CoSigS: COVID 19-Caregivers IGg Seroconversion |
Coronavirus disease 19 infection |
Blood sampling alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University Hospital, Limoges |
|
France |
2020-04-25 |
2020-12-25 |
87RI20_0016/COSIGS, CoSigS, NCT04353323 |
Phase Not Applicable |
Not yet recruiting |
1 |
8 Months |
130 |
Laurent FOURCADE, MD, Laurent Fourcade, MD, laurent.fourcade@unilim.fr |
2020-04-22 |
| Efficacy of Chloroquine in COVID-19 Treatment |
Coronavirus disease 19 infection |
chloroquine alone |
|
|
Tanta University |
|
Egypt |
2020-04-17 |
2030-12-01 |
CHLOROQUINE COVID, NCT04353336 |
Phase 2/Phase 3 Clinical |
Not yet recruiting |
1 |
127 Months |
40 |
Sherief Abd-Elsalam, ass. prof., sherief Abd-Elsalam, Ass. Prof. |
2020-04-22 |
| CALYPSO: WGS Analysis Of SARS-COV-2 Positive Patients |
Coronavirus disease 19 infection |
whole genome sequencing alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Vanda Pharmaceuticals Inc |
Washington University School of Medicine, US |
US |
2020-04-30 |
2020-12-31 |
CALYPSO, NCT04353401, VP-01-01 CALYPSO |
Phase Not Applicable |
Recruiting |
0 |
8 Months |
5000 |
|
2020-04-23 |
| Clinical Trial to Evaluate Mycobacterium w in Preventing COVID-19 in Subjects at Risk of Getting Infected With COVID-19 |
Coronavirus disease 19 infection |
Mycobacterium w alone |
Interferon gamma receptor agonist, MAPK gene modulator, TLR-2 agonist, TLR-4 agonist, TLR-9 agonist |
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Cadila Pharmaceuticals Ltd |
Council of Scientific and Industrial Research (India) |
|
2020-04-30 |
2021-05-30 |
CRSC20005, NCT04353518 |
Phase 3 Clinical |
Not yet recruiting |
0 |
13 Months |
4000 |
Anil Avhad, MBBS, Sanjay Patel, MBBS |
2020-04-23 |
| Retrospective Study on surgical outcomes among surgical patients during the COVID-19 (SARS-CoV-2) Pandemic |
Coronavirus disease 19 infection |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Hopital Tenon |
|
France |
2020-04-22 |
|
ACTRN12620000498998 |
Phase Not Applicable |
Not yet recruiting |
1 |
|
700 |
Dr Julien BUREY, Prof Christophe QUESNEL |
2020-04-22 |
| COVIDCONVERT: Study evaluating Coronavirus (COVID-19) nasal/oral swab results compared to blood antibody results in COVID-19 clinic patients |
Coronavirus disease 19 infection |
analysis of SARS-CoV-2 IgG, IgA and IgM antibody serum sample alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Albury Wodonga Health, Border Medical Oncology |
|
Australia |
2020-04-07 |
|
ACTRN12620000487910, COVIDCONVERT |
Phase Not Applicable |
Recruiting |
2 |
|
500 |
Dr Justin Jackson, Mrs Jacqui McBurnie |
2020-04-22 |
| A Facebook delivered physical activity focused group lifestyle intervention for older adults during the COVID-19 pandemic |
Coronavirus disease 19 infection |
facebook delivered physical activity focused group lifestyle intervention alone |
|
Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University of New South Wales |
|
Australia |
2020-05-21 |
|
ACTRN12620000492954p |
Phase Not Applicable |
Not yet recruiting |
8 |
|
20 |
A/Prof Simon Rosenbaum, Miss Grace McKeon |
2020-04-21 |
| COVIDCONVERT: Study evaluating Front-line health care workers serial blood COVID-19 antibody results in relation to symptom presentation |
Coronavirus disease 19 infection |
analysis of SARS-CoV-2 IgG, IgA and IgM antibody serum sample alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Albury Wodonga Health, Border Medical Oncology |
|
Australia |
2020-04-07 |
|
ACTRN12620000493943, COVIDCONVERT |
Phase Not Applicable |
Recruiting |
2 |
|
50 |
Dr Justin Jackson, Mrs Jacqui McBurnie |
2020-04-22 |
| COVIDSurgRCT-v1.0-20200330: Preventing Pulmonary Complications in Surgical Patients at Risk of COVID-19 |
Coronavirus disease 19 infection |
Plaquenil plus lopinavir + ritonavir |
HIV protease inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
The University of Birmingham |
|
UK |
2020-04-15 |
|
2020-001448-24, COVIDSurgRCT-v1.0-20200330, RG-20-029COVID-19 |
Phase 3 Clinical |
Recruiting |
1 |
|
6400 |
Donna Smith |
2020-04-22 |
| COVID65plus: Test and Treat COVID65plus |
Coronavirus disease 19 infection, Respiratory tract infection |
hydroxychloroquine alone |
|
Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University Hospital Tubingen |
|
Germany |
2020-05-01 |
2021-05-01 |
COVID65PLUS, COVID65plus, NCT04351516 |
Phase 2/Phase 3 Clinical |
Not yet recruiting |
2 |
12 Months |
350 |
Lukas Perkhofer, MD, Manola Zago, PhD, Michael Bitzer, MD, Siri Göpel, MD, Thomas Seufferlein, MD |
2020-04-24 |
| ReCovER: Registry for Clinical Presentation and Management of Patients With COVID-19 in the Emergency Room |
Coronavirus disease 19 infection |
|
|
|
University of Cologne |
|
Germany |
2020-04-20 |
2026-08-31 |
NCT04351854, RECOVER, ReCovER |
Phase Not Applicable |
Not yet recruiting |
1 |
76 Months |
500 |
Victor Suarez, MD, Volker Burst, Volker Burst, MD |
2020-04-23 |
| PRECISE: Prophylaxis of Exposed COVID-19 Individuals With Mild Symptoms Using Choloroquine Compounds |
Coronavirus disease 19 infection |
hydroxychloroquine sulfate alone, standard of care alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) |
Specialized Healthcare and Medical Education Department |
Beth Israel Deaconess Medical Center, Mayo Hospital, Pakistan Kidney and Liver Institute, Services Hospital, Lahore |
US |
2020-04-15 |
2020-05-30 |
NBC-COVID1902, NCT04351191, PRECISE |
Phase 4 Clinical |
Not yet recruiting |
0 |
1 Month |
400 |
Ammar Sarwar |
2020-04-20 |
| ACTICOV-2: Immunological Profiling of Patients With COVID-19 in Respiratory Distress |
Coronavirus disease 19 infection, Respiratory distress syndrome |
immunological profiling alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Centre Hospitalier Universitaire de Nimes |
Institute of Human Genetics |
France |
2020-04-30 |
2020-10-31 |
ACTICOV-2, NCT04351711, NIMAO/2020-01/PC-01 |
Phase Not Applicable |
Not yet recruiting |
1 |
6 Months |
60 |
Albert Sotto, Anissa Megzari, Jean-Yves Lefrant, Laurent Muller, Monsef Benkirane, Pierre Corbeau, Tu Anh Tran |
2020-04-21 |
| DARTS: Diagnostics of COVID-19/DARTS (Development and Assessment of Rapid Testing for SARS-CoV-2 Outbreak) |
Coronavirus disease 19 infection |
ELISA assay alone, RT-PCR alone, lateral flow assay alone, point-of-care test alone, point-of-need test alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
St Georges University of London |
|
UK |
2020-04-15 |
2022-04-15 |
2020.0075, DARTS, NCT04351646 |
Phase Not Applicable |
Not yet recruiting |
1 |
24 Months |
500 |
Timothy D Planche, Dr. |
2020-04-21 |
| OsPsyCOVID: Psychological Impact of Quarantine in Osteoporosis Patient During COVID-19 Outbreak |
Coronavirus disease 19 infection, Osteoporosis |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Centre Hospitalier Regional Universitaire de Lille |
|
France |
2020-04-30 |
2020-12-31 |
2020-A00911-38, EQ_2020_03, NCT04351633, OsPsyCOVID |
Phase Not Applicable |
Not yet recruiting |
1 |
8 Months |
50 |
Bernard Cortet, MD,PhD |
2020-04-24 |
| Professional and Ethical Challenges of Social Media Usage in Providing Healthcare Services During the Period of 19 Covid Pandemics |
Coronavirus disease 19 infection |
social media usage alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) |
Assiut University |
|
Egypt |
2020-04-30 |
2020-08-31 |
2020A20, NCT04351568 |
Phase Not Applicable |
Not yet recruiting |
1 |
4 Months |
874 |
Noha Esmael Ebrahem |
2020-04-20 |
| Phase III Study to Evaluate Efficacy and Safety of Lenzilumab in Hospitalized Patients With COVID-19 Pneumonia |
Coronavirus disease 19 infection, Respiratory failure, Viral pneumonia |
lenzilumab alone, standard of care alone |
GM-CSF ligand inhibitor, Immunoglobulin G1 modulator, Immunoglobulin kappa modulator |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Humanigen Inc |
|
|
2020-05-31 |
2020-09-30 |
HGEN003-06, NCT04351152 |
Phase 3 Clinical |
Not yet recruiting |
0 |
4 Months |
238 |
CTI Clinical Trial & Consulting Services (CRO), Cameron Durrant, MD, Omar Ahmed, PharmD |
2020-04-20 |
| A phase I/II clinical trial to examine an oral solution of nafamostat in preventing or reducing the lethal outcome of COVID-19 infection |
Coronavirus disease 19 infection |
nafamostat mesylate (oral/MPAR/abuse-resistant/repurposed, COVID-19), Ensysce Biosciences alone |
Serine protease inhibitor |
|
Ensysce Biosciences Inc |
|
US |
|
|
|
Phase 1/Phase 2 Clinical |
Planned |
0 |
|
|
|
2020-04-21 |
| ReCOVery-SIRIO: Amiodarone or Verapamil in COVID-19 Hospitalized Patients With Symptoms |
Coronavirus disease 19 infection |
amiodarone alone, verapamil alone |
Calcium channel inhibitor, Potassium channel inhibitor, Sodium channel inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Nicolaus Copernicus University |
|
Poland |
2020-04-27 |
2021-04-10 |
NCT04351763, NCU-COVID19, ReCOVery-SIRIO |
Phase 2/Phase 3 Clinical |
Recruiting |
1 |
11 Months |
804 |
Eliano Pio Navarese, Jacek Kubica, MD, PhD, Prof. Eliano P Navarese, MD, PhD, Prof. Jacek Kubica, MD, PhD |
2020-04-20 |
| Efficacy of Favipiravir in COVID-19 Treatment |
Coronavirus disease 19 infection |
favipiravir alone |
RNA polymerase inhibitor |
|
Tanta University |
|
Egypt |
2020-04-17 |
2030-12-01 |
FAVIPREVIR COVID, NCT04351295 |
Phase 2/Phase 3 Clinical |
Not yet recruiting |
1 |
127 Months |
40 |
Sherief Abd-Elsalam, ass. prof., sherief Abd-Elsalam, Ass. Prof. |
2020-04-22 |
| Multicenter, prospective, cohort study evaluating outcome of COVID-19 in patients with hepatobiliary-pancreatic disease |
Cholangiocarcinoma, Coronavirus disease 19 infection, Hepatobiliary disease, Liver cirrhosis, Liver disease, Liver tumor, Pancreas disease, Pancreas tumor |
|
|
|
School of Medicine, Keio University |
|
Japan |
2020-04-17 |
|
UMIN000040185 |
Phase Not Applicable |
Recruiting |
1 |
|
600 |
Nobuhiro Nakamoto, Nobuhito Taniki |
2020-04-22 |
| A case-series study to assess the effect of Intravenous Immunoglobulin in treating COVID-19 infection |
Coronavirus disease 19 infection |
intravenous immunoglobulin alone |
|
|
Wuhan Jinyintan Hospital |
|
China |
|
|
|
Phase Not Applicable |
Status not specified |
1 |
|
3 |
|
2020-04-22 |
| COVERAGE: Treatments to Decrease the Risk of Hospitalization or Death in Elderly Outpatients With Symptomatic SARS-CoV-2 Infection (COVID-19) |
Coronavirus disease 19 infection |
favipiravir alone, home treatment alone, hydroxychloroquine alone, imatinib alone, telmisartan alone |
Abl tyrosine kinase inhibitor, Angiotensin II receptor antagonist, Bcr protein inhibitor, Kit tyrosine kinase inhibitor, PDGF receptor antagonist, RNA polymerase inhibitor, Signal transduction inhibitor |
Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University Hospital, Bordeaux |
Universite de Bordeaux |
France |
2020-04-15 |
2020-08-15 |
2020-001435-27, CHUBX 2020/12, COVERAGE, NCT04356495 |
Phase 3 Clinical |
Not yet recruiting |
2 |
4 Months |
1057 |
Denis MALVY, Pr, Laura RICHERT, Dr, Xavier ANGLARET, Dr |
2020-04-23 |
| A case-study to assess the effect of Intravenous Immunoglobulin (IVIG) for the treament of COVID-19 infection |
Coronavirus disease 19 infection |
Intravenous Immunoglobulin alone |
|
|
Sharp Memorial Hospital |
|
US |
|
|
|
Phase Not Applicable |
Status not specified |
0 |
|
1 |
George Sakoulas, M.D |
2020-04-23 |
| CounterCovid: Countering Lung Damage in COVID-19 infection |
Coronavirus disease 19 infection |
imatinib alone |
Abl tyrosine kinase inhibitor, Bcr protein inhibitor, Kit tyrosine kinase inhibitor, PDGF receptor antagonist, Signal transduction inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Amsterdam UMC |
|
Netherlands |
2020-03-31 |
|
2020-001236-10, COVID-19, CounterCovid |
Phase 2 Clinical |
No longer recruiting |
1 |
|
304 |
Jurjan Aman |
2020-04-23 |
| Double Therapy With IFN-beta 1b and Hydroxychloroquine |
Coronavirus disease 19 infection |
standard care alone, hydroxychloroquine plus interferon beta-1b |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
The University of Hong Kong |
|
Hong Kong |
2020-04-09 |
2022-07-31 |
NCT04350281, UW 20-211 |
Phase 2 Clinical |
Recruiting |
1 |
27 Months |
80 |
Ivan FN Hung, MD FRCP, Kelvin KW To, MD FRCPath, Kelvin To, MD MRCP |
2020-04-21 |
| An Investigator-initiated, Randomized, Open-Label Study of Standard of Care Plus Intravenous Immunoglobulin (IVIG) Compared to Standard of Care Alone in the Treatment of COVID-19 Infection |
Coronavirus disease 19 infection |
intravenous immunoglobulin alone, standard of care alone |
|
|
Sharp Memorial Hospital |
Octapharma AG |
US |
|
|
|
Phase Not Applicable |
Status not specified |
0 |
|
20 |
George Sakoulas, M.D. |
2020-04-22 |
| Novel coronavirus pneumonia (COVID-19) Intelligent Assistant Analysis System:A Multicenter Clinical Research |
Coronavirus disease 19 infection, Viral pneumonia |
COVID-19 Intelligent Assistant Analysis System alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Union Hospital Tongji Medical School Huazhong University Of Science & Technology |
|
China |
2020-05-01 |
2022-04-30 |
ChiCTR2000032010 |
Phase Not Applicable |
Not yet recruiting |
1 |
24 Months |
|
Fan Yang, Wenliang Fan |
2020-04-22 |
| Clinical characteristics and risk factors of novel coronavirus pneumonia (COVID-19) patients with chronic liver disease |
Coronavirus disease 19 infection, Liver disease, Viral pneumonia |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Renji Hospital |
|
China |
2020-04-17 |
2020-04-23 |
ChiCTR2000032009 |
Phase Not Applicable |
Not yet recruiting |
1 |
|
30 |
Xiao Xiao, Xiong Ma |
2020-04-22 |
| Application of BCG Vaccine for Immune-prophylaxis Among Egyptian Healthcare Workers During the Pandemic of COVID-19 |
Coronavirus disease 19 infection |
Copenhagen Bacillus Calmette-Guerin vaccine alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Ain Shams University |
|
Egypt |
2020-04-20 |
2020-12-01 |
FMASU P19A/ 2020, NCT04350931 |
Phase 3 Clinical |
Not yet recruiting |
2 |
7 Months |
900 |
Adel Khattab, Fatma Soliman E Ebeid, Fatma Soliman E Ebeid, MD, Iman Hassan, MD |
2020-04-23 |
| Efficacy and Safety of Hyperbaric Oxygen Therapy to patients with novel coronavirus pneumonia (COVID-19) |
Coronavirus disease 19 infection, Hypoxia, Viral pneumonia |
hyperbaric oxygen therapy alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Navy General Hospital, Wuhan Huoshenshan Hospital |
|
China |
2020-04-17 |
2020-05-17 |
ChiCTR2000032011 |
Phase 0 Clinical |
Not yet recruiting |
1 |
1 Month |
45 |
Dazhi Guo, Shuyi Pan |
2020-04-22 |
| Description of Respiratory Mechanics in Patients With SARS-CoV-2 Associated ARDS |
Coronavirus disease 19 infection, Respiratory distress syndrome, Viral pneumonia |
deep sedation therapy alone, neuromuscular blocker therapy alone, tidal volume therapy alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University Hospital, Angers |
|
France |
2020-03-18 |
2020-12-31 |
2030/31, NCT04350710 |
Phase Not Applicable |
Recruiting |
1 |
9 Months |
50 |
Francois BELONCLE, MCU-PH, François BELONCLE, MCU PH |
2020-04-21 |
| DARE-19: Dapagliflozin in Respiratory Failure in Patients With COVID-19 |
Coronavirus disease 19 infection, Respiratory failure |
dapagliflozin propanediol alone |
Sodium glucose transporter-2 inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Saint Luke's Health System |
AstraZeneca plc, George Clinical Pty Ltd |
US |
2020-04-15 |
2020-12-31 |
D1690C00081, DARE-19, ESR-20-20653, NCT04350593 |
Phase 3 Clinical |
Recruiting |
0 |
8 Months |
900 |
Mikhail Kosiborod, MD, Sheryl Windsor, Study Coordinator |
2020-04-21 |
| COR-DLUS: Coronavirus (COVID-19) Diagnostic Lung Ultrasound Study |
Coronavirus disease 19 infection, Lung disease |
PCR testing alone, blood tests alone, chest x-ray alone, lung ultrasound alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University Hospital Plymouth NHS Trust |
|
UK |
2020-04-20 |
2021-01-20 |
282661, COR-DLUS, NCT04351802 |
Phase Not Applicable |
Not yet recruiting |
1 |
9 Months |
180 |
John P Corcoran, BMBCh MRCP, UHPNT Research & Development Office |
2020-04-21 |
| IB1aIC: Interferon Beta-1a in Hospitalized COVID-19 Patients |
Coronavirus disease 19 infection |
Variable regimens including hydroxychloroquine , interferon beta-1a , lopinavir + ritonavir |
HIV protease inhibitor |
Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Shaheed Beheshti Medical University |
|
Iran |
2020-04-15 |
2020-04-24 |
IB1aIC, INTERFERON BETA 1A IN COVID-19, NCT04350671 |
Phase 4 Clinical |
Recruiting |
1 |
|
40 |
Ilad Alavi Darazam, MD, Minoosh Shabani, MD, Mohammadreza Haji Esmaelie, MD, Seyed Sina Naghibi Irvani, MD, MPH, MBA, Shervin Shokouhi, MD |
2020-04-21 |
| UAIIC: Umifenovir in Hospitalized COVID-19 Patients |
Coronavirus disease 19 infection |
standards of care alone, Variable regimens including hydroxychloroquine , interferon-beta 1a , lopinavir + ritonavir , umifenovir |
HIV protease inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Shaheed Beheshti Medical University |
|
Iran |
2020-04-15 |
2020-04-24 |
NCT04350684, UAIIC, UMIFENOVIR IN COVID-19 |
Phase 4 Clinical |
Recruiting |
1 |
|
40 |
Ilad Alavi Darazam, MD, Latif Gachkar, MD, Mahdi Amirdosara, MD, Masoud Mardani, MD, Minoosh Shabani, MD, Mohammadreza Haji Esmaelie, MD, Seyed Sina Naghibi Irvani, MD, MPH, MBA, Shervin Shokouhi, MD |
2020-04-21 |
| COVID-GYN: Impact of the COVID-19 Pandemic in Gynecological Oncology |
Breast tumor, Coronavirus disease 19 infection, Ovary tumor, Uterine cervix tumor, Uterus tumor, Vaginal cancer, Vulva disease |
modification of planned therapeutic management alone |
|
Female, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Hospices Civils De Lyon |
|
France |
2020-04-30 |
2020-05-31 |
2020-A01036-33, 69HCL20_0346, COVID-GYN, NCT04351139 |
Phase Not Applicable |
Not yet recruiting |
3 |
1 Month |
400 |
François Golfier, MD, Gil Dubernard, MD, Géry LAMBLIN, Géry LAMBLIN, MD, Marion Cortet, MD |
2020-04-23 |
| Clinical Study to assess positive value of blood plasma from donors having built immunity against the new corona virus (SARS-CoV-2) transfused to patients suffering from SARS-CoV-2 infection |
Coronavirus disease 19 infection |
convalescent plasma alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
DRK-Blutspendedienst Baden-Wurttemberg-Hessen GmbH |
German Ministry of Health |
Germany |
2020-04-06 |
|
2020-001310-38 |
Phase 2 Clinical |
Recruiting |
1 |
|
|
Sixten Körper |
2020-04-21 |
| Low-flow Extracorporeal Carbon Dioxide Removal in COVID-19-associated Acute Respiratory Distress Syndrome |
Coronavirus disease 19 infection, Renal injury, Respiratory distress syndrome |
extracorporeal CO2 removal (ECCO2R) therapy alone, multiFiltrate device alone, renal replacement therapy (RRT) alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University of Giessen |
|
Germany |
2020-04-30 |
2020-05-31 |
AZ 63/20, NCT04351906 |
Phase Not Applicable |
Not yet recruiting |
1 |
1 Month |
20 |
Faeq Husain-Syed, MD, Istvan Vasasz, MD, Werner Seeger, MD |
2020-04-21 |
| The effects of the COVID-19 pandemic on mental health |
Acute stress disorder, Coronavirus disease 19 infection, Psychiatric disorder |
interview alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Klinikum der Albert-Ludwigs Universitaet Freiburg |
|
Germany |
2020-04-20 |
|
174/20, DRKS00021395 |
Phase Not Applicable |
Not yet recruiting |
1 |
|
60 |
Prisca Bauer |
2020-04-21 |
| PRPsyCOVID: Psychological Impact of Quarantine in Rheumatoid Arthritis Patient During COVID-19 Outbreak |
Coronavirus disease 19 infection, Rheumatoid arthritis |
questionnaire assesment alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Centre Hospitalier Regional Universitaire de Lille |
|
France |
2020-04-30 |
2020-12-31 |
2020-A00907-32, EQ_2020_01, NCT04351399, PRPsyCOVID |
Phase Not Applicable |
Not yet recruiting |
1 |
8 Months |
100 |
René-Marc FLIPO, MD,PhD |
2020-04-22 |
| Hydroxychloroquine Treatment of Healthcare Workers With COVID19 Illness at Montefiore |
Coronavirus disease 19 infection |
hydroxychloroquine alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Montefiore Medical Center |
|
US |
2020-04-30 |
2020-08-31 |
2020-11445, NCT04350450 |
Phase 2 Clinical |
Not yet recruiting |
0 |
4 Months |
100 |
Priya Nori, MD, Yi Guo, PharmD |
2020-04-22 |
| PROLIFIC Trial (COVID-19): Preventative Drug Treatment For COVID-19 Infectious Disease |
Coronavirus disease 19 infection |
hydroxychloroquine alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Cambridge University Hospitals NHS Foundation Trust |
Evolution Education Trust |
UK |
2020-04-14 |
|
2020-001331-26, NCT00000000, PROLIFIC Trial (COVID-19), PROLIFIC2020 |
Phase 3 Clinical |
Recruiting |
1 |
|
1000 |
Carrie Bayliss |
2020-04-21 |
| COL-COVID: Randomized, Open-blind, Controlled Trial to Study the Benefit of Colchicine in Patients With COVID-19 |
Coronavirus disease 19 infection |
colchicine alone, standard therapy alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Fundación Para La Formación E Investigación Sanitarias De La Región De Murcia (Ffis) |
|
Spain |
2020-04-20 |
2020-11-20 |
COL-COVID, IMIB-COLVID-2020-03, NCT04350320 |
Phase 3 Clinical |
Not yet recruiting |
1 |
7 Months |
102 |
Domingo A Pascual Figal, MD, Elisa García Vazquez |
2020-04-21 |
| The Efficacy of Ivermectin and Nitazoxanide in COVID-19 Treatment |
Coronavirus disease 19 infection |
chloroquine alone, Variable regimens including chloroquine , ivermectin , nitazoxanide |
Chloride channel modulator |
|
Tanta University |
|
Egypt |
2020-04-17 |
2030-12-01 |
IVERMECIN COVID, NCT04351347 |
Phase 2/Phase 3 Clinical |
Not yet recruiting |
1 |
127 Months |
60 |
Sherief Abd-Elsalam, ass. prof., sherief Abd-Elsalam, Ass. Prof. |
2020-04-21 |
| ZnD3-Cov-Vici: Impact of Zinc and Vitamin D3 Supplementation on the Survival of Aged Patients Infected With COVID-19 |
Coronavirus disease 19 infection, Respiratory distress syndrome |
25-OH cholecalciferol plus zinc gluconate |
|
Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Centre Hospitalier Regional Universitaire de Lille |
|
France |
2020-04-30 |
2020-07-31 |
2020-A00873-36, 2020_30, NCT04351490, ZnD3-Cov-Vici |
Phase Not Applicable |
Not yet recruiting |
1 |
3 Months |
3140 |
David SEGUY, MD,PhD |
2020-04-22 |
| The effect of MCT Oil on COVID-19 |
Coronavirus disease 19 infection |
advice base on traditional medicine instructions alone, medium-chain triglyceride therapy alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Kerman University of Medical Sciences |
|
Iran |
2020-04-02 |
|
IR.KMU.REC.1399.019, IRCT20160313027033N2 |
Phase Not Applicable |
Recruiting |
1 |
|
120 |
Alireza Zahedi Neyestani, Mahdiyehsadat Eftekharafzali, Mohammad Setayesh |
2020-04-23 |
| ACOVACT: Austrian Coronavirus Adaptive Clinical Trial |
Coronavirus disease 19 infection |
candesartan alone, chloroquine alone, clazakizumab alone, lopinavir + ritonavir alone, rivaroxaban alone, chloroquine plus hydroxychloroquine |
Angiotensin II receptor antagonist, Factor Xa antagonist, HIV protease inhibitor, IL-6 receptor antagonist |
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Medical University of Vienna |
Donauspital, Hospital Hietzing Hanuschkrankenhaus, Kaiser Franz Josef Spital, Medizinische Universität Innsbruck, Otto Wagner Hospital, Wilhelminenspital Vienna |
Austria |
2020-04-16 |
2020-12-31 |
ACOVACT, ACOVACT, NCT04351724 |
Phase 2/Phase 3 Clinical |
Recruiting |
6 |
8 Months |
500 |
Alexander Zoufaly, MD, Bernd Jilma, MD, Brigitte Schmied, MD, Christian Schörgenhofer, MD, PHD, Georg-Christian Funk, MD, Günter Weiss, MD, Kurt Redlich, MD, Thomas Stefenelli, MD |
2020-04-21 |
| A trial to evaluate XAV-19 for the treatment of patients with COVID-19 infection |
Coronavirus disease 19 infection |
XAV-19 alone |
|
|
Xenothera |
|
|
|
|
|
Phase Not Applicable |
Planned |
0 |
|
|
|
2020-04-20 |
| ICAR: IgIV in COVID-19 Related ARDS |
Coronavirus disease 19 infection, Respiratory distress syndrome |
Clairyg alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) |
Centre Hospitalier Sainte Anne |
IFSI Virginia Olivier Sainte-Anne Hospital, LFB SA, Ministry of Social Affairs and Health, France |
France |
2020-04-30 |
2020-08-31 |
2020-001570-30, D20-P013, ICAR, NCT04350580 |
Phase 3 Clinical |
Not yet recruiting |
1 |
4 Months |
138 |
AWASSI, Aurélien Mazeraud, MD, PHD, Tarek Sharshar, MD, PHD |
2020-04-21 |
| Chloroquine and hydroxychloroquine for treatment of COVID-19: systematic review of randomized and non-randomized, controlled trial |
Coronavirus disease 19 infection |
Variable regimens including azithromycin , chloroquine , hydroxychloroquine |
|
|
Yokohama City University |
|
Japan, North America |
2020-04-17 |
|
UMIN000040188 |
Phase Not Applicable |
Not yet recruiting |
1 |
|
|
Nobuyuki Horita |
2020-04-21 |
| A Phase III trial of mRNA-1273 for Coronavirus disease 19 infection |
Coronavirus disease 19 infection |
mRNA-1273 alone |
Moesin modulator |
|
ModeRNA Therapeutics |
|
|
|
|
|
Phase 3 Clinical |
Planned |
0 |
|
|
|
2020-04-20 |
| COVID+PA: Assessment of Efficacy and Safety of HCQ and Antibiotics Administrated to Patients COVID-19(+) |
Coronavirus disease 19 infection |
azithromycin plus hydroxychloroquine |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Abderrahmane Mami Hospital |
Dacima Consulting, Eshmoun Clinical Research Centre |
Tunisia |
2020-04-15 |
2020-07-15 |
COVID+PA, ECC2020-04, NCT04351919 |
Phase 4 Clinical |
Not yet recruiting |
1 |
3 Months |
400 |
Chokri Jeribi, Dr, Dr Jalila Ben Khelil, Eshmoun team |
2020-04-22 |
| Austrian COVID-19 Registry |
Coronavirus disease 19 infection |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Arbeitsgemeinschaft Medikamentoese Tumortherapie |
|
Austria |
2020-04-01 |
2021-12-31 |
AGMT_COVID-19, NCT04351529 |
Phase Not Applicable |
Recruiting |
1 |
21 Months |
1000 |
Daniela Wolkersdorfer, Dr., Richard Greil, MD, Stephanie Esmaeilzadeh-Leithner, MSc. |
2020-04-21 |
| Novel Adoptive Cellular Therapy With SARS-CoV-2 Specific T-Cells in Patients With Severe COVID-19 |
Coronavirus disease 19 infection |
SARS-CoV-2 specific T-cells alone, convalescent donor blood donation alone, leukapheresis alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
KK Women's and Children's Hospital |
National University Hospital (Singapore) Pte Ltd, Singapore General Hospital Pte Ltd |
Singapore |
2020-04-30 |
2020-08-31 |
COVID-T 1.0, NCT04351659 |
Phase Not Applicable |
Recruiting |
2 |
4 Months |
8 |
Lip Kun Tan, Michaela Seng, Wing Hang Leung, Yeh Ching Linn |
2020-04-21 |
| BREATHE: A Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19 |
Acute lung injury, Coronavirus disease 19 infection, Respiratory distress syndrome |
gimsilumab alone |
GM-CSF ligand inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Kinevant Sciences GmbH, Roivant Sciences Ltd |
|
US |
2020-04-30 |
2020-10-31 |
BREATHE, KIN-1901-2001, NCT04351243 |
Phase 2 Clinical |
Recruiting |
0 |
6 Months |
270 |
Arnaud Bastien, MD, Dr. Gerard Criner, Mathews, MD, Puja Dubal |
2020-04-22 |
| High-dose Hydroxychloroquine for the Treatment of Ambulatory Patients With Mild COVID-19 |
Asthma, Bronchiectasis, Chronic obstructive pulmonary disease, Coronavirus disease 19 infection, Cough, Cystic fibrosis, Fatigue, Headache, Interstitial lung disease, Lung tumor, Myalgia, Nasal congestion, Pharyngitis, Pulmonary hypertension, Sleep apnea, Upper respiratory tract infection |
hydroxychloroquine alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University of Chicago |
|
US |
2020-04-30 |
2020-06-30 |
IRB20-0572, NCT04351620 |
Phase 1 Clinical |
Recruiting |
0 |
2 Months |
20 |
Iazsmin Ventura, MD, Reem Jan, Reem Jan, MBBS BSc |
2020-04-21 |
| A Systems Approach to Predict the Outcome of SARS-CoV-2 in the Population of a City |
Coronavirus disease 19 infection |
bioolgical sampling alone, whole genome sequencing alone |
|
Healthy volunteers accepted |
University Hospital Basel |
Leonhard Med IT ETH Zurich, Swiss Institute Of Bioinformatics, sciCORE University of Basel |
Switzerland |
2020-04-09 |
2022-04-30 |
2020-00769, QU20EGLI2, NCT04351503 |
Phase Not Applicable |
Recruiting |
6 |
24 Months |
10000 |
Adrian Egli, Prof. Dr. med, Adrian Egli, Prof. Dr. med., Aitana Lebrand, Dr. med., Andreas Buser, Prof. Dr. med, Bram Stieltjes, Dr. med, Diana Ciardo, Dr. med, Hans Hirsch, Prof. Dr. med., Hans Pargger, Prof. Dr. med, Karsten Borgwardt, Prof.Dr. med, Richard Neher, Prof. Dr. med, Roland Bingisser, Prof. Dr. med, Sarah Tschudin- Sutter, Prof. Dr. med., Stefano Bassetti, Prof. Dr. med., Thierry Sengstag, Dr., Valérie Barbié, Dr. med, Valérie Barbié, Dr. med. |
2020-04-21 |
| A medical records based study for the curative effect of combined traditional Chinese and western medicine in the treatment of severe novel coronavirus pneumonia (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
Variable regimens including Ma-Xing-Shi-Gan tang , Yin-Qiao powder , thymosin a1 |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
The Affiliated Hospital of Guangdong Medical College |
Zhanjiang municipal bureau of science and technology |
China |
2020-03-01 |
2020-08-01 |
ChiCTR2000032040, ChiMCTR2000003220 |
Phase Not Applicable |
Recruiting |
1 |
5 Months |
30 |
Huang Jianan, Zhang Yuanli |
2020-04-21 |
| Danggui Shaoyao Powder in the synergistic treatment of novel coronavirus pneumonia (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
Danggui Shaoyao Powder alone, western medicine therapy alone |
|
|
Union Hospital Tongji Medical School Huazhong University Of Science & Technology |
|
China |
2020-01-20 |
2020-07-31 |
ChiCTR2000032098, ChiMCTR2000003225 |
Phase Not Applicable |
Recruiting |
1 |
6 Months |
300 |
Liu yuhan, Yang shenglan |
2020-04-21 |
| The effect of hydroxychloroquine to prevent coronavirus disease |
Coronavirus disease 19 infection |
Quarantine alone, hydroxychloroquine alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Iran University of Medical Sciences |
|
Iran |
2020-04-20 |
|
IR.IUMS.REC.1399.076, IRCT20190122042450N4 |
Phase 3 Clinical |
Recruiting |
1 |
|
1000 |
Dr. Abbas Motavallian, Fereshteh Abdolmaleki, Mohammad Ebrahim Khamseh |
2020-04-21 |
| A retrospective, observational study to assess neurological manifestations of hospitalized patients With COVID-19 in Wuhan, China |
Coronavirus disease 19 infection |
|
|
|
Wuhan Union Hospital, China |
|
China |
|
|
|
Phase Not Applicable |
Status not specified |
1 |
|
214 |
|
2020-04-20 |
| A clinical study to assess itanapraced in the treatment of COVID-19 patients showing evidence of brain infection |
Brain disease, Coronavirus disease 19 infection |
itanapraced alone |
Amyloid protein deposition inhibitor, Gamma-secretase inhibitor |
|
CereSpir Inc |
|
|
|
|
|
Phase Not Applicable |
Planned |
0 |
|
|
|
2020-04-20 |
| An open-label clinical study to assess inhaled nitric oxide (NO) delivered through LungFit system in the treatment of patients with COVID-19 |
Coronavirus disease 19 infection |
LungFit system alone, nitric oxide (inhalant formulation, cystic fibrosis/COVID-19/bronchiolitis/NTM/COPD/pulmonary hypertension), Beyond Air alone |
|
|
Beyond Air Inc |
|
Israel |
|
|
|
Phase Not Applicable |
Planned |
1 |
|
|
|
2020-04-20 |
| An open-label clinical study to assess inhaled nitric oxide (NO) delivered using LungFit system in the treatment of patients with COVID-19 |
Coronavirus disease 19 infection |
LungFit system alone, nitric oxide (inhalant formulation, cystic fibrosis/COVID-19/bronchiolitis/NTM/COPD/pulmonary hypertension), Beyond Air alone |
|
|
Beyond Air Inc |
|
Canada |
|
|
|
Phase Not Applicable |
Planned |
1 |
|
|
|
2020-04-20 |
| COVID-19 Remote Monitoring |
Coronavirus disease 19 infection, Heart arrhythmia |
VitalConnect Vital Sign Patch alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Mount Sinai Medical Center |
|
US |
2020-04-30 |
2021-04-30 |
GCO 20-0932, NCT04350476 |
Phase Not Applicable |
Not yet recruiting |
0 |
12 Months |
1000 |
Betsy Ellsworth, ANP, Martin Goldman, MD, Sam Cammack, Sam Cammack, MA, MPH, Vivek Y Reddy, MD |
2020-04-21 |
| First in Human SAD and MAD Study of Inhaled TD-0903, a Potential Treatment for ALI Associated With COVID-19 |
Acute lung injury, Coronavirus disease 19 infection |
TD-0903 alone |
JAK tyrosine kinase inhibitor |
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) |
Theravance Biopharma Inc |
|
UK |
2020-04-30 |
2020-06-30 |
0183, 2020-000577-24, NCT04350736 |
Phase 1 Clinical |
Not yet recruiting |
1 |
2 Months |
54 |
Medical Monitor, Theravance Biopharma Call Center |
2020-04-22 |
| Lung ultrasound versus CT scan in COVID-19 disease |
Coronavirus disease 19 infection, Viral pneumonia |
Lung UltraSound alone, low-dose CT-scan alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Radboudumc |
|
Netherlands |
2020-03-15 |
2020-06-30 |
2020-6372, NL8497 |
Phase Not Applicable |
Recruiting |
1 |
3 Months |
200 |
Frank Bosch |
2020-04-20 |
| BCG Vaccine for Health Care Workers as Defense Against SARS-COV2 |
Coronavirus disease 19 infection |
BCG vaccine alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Baylor College of Medicine |
Harvard University, MD Anderson Cancer Center, University Medical Centre St Radboud |
US |
2020-04-30 |
2021-11-30 |
H-47454, NCT04348370 |
Phase 4 Clinical |
Not yet recruiting |
0 |
19 Months |
700 |
Andrew DiNardo, MD, Anna Mandalakas, MD, Ashish Kamat, MD, Marisa Lozano, Megan Murray, MD, MPH, Seth Lerner, MD |
2020-04-20 |
| CounterCovid19: Countering Lung Damage in COVID-19 infection (CounterCovid) studyCountering Lung Damage in COVID-19 infection study |
Coronavirus disease 19 infection, Lung injury |
imatinib alone |
Abl tyrosine kinase inhibitor, Bcr protein inhibitor, Kit tyrosine kinase inhibitor, PDGF receptor antagonist, Signal transduction inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Amsterdam UMC |
|
Netherlands |
2020-03-31 |
2020-06-30 |
2020.158, CounterCovid19, NL8491 |
Phase 3 Clinical |
Recruiting |
1 |
3 Months |
386 |
Harm Jan Bogaard |
2020-04-17 |
| PVC-RAM: Post Discharge After Surgery Virtual Care With Remote Automated Monitoring Technology (PVC-RAM) Trial |
Coronavirus disease 19 infection |
Virtual Care and Remote Automated Monitoring alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Population Health Research Institute |
Hamilton Health Sciences Corp, McMaster University |
Canada |
2020-04-30 |
2020-09-30 |
NCT04344665, PVC-RAM, V1.0, 2020.04.06 |
Phase Not Applicable |
Not yet recruiting |
2 |
5 Months |
900 |
Michael McGillion, PhD, PJ Devereaux, PhD, Valerie Harvey, BSc |
2020-04-17 |
| LUS-CC: Lung ultrasound (LUS) as a tool to determine the clinical course in COVID-19 patients |
Coronavirus disease 19 infection, Viral pneumonia |
Lung ultrasound alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Radboudumc |
|
Netherlands |
2020-03-15 |
2020-05-31 |
2020-6371, LUS-CC, NL8498 |
Phase Not Applicable |
Recruiting |
1 |
2 Months |
20 |
Frank Bosch |
2020-04-22 |
| A clinicla trial of repurposed NP-120 for teh treatment of acute lung injury due to COVID-19 |
Acute lung injury, Coronavirus disease 19 infection |
repurposed ifenprodil (oral, IPF/UC/IBD/crohn's disease/cough), Nash Pharmaceuticals alone |
NMDA receptor epsilon 2 subunit inhibitor |
|
Algernon Pharmaceuticals |
|
|
|
|
|
Phase Not Applicable |
Planned |
0 |
|
|
|
2020-04-17 |
| Ayurveda Self-Management for Flu Like Symptoms During the Covid-19 Outbreak |
Coronavirus disease 19 infection |
Ayurveda Self-Management alone, Yoga breathing alone, paracetamol alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) |
Aarogyam UK |
|
UK |
2020-02-26 |
2020-03-30 |
AU08, NCT04345549 |
Phase Not Applicable |
Completed |
1 |
1 Month |
18 |
Jaydeep Joshi, Neha Sharma |
2020-04-17 |
| CATNAP: COVID-19 smArtphone-based Trial of Non-ICU Admission Prone Positioning |
Coronavirus disease 19 infection |
Self-prone position recommendation alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Boston University |
|
US |
2020-04-30 |
2020-07-31 |
CATNAP, H-40070, NCT04344587 |
Phase Not Applicable |
Not yet recruiting |
0 |
3 Months |
380 |
Allan J Walkey, MD, Michael Garcia, MD, Nicholas A Bosch, MD |
2020-04-17 |
| LEEP-COVID: Longitudinal Energy Expenditure and Metabolic Effects in Patients With COVID-19 |
Coronavirus disease 19 infection, Respiratory failure |
Multifrequency Bioimpedance Spectroscopy alone, Q-NRG metabolic cart device alone, muscle sound ultrasound alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Duke University |
|
US |
2020-04-20 |
2020-12-01 |
LEEP-COVID, NCT04350073, PRO00105221 |
Phase Not Applicable |
Recruiting |
0 |
7 Months |
120 |
Jeroen Molinger, Paul E Wischmeyer, MD, EDIC, FASPEN, FCCM, Paul Wischmeyer, MD, EDIC, FASPEN, FCCM |
2020-04-23 |
| ReportAge-COVID: Clinical and Biological Predictors of COVID-19 Disease in Older Patients |
Coronavirus disease 19 infection |
|
|
Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Istituto Nazionale di Ricovero e Cura per Anziani |
|
Italy |
2020-04-30 |
2020-12-31 |
INRCA_01_2020, NCT04348396, ReportAge-COVID |
Phase Not Applicable |
Not yet recruiting |
1 |
8 Months |
300 |
Antonio Cherubini, MD, Silvia Bustacchini, MD |
2020-04-20 |
| UPSAT: Incline Positioning in COVID-19 Patients for Improvement in Oxygen Saturation |
Coronavirus disease 19 infection, Hypoxia, Respiratory failure |
postural positioning alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Johns Hopkins University |
|
US |
2020-04-20 |
2021-05-31 |
IRB00246834, NCT04344561, UPSAT |
Phase Not Applicable |
Not yet recruiting |
0 |
13 Months |
70 |
Luu Pham, MD, Trishul Siddharthan, MD |
2020-04-17 |
| COVIDIMMUNE: Evaluating the Immune Response for COVID-19 |
Coronavirus disease 19 infection |
2019-NCoV IgM/IgG (MAGLUMI) alone, Anti-SARS-CoV-2 (EuroImmun) alone, COVID-19 IgM/IgG (DIA PRO) alone, Coronavirus COVID-19 IgG ELISA (IBL) alone, Immunocomb (BioGal) alone, NADAL COVID-19 IgG/Igm (Nal Von Minden) alone, Rt-PCR kit alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Assaf-Harofeh Medical Center |
|
Israel |
2020-04-20 |
2020-12-31 |
105-20-ASF, COVIDIMMUNE, NCT04348422 |
Phase Not Applicable |
Not yet recruiting |
1 |
8 Months |
1000 |
Amir Hadanny, MD, Prof. Shay Efrati, Shai Efrati, MD |
2020-04-22 |
| Saved From COVID-19 |
Coronavirus disease 19 infection |
chloroquine alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Columbia University |
|
US |
2020-04-30 |
2021-04-30 |
AAAS9992, NCT04349371 |
Phase 2 Clinical |
Recruiting |
0 |
12 Months |
350 |
Anca Askanase, MD, MPH, Anca D. Askanase, MD, MPH, Deborah A Theodore, MD, Tommy Chen, Yevgeniya Gartshyten, MD |
2020-04-22 |
| PRODEX: Use of Dexmedetomidine in Light to Moderate Sedation in the Patient in the Palliative Situation of a Sars-cov-2 / COVID-19 Infection |
Coronavirus disease 19 infection, Respiratory failure |
dexmedetomidine alone |
Alpha 2 adrenoceptor agonist |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University Hospital, Limoges |
|
France |
2020-04-20 |
2020-11-20 |
87RI20_0011 (PRODEX), NCT04350086, PRODEX |
Phase 4 Clinical |
Not yet recruiting |
1 |
7 Months |
10 |
Paul-Antoine QUESNEL, MD |
2020-04-21 |
| Study for early biological warning signals in patients with acute renal injury caused by novel coronavirus pneumonia (COVID-19) |
Coronavirus disease 19 infection, Renal injury, Viral pneumonia |
|
|
Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Shanghai Jiao Tong University |
|
China |
2020-03-10 |
2022-12-31 |
ChiCTR2000031705 |
Phase Not Applicable |
Recruiting |
1 |
33 Months |
200 |
Ying Fan |
2020-04-22 |
| A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Allogeneic Mesenchymal Stem Cell Therapy (HB-adMSCs) to Provide Protection Against COVID-19 |
Coronavirus disease 19 infection |
autologous adipose-derived mesenchymal stem cells (iv infusion, rheumatoid arthritis), Hope Biosciences alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Hope Biosciences Inc |
Hope Biosciences Stem Cell Research Foundation |
US |
2020-04-23 |
2021-04-30 |
ALLOGENEIC COVID-19 PROTECTION, NCT04348435 |
Phase 2 Clinical |
Recruiting |
0 |
12 Months |
100 |
Thanh Cheng, MD |
2020-04-24 |
| Telerehabilitation for Patients Diagnosed With Coronavirus |
Coronavirus disease 19 infection |
Telerehabilitation alone, exercise brochure alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Istinye Universitesi |
|
|
2020-04-10 |
2020-07-31 |
009, NCT04346927 |
Phase Not Applicable |
Not yet recruiting |
0 |
3 Months |
30 |
Yasemin Çırak |
2020-04-20 |
| Study for sleep quality of medical teams members moved to Hubei for the fighting of novel coronavirus pneumonia (COVID-19) pandemic |
Coronavirus disease 19 infection, Viral pneumonia |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) |
Shanghai East Hospital |
|
China |
2020-03-01 |
2020-04-30 |
ChiCTR2000031707 |
Phase Not Applicable |
Recruiting |
1 |
2 Months |
47 |
Chen Li |
2020-04-20 |
| Study for prevention of novel coronavirus pneumonia (COVID-19) in high risk population by Chinese medicine |
Coronavirus disease 19 infection, Viral pneumonia |
Traditional Chinese medicine sachet alone, general basic epidemic prevention measures alone, oral and nasal spray alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Beijing institute of Traditional Chinese Medicine |
|
China |
2020-04-01 |
2020-12-31 |
ChiCTR2000031955 |
Phase 0 Clinical |
Recruiting |
1 |
9 Months |
3808 |
Lingru Li |
2020-04-20 |
| Efficacy and Safety of Hydroxychloroquine and Azithromycin for the Treatment of Ambulatory Patients With Mild COVID-19 |
Coronavirus disease 19 infection |
azithromycin plus hydroxychloroquine |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Azidus Brasil |
|
Brazil |
2020-04-20 |
2020-07-31 |
HIAPRE0420OR, NCT04348474 |
Phase 0 Clinical |
Suspended |
1 |
3 Months |
200 |
|
2020-04-23 |
| Clinical observation for the effect of Ke-Gan-Li-Yan oral liquid on the relief of laryngeal symptoms of novel coronavirus pneumonia (COVID-19) convalescence and suspected patients and other susceptible people |
Coronavirus disease 19 infection, Viral pneumonia |
Ke-Gan-Li-Yan oral liquid alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Fifth Affiliated Hospital, Sun Yat-Sen University |
|
China |
2020-04-01 |
2020-08-31 |
ChiCTR2000031982, ChiMCTR2000003216 |
Phase 4 Clinical |
Not yet recruiting |
1 |
5 Months |
240 |
Hu Guanying, Huang Mingxing |
2020-04-21 |
| Study for the influence of novel coronavirus pneumonia (COVID-19) on mental health of Chinese public hospital stuffs |
Coronavirus disease 19 infection, Viral pneumonia |
|
|
Asian Ancestry |
Fujian Provincial Hospital |
|
China |
2020-02-05 |
2020-02-10 |
ChiCTR2000031896 |
Phase Not Applicable |
No longer recruiting |
1 |
|
923 |
Miao Xing |
2020-04-21 |
| Delineate the prevalence, risk factors, temporal distribution and epidemiological characteristics of hidden novel coronavirus (2019-nCoV) infection in the community |
Coronavirus disease 19 infection |
|
|
Newborn Infants (up to 5 months), Infants (6-23 months), Preschool Children (2-5 yrs), Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Chinese University of Hong Kong |
Health and Medical Research Fund, Hong Kong |
China |
2020-04-15 |
2021-04-14 |
ChiCTR2000031928 |
Phase Not Applicable |
Not yet recruiting |
1 |
12 Months |
3000 |
Peter Choi Ching Lam, Prof. KS Chan Paul |
2020-04-21 |
| POINT-C: ICU Trial in Critical Ill COVID-19 Patients |
Cardiovascular disease, Coronavirus disease 19 infection |
blood sampling alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Medical University of Graz |
|
Austria |
2020-04-08 |
2020-07-31 |
250320, NCT04349982, POINT-C |
Phase Not Applicable |
Recruiting |
1 |
3 Months |
50 |
Christoph Klivinyi, Dr., Martin Rief, Dr, Martin Rief, Dr. |
2020-04-21 |
| A Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Autologous Mesenchymal Stem Cell Therapy (HB-adMSCs) to Provide Protection Against COVID-19 |
Coronavirus disease 19 infection |
autologous adipose-derived mesenchymal stem cells (iv infusion, rheumatoid arthritis), Hope Biosciences alone |
|
Healthy volunteers accepted, Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Hope Biosciences Inc |
|
US |
2020-04-16 |
2020-12-31 |
NCT04349631, PROTECTION AGAINST COVID-19 |
Phase 2 Clinical |
Recruiting |
0 |
8 Months |
56 |
Thanh Cheng, MD |
2020-04-20 |
| Resi-CoV: Resilience Evaluation of Caregivers During the SARS-CoV2 Epidemic Period : Prospective Cohort |
Coronavirus disease 19 infection |
CD-RISC 25 questionnaire alone |
|
Healthy volunteers accepted |
University Hospital, Angers |
|
|
2020-04-15 |
2020-05-25 |
2020-A00831-39, NCT04349163, Resi-CoV |
Phase Not Applicable |
Not yet recruiting |
0 |
1 Month |
280 |
Delphine Douillet, Delphine Douillet, MD |
2020-04-21 |
| A COVID-19 Symptom, Exposure and Immune Response Registry |
Coronavirus disease 19 infection |
|
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
ObvioHealth |
|
|
2020-04-20 |
2021-05-01 |
NCT04348942, OBVIO-OBV-001 |
Phase Not Applicable |
Not yet recruiting |
0 |
12 Months |
10000 |
Jalisa Watson, MHA, Parth Shah, MD |
2020-04-25 |
| Transmissibility and Viral Load of SARS-CoV-2 Through Oral Secretions |
Coronavirus disease 19 infection |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
National Institute of Dental and Craniofacial Research |
National Institutes of Health Clinical Center |
US |
2020-04-16 |
2020-07-01 |
20-D-0094, 200094, NCT04348240 |
Phase Not Applicable |
Recruiting |
0 |
2 Months |
30 |
Blake M Warner, D.D.S., Eileen M Pelayo |
2020-04-25 |
| APPROVE-CARE: Awake Prone Positioning to Reduce Invasive Ventilation in COVID-19 Induced Acute Respiratory failure |
Coronavirus disease 19 infection, Respiratory distress syndrome, Respiratory failure |
Prone positioning alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University College Galway |
|
Ireland |
2020-04-11 |
2021-05-11 |
APPROVE-CARE, APPROVE-CARE-2020, NCT04347941 |
Phase Not Applicable |
Not yet recruiting |
1 |
13 Months |
200 |
Bairbre A McNicholas, MB BCh PhD, David Cosgrave, MB BCh FARSI |
2020-04-24 |
| Efficacy and Safety of Nitazoxanide for the Treatment of Hospitalized Patients With Moderate COVID-19 |
Coronavirus disease 19 infection |
nitazoxanide alone, standard care alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Azidus Brasil |
Centro De Genomas, Emilio Ribas Infectious Diseases Institute, Farmoquimica SA, Hospital Vera Cruz |
Brazil |
2020-04-12 |
2020-06-30 |
NCT04348409, NITFQM0320OR |
Phase 2 Clinical |
Not yet recruiting |
3 |
2 Months |
50 |
Florentino de Araujo Cardoso Filho, Florentino de Araujo Cardoso Filho, MD, PhD, Luciana Ferrara, Ricardo Diaz, MD, PhD, Sérgio Cimerman, MD, PhD |
2020-04-23 |
| CoPE It: An e-Mental Health Intervention to Support burdened People in Times of the COVID-19 pandemic |
Acute stress disorder, Anxiety disorder, Coronavirus disease 19 infection |
CoPE It training alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Klinik für Psychosomatische Medizin und Psychotherapie am LVR-Klinikum Essen, Universität Duisburg-Essen |
|
Germany |
2020-04-23 |
|
20-9243-BO, CoPE It, DRKS00021301 |
Phase Not Applicable |
Not yet recruiting |
2 |
|
90 |
Alexander Bäuerle, Martin Teufel |
2020-04-21 |
| Analysis of clinical characteristics and therapeutic effect of nine cases of novel coronavirus pneumonia (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
|
|
|
Affiliated Hospital of Zunyi Medical College |
National Natural Science Foundation of China |
China |
2019-12-31 |
2020-03-01 |
ChiCTR2000031930 |
Phase Not Applicable |
No longer recruiting |
1 |
2 Months |
9 |
Chen Hongjun, Chen Miao |
2020-04-21 |
| An Open, Randomized Study of Dalargin Effectiveness in Patients With Severe and Critical Manifestations of SARS-COVID-19 |
Coronavirus disease 19 infection, Lung disease, Respiratory distress syndrome |
Variable regimens including Dalargin , azithromycin , hydroxychloroquine , tocilizumab |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Burnasyan Federal Medical Biophysical Center |
|
Russian Federation |
2020-04-08 |
2020-12-31 |
DAL-05-04-2020, NCT04346693 |
Phase 3 Clinical |
Recruiting |
1 |
8 Months |
320 |
Tatyana Astrelina |
2020-04-18 |
| Thy-Support: Triiodothyronine for the Treatment of Critically Ill Patients With COVID-19 Infection |
Coronavirus disease 19 infection |
triiodothyronine alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories Sa |
Attikon Hospital |
Greece |
2020-05-02 |
2021-05-31 |
NCT04348513, T3INJ-02/THYSUPPORT, Thy-Support |
Phase 2 Clinical |
Not yet recruiting |
1 |
12 Months |
60 |
Apostolos Armaganidis, MD, Georgia Kostopanagiotou, MD |
2020-04-18 |
| Evaluation of the concentration/viral effect relationship of hydroxychloroquine in COVID-19 patients in the intensive care unit |
Coronavirus disease 19 infection |
hydroxychloroquine alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Centre Hospitalier Universitaire de Saint Etienne |
|
France |
2020-03-30 |
|
2020-001281-11, 20CH065 |
Phase 4 Clinical |
Recruiting |
1 |
|
50 |
project manager |
2020-04-21 |
| A potential clinical trial of SARS-CoV-2 3C-like (3CL) protease inhibitors for the potential iv treatment of COVID-19 caused by SARS-CoV-2 (2019-nCoV) |
Coronavirus disease 19 infection |
SARS-CoV-2 3C-like (3CL) protease inhibitors (Coronavirus disease 19 infection), Pfizer alone |
Protease inhibitor |
|
Pfizer Inc |
|
|
2020-09-30 |
|
|
Phase Not Applicable |
Planned |
0 |
|
|
|
2020-04-17 |
| CORIPLASM: Efficacy of Convalescent Plasma to Treat COVID-19 Patients, a Nested Trial in the CORIMUNO-19 Cohort |
Coronavirus disease 19 infection |
convalescent plasma alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Assistance Publique Hopitaux de Paris |
Etablissement Francais du Sang |
France |
2020-04-14 |
2020-06-01 |
2020-001246-18, APHP200375-10, CORIPLASM, NCT04345991 |
Phase 2 Clinical |
Not yet recruiting |
1 |
1 Month |
120 |
Karine LACOMBE |
2020-04-21 |
| Efficacy of Chinese Herbal Tea in the Prevention of Novel Coronavirus Pneumonia (COVID-19): A Randomized Controlled Trial |
Coronavirus disease 19 infection, Viral pneumonia |
Chinese herbal tea alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
China Academy of Chinese Medical Sciences |
|
China |
2020-04-16 |
2020-12-31 |
ChiCTR2000031944, ChiMCTR2000003212 |
Phase Not Applicable |
Recruiting |
1 |
8 Months |
2000 |
Liu Bin, Lu Cheng |
2020-04-21 |
| A clinical study of haNK cells combined with convalescent plasma for the treatment in mild, moderate to the severe or critically ill COVID-19 patients |
Coronavirus disease 19 infection |
convalescent plasma plus haNK cells (cancer), NantKwest/Fox Chase Cancer Center |
|
|
NantKwest Inc |
|
US |
2020-06-30 |
|
|
Phase Not Applicable |
Planned |
0 |
|
|
|
2020-04-17 |
| Efficacy and safety of convalescent plasma in the treatment of COVID-19 |
Coronavirus disease 19 infection, Viral pneumonia |
convalescent plasma alone, conventional therapy alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Artesh University of Medical Sciences |
|
Iran |
2020-04-13 |
|
IR.AJAUMS.REC.1399.007, IRCT20200404046948N1 |
Phase 3 Clinical |
Recruiting |
3 |
|
60 |
Ebrahim Hazrati, Mohammad Aminianfar, Ramin Hamidi Farahani, Saeed Soleimani Meigouni, Seyed Javad Hosseini Shokouh |
2020-04-21 |
| PSI RECORd-XP: Non-COVID Patient-safety Incidents Reported by Primary Care Professionals in Time of Lockdown: Protocol for a Cross-sectional, Descriptive Study |
Coronavirus disease 19 infection |
|
|
Healthy volunteers accepted |
CHU De Nantes |
|
France |
2020-04-15 |
2020-06-15 |
NCT04348552, PSI RECORd-XP, RC20_0183 |
Phase Not Applicable |
Not yet recruiting |
1 |
2 Months |
1000 |
Jean-Pascal FOURNIER, Doctor |
2020-04-21 |
| Medical Records Based Study for Maternal and Perinatal Outcomes of Women with novel coronavirus pneumonia (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
|
|
Female |
International Peace Maternity and Child Health Hospital, Renmin Hospital of Wuhan University, Wuhan medical care center for women and children |
Wuhan Central Hospital |
China |
2020-04-15 |
2020-04-30 |
ChiCTR2000031954 |
Phase Not Applicable |
Recruiting |
3 |
|
30 |
He-Feng Huang, Yan-Ting Wu |
2020-04-21 |
| BLAST COVID-19: Beaumont Health Large-scale Automated Serologic Testing for COVID-19 |
Coronavirus disease 19 infection |
EUROIMMUN Anti-SARS-CoV-2 ELISA testing kits alone, EUROIMMUN assay alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
William Beaumont Hospitals |
|
US |
2020-04-30 |
2021-06-30 |
2020-134, BLAST COVID-19, NCT04349202 |
Phase Not Applicable |
Recruiting |
0 |
14 Months |
50000 |
Matthew Sims, MD, PhD, Maureen Cooney, RN, BSN |
2020-04-20 |
| COVID-2Pro: Assessment of the Efficacy and Safety of (HCQ) as a Prophylaxis for COVID-19 for Health Professionals |
Coronavirus disease 19 infection |
hydroxychloroquine alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Abderrahmane Mami Hospital |
Datametrix AG, Eshmoun Clinical Research Centre |
Tunisia |
2020-04-15 |
2020-07-15 |
ABDERRAHMANEMH, COVID-2Pro, ECC2020-03, NCT04349228 |
Phase 3 Clinical |
Not yet recruiting |
2 |
3 Months |
530 |
Chokri Jeribi, Dr, Dr Jalila Ben Khelil, Eshmoun Clinical Research Centre, Jalila Ben Khelil, Pr |
2020-04-22 |
| A clinical study of N-803 in COVID-19 patients with mild, moderate to the severe or critically ill state |
Coronavirus disease 19 infection |
ALT-803 alone |
IL-15 receptor agonist, IL-15 receptor modulator |
|
NantKwest Inc |
|
|
2020-06-30 |
|
|
Phase Not Applicable |
Planned |
0 |
|
|
|
2020-04-17 |
| ARCHAIC: An open-label, randomized, controlled trial of chloroquine, hydroxychloroquine or only supportive care in patients admitted with moderate to severe COVID-19 |
Coronavirus disease 19 infection |
chloroquine alone, hydroxychloroquine alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Universitair Medisch Centrum Utrecht |
The Netherlands Organisation for Health Research and Development |
Netherlands |
2020-04-12 |
2021-04-12 |
ARCHAIC, NL73529.041.20, NL8490 |
Phase 3 Clinical |
Not yet recruiting |
1 |
12 Months |
950 |
Jesper Weehuizen |
2020-04-23 |
| Evaluation of Activity and Safety of Oral Selinexor in Participants With Severe COVID-19 Infection (Coronavirus) |
Coronavirus disease 19 infection |
selinexor alone |
Exportin 1 inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Karyopharm Therapeutics Inc |
|
Austria, Israel, Spain, US, Europe |
2020-04-17 |
2020-08-31 |
2020-001411-25, NCT04349098, XPORT-COV-1001 |
Phase 2 Clinical |
Recruiting |
4 |
4 Months |
230 |
Clinical Trial Information Desk, Dayana Michel, Don Stevens, Hadil Onalla, Jatin Shah, Chief Medical Officer, Jeffrey Zonder, Kurt Redlich, Magdalena García Astorga, Marcelo Gareca, Mezgebe Berhe, Miguel Marcos Martin, Otto Yang, Ran Nir-Paz, Sharon Shacham, President and CSO |
2020-04-23 |
| Using eHealth to support COVID-19 self-assessment and collection of self-reported health data |
Coronavirus disease 19 infection |
|
|
|
Interactive Studios |
|
Netherlands |
2020-03-23 |
2020-06-30 |
20.039, NL8501, TBA |
Phase Not Applicable |
Recruiting |
1 |
3 Months |
2000 |
Thomas Timmers |
2020-04-20 |
| Covid-19 en ACE remmers: The use of ACE2 receptor increasing medication at hospital admission and mortality rates in COVID-19 patiënts |
Coronavirus disease 19 infection |
|
|
|
Noordwest Ziekenhuisgroep |
|
Netherlands |
2020-03-18 |
2020-09-18 |
2020.165, Covid-19 en ACE remmers, NL8512 |
Phase Not Applicable |
Recruiting |
1 |
6 Months |
400 |
Diederik van Wijk |
2020-04-20 |
| Observational Study, Use of Canakinumab Administered Subcutaneously in the Treatment COVID-19 Pneumonia |
Coronavirus disease 19 infection, Viral pneumonia |
canakinumab alone |
Immunoglobulin G1 agonist, Interleukin-1 beta ligand inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Azienda Unita Sanitaria Locale Della Romagna |
|
|
2020-04-30 |
2020-09-30 |
CANASCOV, NCT04348448 |
Phase Not Applicable |
Not yet recruiting |
0 |
5 Months |
100 |
|
2020-04-20 |
| PreToVid: Pre-emptive tocilizumab in hypoxic COVID-19 patients, a prospective, randomized trial |
Coronavirus disease 19 infection, Hypoxia |
tocilizumab (intravenous), Roche/Chugai alone |
IL-6 receptor antagonist, IL-6 receptor modulator |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Roche Holding AG, University Medical Center Groningen |
|
Netherlands |
2020-04-06 |
2020-12-31 |
NL8504, PreToVid |
Phase 3 Clinical |
Recruiting |
1 |
8 Months |
354 |
Margriet Dijkstra |
2020-04-23 |
| FMTVDM: The Fleming Directed CoVid-19 Treatment Protocol |
Coronavirus disease 19 infection, Viral pneumonia |
convalescent plasma alone, interferon alfa-2b alone, losartan alone, methylprednisolone alone, remdesivir alone, tocilizumab alone, Variable regimens including azithromycin , clindamycin , doxycycline , hydroxychloroquine , primaquine |
Angiotensin II AT-1 receptor antagonist, Angiotensin II receptor antagonist, Interferon alpha ligand modulator, RNA polymerase modulator |
|
The Camelot Foundation |
|
US |
2020-04-11 |
2020-11-11 |
FMTVDM, FMTVDM2020, NCT04349410 |
Phase 2/Phase 3 Clinical |
Recruiting |
0 |
7 Months |
500 |
RM Fleming, MD, Principle Investigator, Richard M Fleming, PhD, MD, JD |
2020-04-20 |
| COVID-19 in rheumatic patients: a prospective, cohort study |
Ankylosing spondylitis, Coronavirus disease 19 infection, Psoriatic arthritis, Rheumatoid arthritis |
|
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Jan van Breemen Institute |
|
Netherlands |
2020-04-13 |
2021-04-13 |
2020.169 - NL73521.029.20, NL8513, TBA |
Phase Not Applicable |
Not yet recruiting |
3 |
12 Months |
8000 |
Femke Hooijberg |
2020-04-23 |
| How COVID-19 Virus Outbreak Affects Antimicrobial Resistance in a Low-middle-income Country's ICU? |
Coronavirus disease 19 infection |
enhanced hygiene measures alone |
|
|
Hôpital Universitaire Fattouma Bourguiba |
|
Tunisia |
2019-01-01 |
2021-02-04 |
KM2020-1, MALEK KHEMILI, NCT04348227 |
Phase Not Applicable |
No longer recruiting |
1 |
25 Months |
120 |
Malek Khemili, Resident |
2020-04-20 |
| Evaluation the effect of asafoetida in the treatment of coronavirus infection |
Coronavirus disease 19 infection |
Variable regimens including asafoetida (Mashhad School of Pharmacy) , azithromycin , hydroxychloroquine |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Mashhad University of Medical Sciences |
|
Iran |
2020-04-20 |
|
IR.MUMS.REC.1399.071, IRCT20200413047053N1 |
Phase 2 Clinical |
Recruiting |
1 |
|
60 |
Dr. Dehghan Nayeri, Mehrdad Iranshahi, Mohsen Tafaghodi |
2020-04-21 |
| CWC-19: COPING With COVID-19 |
Coronavirus disease 19 infection |
crisis management coaching alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Duke University |
|
US |
2020-04-13 |
2020-06-30 |
CWC-19, NCT04343690, PRO00105319 |
Phase Not Applicable |
Not yet recruiting |
0 |
2 Months |
100 |
Erika Ratcliffe, Patty Lee, MD, Sangeeta Joshi, MD |
2020-04-20 |
| Tocilizumab-Corticosteroids COVID-19 Trial |
Coronavirus disease 19 infection |
tocilizumab alone |
|
|
National Institutes of Health |
|
Malaysia |
2020-04-27 |
2020-10-30 |
54656, NMRR-20-735-54656 |
Phase 3 Clinical |
Not yet recruiting |
1 |
6 Months |
310 |
Dr Suresh Kumar, Norazida binti Ab. Rahman |
2020-04-20 |
| Investigating the efficacy and safety of umifenovir in controlling the symptoms of patients with COVID-19 |
Coronavirus disease 19 infection, Respiratory disease |
routine treatment alone, umifenovir alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Center for Progress and Development of Iran |
|
Iran |
2020-03-30 |
|
IR.BMSU.REC.1399.037, IRCT20080901001165N46 |
Phase 3 Clinical |
Recruiting |
1 |
|
200 |
Morteza Pirali, Parisa Kianpour, Yunes Panahi |
2020-04-21 |
| Potential Efficacy of Convalescent Plasma to Treat Severe COVID-19 and Patients at High Risk of Developing Severe COVID-19 |
Coronavirus disease 19 infection |
convalescent plasma alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
King Fahad Specialist Hospital Dammam |
Johns Hopkins Aramco Healthcare, King Fahad Medical City, King Fahad National Guard Hospital, King Fahd Military Medical Complex, King Faisal Specialized Hospital & Research Center, King Faisal University, King Khalid University Hospital, King Saud University, Taibah University |
Saudi Arabia |
2020-04-12 |
2021-04-11 |
HAEM0321, NCT04347681 |
Phase 2 Clinical |
Recruiting |
10 |
12 Months |
40 |
Afra Al-Dayel, MD, Ahmed Al Askar, MD, Ahmed Albahrani, MD, Ahmed Alsagheir, MD, Arwa Nabhan, MD, Hani Al-Hashmi, MD, Hazza AlZahrani, MD, Jawaher AlOtaibi, MD, Mahammad Awadallah, MSc, Mohammed Albalawi, MD, Mona Alfaraj, MD, Nawal AlShehry, MD, Nour AlMozain, MD, Rehab Al-Ansari, MD, Yem Abulhamayel, MD |
2020-04-22 |
| ATTAC-Co: Pro-thrombotic Status in Patients With SARS-Cov-2 Infection |
Coronavirus disease 19 infection, Respiratory failure, SARS coronavirus infection |
blood sampling alone, computed tomography alone, pulmonary ultrasonography alone, transthoracic echocardiogram alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Azienda Ospedaliero-Universitaria di Ferrara |
|
Italy |
2020-04-08 |
2021-06-30 |
250320, ATTAC-Co, NCT04343053 |
Phase Not Applicable |
Recruiting |
1 |
14 Months |
60 |
Gianluca Campo, MD, Marco Contoli, MD, Savino Spadaro, MD, Veronica Lodolini |
2020-04-23 |
| Early Extubation for Patients With Acute Hypoxemic Respiratory Failure |
Coronavirus disease 19 infection, Hypoxia, Respiratory failure |
air flow meter alone, arterial blood gas sampling alone, endotracheal intubation alone, helmet alone, non-invasive ventilation alone, oxygen therapy alone, positive-end expiratory pressure valve alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University of Chicago |
|
US |
2020-04-15 |
2021-06-01 |
20-0594, NCT04349332 |
Phase Not Applicable |
Not yet recruiting |
0 |
13 Months |
108 |
Anne Pohlman, MSN, Bhakti Patel, MD |
2020-04-20 |
| Battle Against COVID-19 Using Mesenchymal Stromal Cells |
Coronavirus disease 19 infection, Respiratory distress syndrome |
allogeneic and expanded adipose tissue-derived mesenchymal stromal cells alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Instituto de Investigación Sanitaria de la Fundacion Jimenez Diaz |
Clinica Universidad de Navarra, Fundacion De La Comunitat Valenciana Para La Gestión De Instituto De Investigación Sanitaria Y Biomédica De Alicante (Fundación Para La Gestión De Isabial), Hospital General Universitario De Alicante, Hospital General Universitario Gregorio Marañon, Hospital Universitario Virgen de la Arrixa, Instituto de Salud Carlos III, University Hospital of Salamanca |
Spain |
2020-04-06 |
2020-09-30 |
2020-001266-11, BALMYS-19, NCT04348461 |
Phase 2 Clinical |
Not yet recruiting |
1 |
5 Months |
100 |
Barbara Juan, MD, Mireia Arcas, Unidad de Investigación Clínica |
2020-04-20 |
| Impact of Nasal Saline Irrigations on Viral Load in Patients With COVID-19 |
Coronavirus disease 19 infection, Rhinopharyngitis |
Johnson's baby shampoo nasal irrigation therapy alone, saline nasal irrigation therapy alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Vanderbilt University Medical Center, US |
|
US |
2020-05-31 |
2022-06-30 |
200693, NCT04347538, PENDING IRB |
Phase Not Applicable |
Not yet recruiting |
0 |
25 Months |
90 |
Justin H. Turner, MD, PhD, Kate Von Wahlde, MJ, CCRP, Kyle Kimura, MD |
2020-04-21 |
| LACCTT: Lagos COVID-19 Chloroquine Treatment Trial |
Coronavirus disease 19 infection |
Chloroquine phosphate alone, Hydroxychloroquine alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Lagos State University |
Nigerian Institute of Medical Research |
Nigeria |
2020-04-17 |
2020-10-16 |
LACCTT, PACTR202004801273802 |
Phase 3 Clinical |
Not yet recruiting |
1 |
6 Months |
600 |
Akin Abayomi, Hussein AbdurRazzaq, Samuel Anya |
2020-04-20 |
| Q-PROTECT: Qatar Prospective, RCT Of Therapy Eliminating Covid Transmission |
Coronavirus disease 19 infection |
azithromycin plus hydroxychloroquine |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Hamad Medical Corp |
|
Qatar |
2020-04-14 |
2020-05-30 |
MRC-05-001, NCT04349592, Q-PROTECT |
Phase 2 Clinical |
Not yet recruiting |
1 |
1 Month |
456 |
Tim Richard Edmund Harris |
2020-04-20 |
| Screening and Risk Assessment of Healthcare Workers and Infection Control in University and COVID-19 Quarantine Hospitals |
Coronavirus disease 19 infection |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Ain Shams University |
|
Egypt |
2020-04-20 |
2020-12-01 |
FMASU P18A/ 2020, NCT04348214 |
Phase Not Applicable |
Not yet recruiting |
2 |
7 Months |
3000 |
Aya Mostafa, Fatma Soliman E Ebeid, Fatma Soliman Elsayed Ebeid |
2020-04-21 |
| COVID-19 Antibody Self-testing Using Virtual Point-of-care |
Coronavirus disease 19 infection |
COVID-19 IgM/IgG rapid testing alone, telemedicine alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Neuroganics LLC |
|
US |
2020-04-16 |
2021-04-30 |
2020/03/18, NCT04348864 |
Phase Not Applicable |
Recruiting |
0 |
12 Months |
100 |
Donald Cooper, Ph.D., Joe Ramos, MD/JD |
2020-04-21 |
| save: suPAR-guided Anakinra Treatment for Validation of the Risk and Management of Respiratory Failure by COVID-19 |
Coronavirus disease 19 infection, Respiratory failure |
Bactrimel plus anakinra |
Type I IL-1 receptor antagonist |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Hellenic Institute for the Study of Sepsis |
|
Greece |
2020-04-15 |
2022-04-15 |
2020-001466-11, NCT04357366, SAVE, save |
Phase 2 Clinical |
Recruiting |
15 |
24 Months |
100 |
Aikaterini Argyraki, MD, Antigoni Kotsaki, MD, PhD, Charalambos Gogos, MD, PhD, Charalambos Milionis, MD, PhD, Evangelos Giamarellos-Bourboulis, MD, PhD, Evangelos Kostis, MD, Garyfallia Poulakou, MD, PhD, George Dalekos, MD, PhD, Georgios Adamis, MD, Helen Sambatakou, Ilias Papanikolaou, MD, Ioannis Baraboutis, MD, Malvina Lada, MD, Michael Samarkos, MD, PhD, Periklis Panagopoulos, MD, PhD, President of the Board, Simeon Metallidis, MD, PhD |
2020-04-23 |
| FAV-001: Efficacy and Safety of Favipiravir in Management of COVID-19 |
Coronavirus disease 19 infection |
favipiravir alone |
RNA polymerase inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Ain Shams University |
|
Egypt |
2020-04-20 |
2020-12-01 |
FAV-001, FMASU P14 / 2020, NCT04349241 |
Phase 3 Clinical |
Not yet recruiting |
2 |
7 Months |
100 |
Fatma Soliman E Ebeid, Hany Dabbous |
2020-04-21 |
| Effect of Methylprednisolone on Treatment of COVID-19 |
Coronavirus disease 19 infection, Respiratory distress syndrome |
methylprednisolone alone, standard treatment alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Tehran University of Medical Sciences |
|
Iran |
2020-03-28 |
|
IR.TUMS.VCR.REC.1399.054, IRCT20200404046947N1 |
Phase 3 Clinical |
Recruiting |
3 |
|
40 |
Abdorahman Rostamian, Ahmadreza Jamshidi, Mahdi Mahmoudi, Maryam Akhtari, Maryam Edalatifard, Zohre Naderi, mohammad ali sahraian |
2020-04-20 |
| COVID STEROID: Hydrocortisone for COVID-19 and Severe Hypoxia |
Coronavirus disease 19 infection, Hypoxia |
hydrocortisone alone, standard care alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Scandinavian Critical Care Trials Group |
Aarhus University Hospital, Copenhagen Trial Unit, Koebenhavns Universitet, Rigshospitalet, Denmark |
Denmark |
2020-04-15 |
2021-12-30 |
2020-001395-15, COVID STEROID, NCT04348305, RH-ITA-008 |
Phase 3 Clinical |
Recruiting |
6 |
20 Months |
1000 |
Anders Møller, Anders Perner, Anders Perner, MD, PhD, Anne C Brøchner, Christoffer Sølling, Maj-brit N Kjær, RN, MSc, Marie Warrer Petersen, MD, PhD, Professor |
2020-04-25 |
| Emocovid: Emotional Burden of Healthcare Professionals and Covid Infection 19 |
Anxiety disorder, Coronavirus disease 19 infection |
|
|
|
University Hospital, Limoges |
|
France |
2020-04-15 |
2021-06-15 |
87RI20-0015/EMOCOVID, Emocovid, NCT04350099 |
Phase Not Applicable |
Not yet recruiting |
2 |
14 Months |
200 |
Anne Laure Fauchais, MD, Anne-Laure FAUCHAIS, MD, Philippe NUBUKPO, MD, Stéphanie DUMONTEIL |
2020-04-20 |
| Clazakizumab (Anti-IL- 6 Monoclonal) Compared to Placebo for COVID19 Disease |
Coronavirus disease 19 infection |
clazakizumab alone |
IL-6 receptor antagonist |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Cedars-Sinai Medical Center |
|
US |
2020-04-21 |
2021-03-31 |
00000644, NCT04348500 |
Phase 2 Clinical |
Not yet recruiting |
0 |
11 Months |
60 |
Noriko Ammerman, PharmD, Stanley Jorda |
2020-04-20 |
| SR-NOCS: Observational, clinical trial for the evaluation of an automated nasal and pharyngeal swab exam to test COVID-19 patients |
Coronavirus disease 19 infection |
robotic autonomous naso-oropharyngeal swab collection alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Klinikum rechts der Isar der Technischen Universitaet Muenchen |
Technical University of Munich |
Germany |
2020-04-01 |
|
152/20 S-KH, DRKS00021420, SR-NOCS |
Phase 1 Clinical |
Recruiting |
1 |
|
30 |
Dirk Wilhelm |
2020-04-20 |
| COVID19-BMT: Role of Immune and Inflammatory Response in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation (SCT) Affected by Severe COVID19 |
Coronavirus disease 19 infection |
blood sampling alone |
|
Newborn Infants (up to 5 months), Infants (6-23 months), Preschool Children (2-5 yrs), Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Great Ormond Street Hospital for Children NHS Foundation Trust |
|
UK |
2020-04-15 |
2021-01-15 |
20BO08, COVID19-BMT, NCT04349540 |
Phase Not Applicable |
No longer recruiting |
1 |
9 Months |
40 |
|
2020-04-20 |
| COVVA: Occupational health and safety among health care personnel in a COVID-19 pandemic |
Coronavirus disease 19 infection |
|
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Universidad de Valladolid |
|
Spain |
2020-04-01 |
2020-04-22 |
COVVA, ISRCTN18348009, V_01_2020_REF.03.V_02 |
Phase Not Applicable |
Completed |
2 |
|
80 |
Prof Martín-Rodríguez |
2020-04-23 |
| A randomized, double-blind, placebo, parallel-controlled, phase I/II clinical trial to assess safety and efficacy of COVID-19 vaccine (inactivated, Vero cells) in Chinese healthy subjects for the treatment of COVID-19 infection |
Coronavirus disease 19 infection |
COVID-19 vaccine (inactivated, Vero cells/intramuscular), Wuhan Institute of Biological Products/Wuhan Institute of Virology, CAS alone |
|
Healthy volunteers accepted, Asian Ancestry |
Wuhan Institute of Biological Products Co Ltd |
|
China |
|
|
|
Phase 1/Phase 2 Clinical |
Recruiting |
1 |
|
336 |
Xia Shengli |
2020-04-17 |
| A clinical trial to assess the safety , tolerability and immunogenicity of Inactivated vaccine (COVID-19), Sinovac Biotech in healthy volunteers |
Coronavirus disease 19 infection |
Inactivated vaccine (COVID-19), Sinovac Biotech alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) |
Sinovac Biotech Ltd |
|
China |
|
|
|
Phase 1 Clinical |
Recruiting |
1 |
|
144 |
|
2020-04-21 |
| Effect of a Brief Problem Management Intervention on COVID 19-Related Anxiety and Depression |
Anxiety disorder, Coronavirus disease 19 infection, Depression |
Problem Management Plus alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
UNSW Sydney |
National Health and Medical Research Council |
Australia |
2020-04-20 |
|
ACTRN12620000468921p |
Phase Not Applicable |
Not yet recruiting |
1 |
|
140 |
Prof Richard Bryant |
2020-04-20 |
| Virucidal pilot study of Nasodine Antiseptic Nasal Spray (povidone-iodine 0.5%) in people with COVID-19 and confirmed nasal shedding of SARS-CoV-2 virus |
Coronavirus disease 19 infection |
Nasodine alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Firebrick Pharma Pty Ltd |
|
Australia |
2020-04-20 |
|
ACTRN12620000470998p, FBP-004 |
Phase 0 Clinical |
Not yet recruiting |
1 |
|
20 |
Prof Peter Friedland |
2020-04-20 |
| CoronaStem 1: A clinical study of stem cells to treate hospitalized patients with COVID-19 infection |
Coronavirus disease 19 infection |
stem cells, Calidi Biotherapeutics Inc alone |
|
|
Personalized Stem Cells Inc |
Calidi Biotherapeutics Inc |
US |
2020-05-31 |
|
CoronaStem 1 |
Phase Not Applicable |
Planned |
0 |
|
|
|
2020-04-24 |
| PVP-I Nasal Sprays and SARS-CoV-2 Nasopharyngeal Titers (for COVID-19) |
Coronavirus disease 19 infection |
povidone-iodine alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Stanford University |
|
US |
2020-05-31 |
2020-08-31 |
IRB-56134, NCT04347954 |
Phase 1/Phase 2 Clinical |
Not yet recruiting |
0 |
3 Months |
45 |
Neelaysh Vukkadala, MD, Peter H Hwang, MD |
2020-04-17 |
| UPMC-REMAP-COVID19: A novel clinical trial to evaluate the effect of hydroxychloroquine in the treatment of patients with COVID-19 infection |
Coronavirus disease 19 infection |
hydroxycloroquine alone, immunomodulators alone, standard of care alone, steroids alone |
|
|
University of Pittsburgh School of Medicine |
|
US |
|
|
UPMC-REMAP-COVID19 |
Phase Not Applicable |
Not yet recruiting |
0 |
|
|
Derek Angus |
2020-04-16 |
| Convalescent Antibodies Infusion in Critically Ill COVID 19 Patients |
Coronavirus disease 19 infection, Viral pneumonia |
anti-coronavirus antibody (immunoglobulin) therapy alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Ospedale Papa Giovanni XXIII |
Aferetica Srl |
Italy |
2020-04-30 |
2020-07-31 |
DFPP COVID 19, NCT04346589 |
Phase Not Applicable |
Not yet recruiting |
5 |
3 Months |
10 |
Anna Falanga, MD, Annalisa Perna, Stat., Annapaola Callegaro, MD, Claudio Farina, MD, Diego Curto, MD, Diego Curtò, MD, Ferdinando Luca Lorini, MD, Giuseppe Remuzzi, MD, Lorenzo Grazioli, MD, Luca Barcella, MD, Marina Marchetti, Biol. Sci.D., Marina Noris, Ch., Miriam Galbusera, Biol.Sci. D., Piero Luigi Ruggenenti, Piero Luigi Ruggenenti, MD, Stefano Rota, MD |
2020-04-18 |
| Feasibility of Online Based Mindfulness Interventions During COVID-19 Outbreak |
Acute stress disorder, Anxiety disorder, Coronavirus disease 19 infection, Depression |
online mindfulness session alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Chinese University of Hong Kong |
|
Hong Kong |
2020-05-01 |
2021-04-30 |
NCT04346082, ONLINE-MIND |
Phase Not Applicable |
Not yet recruiting |
1 |
12 Months |
30 |
Kam Pui Lee, MSc, kam pui Lee, Msc |
2020-04-20 |
| A study to investigate the therapeutic benefit and safety of convalescent plasma in patients with Covid-19 |
Coronavirus disease 19 infection |
convalescent plasma alone |
|
|
Feinstein Institute for Medical Research, Mayo Clinic Foundation, Northwell Health Inc |
|
US |
|
|
|
Phase Not Applicable |
Planned |
0 |
|
|
Craig Devoe, MD |
2020-04-16 |
| Compassionate Use Open-Label, Anti-CD14 Treatment in Patients With SARS-CoV-2 (COVID-19) |
Coronavirus disease 19 infection, Respiratory disease |
IC-14 alone |
Monocyte differentiation antigen CD14 inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Implicit Bioscience Ltd |
|
Italy |
|
|
COV02, NCT04346277 |
Phase Not Applicable |
Recruiting |
1 |
|
|
Lorenzo Dagna, MD |
2020-04-20 |
| ProCov: Prone Positioning in Spontaneously Breathing Nonintubated Covid-19 Patient: A Pilot Study |
Coronavirus disease 19 infection |
prone positioning alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Centre Hospitalier Intercommunal Aix-Pertuis |
|
France |
2020-04-01 |
2020-05-01 |
20202703-2, NCT04344106, ProCov |
Phase Not Applicable |
Recruiting |
1 |
1 Month |
25 |
Camille begne, MD, Laurence Maulin, MD, Laurent Lefebvre, MD, Marie Bernardi, MD, Stephanie Martinez, MD, Thibaut Helbert, MD, Xavier ELHARRAR, Xavier ELHARRAR, MD, Youssef Trigui, MD |
2020-04-17 |
| Explore: Retrospective Study on Severe Respiratory Illness to Access the Presence of COVID-19 |
Coronavirus disease 19 infection, Respiratory disease |
|
|
Infants (6-23 months), Preschool Children (2-5 yrs), Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Ain Shams University |
|
Egypt |
2020-04-14 |
2020-12-01 |
Explore, FMASU P17A/ 2020, NCT04346056 |
Phase Not Applicable |
Recruiting |
3 |
7 Months |
500 |
Fatma Soliman E Ebeid, Sara Hassan, Sara Hassan Agwa |
2020-04-22 |
| Strain: To Access the Egyptian COVID-19 Whole Genome by NGS and Compare to the International Worldwide Database |
Coronavirus disease 19 infection |
Ion AmpliSeq alone, next-generation sequencing (NGS) alone, phylogenetic analysis alone, polymerase chain reaction (PCR) alone, reverse transcription polymerase chain reaction (rRT-PCR) alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Ain Shams University |
|
Egypt |
2020-04-20 |
2020-12-01 |
FMASU P16A/ 2020, NCT04346043, Strain |
Phase Not Applicable |
Not yet recruiting |
2 |
7 Months |
100 |
Fatma Soliman E Ebeid, Hesham Elghazaly,MD |
2020-04-21 |
| COVIDOC: Hydroxychloroquine Plus Azithromycin Versus Hydroxychloroquine for COVID-19 Pneumonia |
Coronavirus disease 19 infection, Viral pneumonia |
azithromycin plus hydroxychloroquine |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
University Hospital, Montpellier |
|
France |
2020-04-11 |
2021-04-06 |
2020-001406-27, COVIDOC, NCT04345861, RECHMPL20_168 |
Phase 2/Phase 3 Clinical |
Recruiting |
1 |
11 Months |
150 |
Claire CHAUVETON, Jacques REYNES, MD PhD, Jacques REYNES, MD,PhD, jacques REYNES, MD, PhD |
2020-04-25 |
| Impact of Tele-interventions During the COVID-19 Pandemic in Patients With Diabetes Mellitus |
Coronavirus disease 19 infection, Insulin dependent diabetes, Non-insulin dependent diabetes |
tele-intervention alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Federal University of Rio Grande do Sul |
|
Brazil |
2020-04-17 |
2020-08-30 |
2020241093, NCT04344210 |
Phase Not Applicable |
Recruiting |
1 |
4 Months |
149 |
|
2020-04-17 |
| COVID-19 Plasma Collection |
Coronavirus disease 19 infection |
convalescent plasma collection alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Thomas Jefferson University |
|
US |
2020-04-13 |
2021-04-12 |
20D.346, NCT04344015 |
Phase Not Applicable |
Recruiting |
0 |
12 Months |
2000 |
Julie Karp, MD, Mackenzie Kemp, MPH |
2020-04-20 |
| A randomized, double-blinded, placebo-controlled, phase II clinical trial for Recombinant Novel Coronavirus (2019-nCOV) Vaccine (Adenovirus Vector) |
Coronavirus disease 19 infection |
Recombinant Novel Coronavirus Disease Vaccine (Adenovirus Vector) alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
CanSino Biologics Inc, Institute of Biotechnology the Academy of Military Medical Sciences PLA, Jiangsu Province Centers for Disease Control and Prevention |
Ministry of Science and Technology of the People´s Republic of China |
China |
2020-04-12 |
2021-01-31 |
ChiCTR2000031781 |
Phase 2 Clinical |
Not yet recruiting |
3 |
9 Months |
500 |
Hou Lihua, Zhu Fengcai |
2020-04-20 |
| Safety and Efficacy Trial of Vazegepant Intranasal for Hospitalized Patients With COVID-19 Requiring Supplemental Oxygen |
Coronavirus disease 19 infection |
vazegepant alone |
CGRP receptor antagonist |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Biohaven Pharmaceutical Holding Co Ltd |
|
US |
2020-04-30 |
2020-07-31 |
BHV3500-203, NCT04346615 |
Phase 2/Phase 3 Clinical |
Recruiting |
0 |
3 Months |
120 |
Agbenu Amali |
2020-04-23 |
| PHYSIO-COVID: Implementation of Physiotherapy on COVID-19 Patients in ICU |
Coronavirus disease 19 infection |
phsyiotherapy alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University Hospital, Montpellier |
Sociedad Española de Neumología y Cirugía Torácica, Societe française de kinésithérapie en réanimation |
Argentina, France, Spain, Chile, Belgium, Italy |
2017-04-01 |
2022-12-01 |
NCT04347070, PHYSIO-COVID, RECHMPL20_0175 |
Phase Not Applicable |
Recruiting |
6 |
68 Months |
150 |
Gustavo Plotnikow, Gustavo Plotnikow, Physiotherapis, Roberto Martinez-Alejos, Roberto Martinez-Alejos, MD, PhD, roberto Martinez-Alejos, Physiotherapis |
2020-04-17 |
| Outcome of COVID-19 Cases Based on Tuberculin Test: Can Previous BCG Alter the Prognosis? |
Coronavirus disease 19 infection |
tuberculin test alone |
|
Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Assiut University |
|
Egypt |
2020-04-11 |
2020-06-30 |
ASSIUTU12, NCT04347876 |
Phase Not Applicable |
Recruiting |
1 |
2 Months |
100 |
Aliae AR Mohamed Hussein, Aliae AR Mohamed-Hussein |
2020-04-17 |
| CORIMUNO19-ECU: Trial Evaluating Efficacy and Safety of Eculizumab (Soliris) in Patients With COVID-19 Infection, Nested in the CORIMUNO-19 Cohort |
Coronavirus disease 19 infection, Viral pneumonia |
eculizumab alone |
Complement C5 factor inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Assistance Publique Hopitaux de Paris |
|
|
2020-04-30 |
2020-08-31 |
APHP200375-4, CORIMUNO19-ECU, NCT04346797 |
Phase 2 Clinical |
Not yet recruiting |
0 |
4 Months |
120 |
Régis Peffault de Latour, MD PhD |
2020-04-17 |
| Burnout Among Caregivers Facing COVID-19 Health Crisis at a Non-conventional Intensive Care Unit Compared to a Conventional Intensive Care Unit |
Acute stress disorder, Coronavirus disease 19 infection |
|
|
|
Raymond Poincare University Hospital |
Hôpital Cochin |
France |
2020-04-15 |
2020-09-01 |
CSC19APR, NCT04346810 |
Phase Not Applicable |
Not yet recruiting |
1 |
4 Months |
100 |
Dominique Fletcher, MD, PhD, HARKOUK Hakim, Hakim Harkouk, M.D. |
2020-04-18 |
| Study to Evaluate the Efficacy and Safety of Leronlimab for Patients With Severe or Critical Coronavirus Disease 2019 (COVID-19) |
Coronavirus disease 19 infection |
leronlimab alone |
CCR5 chemokine antagonist |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
CytoDyn Inc |
|
US |
2020-04-15 |
2021-04-01 |
CD12_COVID-19, NCT04347239 |
Phase 2 Clinical |
Recruiting |
0 |
11 Months |
390 |
Kush Dhody, MBBS, MS, CCRA |
2020-04-20 |
| A Study on the Clinical and Psychological Characteristics of Patients With COVID-2019 |
Coronavirus disease 19 infection |
standard treatment alone |
|
Infants (6-23 months), Preschool Children (2-5 yrs), Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Jilin University |
|
China |
2020-02-01 |
2020-12-01 |
130004, NCT04346602 |
Phase Not Applicable |
Recruiting |
1 |
10 Months |
132 |
Bai ling Yan, Doctor, Dong Yang, Master |
2020-04-17 |
| An Open, Randomized Study of the Effectiveness of Mefloquine for the Treatment of Patients With COVID-19 |
Coronavirus disease 19 infection |
hydroxychloroquine alone, mefloquine (Farmzashita) alone, Variable regimens including azithromycin , hydroxychloroquine , mefloquine (Farmzashita) , tocilizumab |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) |
Burnasyan Federal Medical Biophysical Center |
|
Russian Federation |
2020-04-08 |
2020-08-01 |
FL-01/20, NCT04347031 |
Phase 2 Clinical |
Recruiting |
1 |
3 Months |
320 |
Tatiana Astrelina, MD PhD,DSc. |
2020-04-17 |
| A Clinical Trial of Mycobacterium w in Critically Ill COVID 19 Patients |
Coronavirus disease 19 infection |
Mycobacterium w alone, standard care therapy alone |
Interferon gamma receptor agonist, MAPK gene modulator, TLR-2 agonist, TLR-4 agonist, TLR-9 agonist |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Cadila Pharmaceuticals Ltd |
Council of Scientific and Industrial Research (India) |
India |
2020-04-20 |
2020-07-30 |
CRSC20004, NCT04347174 |
Phase 2 Clinical |
Not yet recruiting |
1 |
3 Months |
40 |
Anil Avhad, MBBS, Sanjay Patel, MBBS |
2020-04-20 |
| CONEC: Study to Determine the Immunization Status Among Nephrological Health Care Personnel Against SARS-CoV-2 in a Single-Center Over the Course of 12 Months During the Worldwide COVID-19 Pandemic |
Coronavirus disease 19 infection |
blood and urine analysis alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Medical University of Vienna |
|
Austria |
2020-04-11 |
2021-04-11 |
1357/2020, 1375/2020, CONEC, NCT04347694 |
Phase Not Applicable |
Recruiting |
1 |
12 Months |
400 |
Gere Sunder-Plassmann, MD, Thomas J Reiter, MD |
2020-04-23 |
| PHYSIO-COVID: Respiratory and Hemodynamic Changes Induced in Mechanically Ventilated Patients for COVID-19 |
Coronavirus disease 19 infection |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Centre Hospitalier Regional Universitaire de Lille |
|
France |
2020-04-30 |
2020-09-30 |
2020-A00957-32, 2020_32, NCT04347928, PHYSIO-COVID |
Phase Not Applicable |
Not yet recruiting |
1 |
5 Months |
15 |
Thibault Duburcq, MD |
2020-04-20 |
| A clinical study of COVID-19 vaccine against the SARS-Cov-2 virus, producing potent immunity and prophylaxis in non-infected patients in addition to a therapeutic treatment for patients with active COVID-19 disease |
Coronavirus disease 19 infection |
COVID-19 vaccine (coronavirus disease 19 infection), Epitopoietic Research Corp alone |
|
|
Epitopoietic Research Corp |
|
|
|
|
|
Phase Not Applicable |
Planned |
0 |
|
|
|
2020-04-20 |
| TEACHCOVID: Azithromycin-Hydroxychloroquine Combination in Sars-CoV-2 Pneumonia Study |
Coronavirus disease 19 infection, Viral pneumonia |
Hydroxychloroquine alone, standard of care alone, Variable regimens including Hydroxychloroquine , azithromycin , ceftriaxone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Hopitaux Universitaires de Strasbourg |
|
|
2020-05-01 |
2021-08-01 |
7783, NCT04347512, TEACHCOVID |
Phase 3 Clinical |
Not yet recruiting |
0 |
15 Months |
405 |
Loic Kassegne, MD |
2020-04-17 |
| The Phase II Study to Evaluate the Safety and Efficacy of Clevudine in Patients With Moderate COVID-19 |
Coronavirus disease 19 infection |
clevudine alone, hydroxychloroquine alone |
DNA polymerase inhibitor, Nucleoside reverse transcriptase inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Bukwang Pharmaceutical Co Ltd |
|
South Korea |
2020-04-24 |
2020-12-31 |
BK-CLV-201, NCT04347915 |
Phase 2 Clinical |
Not yet recruiting |
1 |
8 Months |
60 |
Bukwang Bukwang, Woo-Joo Kim, M.D.,Ph.D. |
2020-04-24 |
| A Prospective 'Universal' Observational Database for COVID-19 |
Coronavirus disease 19 infection |
|
|
|
Hackensack Meridian Health |
Cota Inc |
US |
2020-03-27 |
2021-04-30 |
NCT04347993, PRO2020-0342 |
Phase Not Applicable |
Recruiting |
0 |
13 Months |
5000 |
Andrew Ip, MD, Brittany Sinclaire, Urszula Bednarz |
2020-04-20 |
| RAPID-19: Rapid Diagnostics, Antibody Testing and Host Response in Children With COVID-19 |
Coronavirus disease 19 infection |
Covid-19 Antibody testing alone, Loop mediated isothermal amplification alone |
|
Healthy volunteers accepted, Newborn Infants (up to 5 months), Infants (6-23 months), Preschool Children (2-5 yrs), Children (6-12 yrs), Adolescents (13-17 yrs) |
Queens University of Belfast |
Belfast Health & Social Care Trust |
UK |
2020-04-13 |
2020-10-13 |
282617, NCT04347408, RAPID-19 |
Phase Not Applicable |
Not yet recruiting |
1 |
6 Months |
150 |
Sharon Christie, PhD, Thomas Waterfield, BMBCh |
2020-04-17 |
| Oral Favipiravir Compared to Standard Supportive Care in Subjects With Mild COVID-19 |
Coronavirus disease 19 infection |
favipiravir alone, standard of care treatment alone |
RNA polymerase inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Stanford University |
|
US |
2020-04-30 |
2021-04-30 |
56032, NCT04346628 |
Phase 2 Clinical |
Not yet recruiting |
0 |
12 Months |
120 |
Study Team, Yvonne (Bonnie) A Maldonado, MD |
2020-04-20 |
| COVIDHLH: Establishing a COVID-19 Prospective Cohort for Identification of Secondary HLH |
Coronavirus disease 19 infection, Hemophagocytic lymphohistiocytosis, Macrophage activation syndrome, Viral pneumonia |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Technical University of Munich |
|
Germany |
2020-03-27 |
2020-08-31 |
161/20 S, COVIDHLH, NCT04347460 |
Phase Not Applicable |
Recruiting |
1 |
5 Months |
20 |
Christoph Schmaderer, M.D., Georg Lorenz, M.D., Philipp Moog, M.D. |
2020-04-17 |
| Multicenter, observational study to examine the efficacy of protection during endoscopy examination for Covid-19 infection |
Coronavirus disease 19 infection |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University of Tokyo |
|
Japan |
2020-04-14 |
|
UMIN000040162 |
Phase Not Applicable |
Recruiting |
1 |
|
1000 |
Ryota Niikura |
2020-04-20 |
| IMPACT: Impact of Antimalarials on Covid-19 Infections in RAPPORT |
Coronavirus disease 19 infection, Rheumatoid arthritis |
B-cell depletor therapy alone, IL-17 blocker therapy alone, JAK kinase inhibitor therapy alone, T-cell c-stimulation inhibitor therapy alone, anti-IL-6 blocker therapy alone, anti-TNF inhibitor therapy alone, chloroquine alone, disease modifying anti-rheumatic drug therapy alone, hydroxychloroquine alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University of Alberta |
|
Canada |
2020-04-15 |
2021-04-30 |
IMPACT, NCT04347798, PRO00100000 |
Phase Not Applicable |
Recruiting |
1 |
12 Months |
500 |
Stephanie O Keeling, MD, Walter P Maksymowych, MD |
2020-04-21 |
| PRoVENT-COVID: Paactice of Ventilation in COVID-19 Patients |
Coronavirus disease 19 infection |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Academic Medical Center, University of Amsterdam |
|
Netherlands |
2020-03-06 |
2020-08-31 |
NCT04346342, PROVENT-COVID, PRoVENT-COVID |
Phase Not Applicable |
Recruiting |
19 |
5 Months |
1000 |
Anissa Tsonas, MD, Anna Geke Algera, MD, Ary Serpa Neto, MD, PhD, Frederique Paulus, PhD, Marcus Schultz, MD, PhD, Michela Botta, Michela Botta, MD |
2020-04-17 |
| A phase III study of Actemra for the treatment of hospitalized patients with severe COVID-19 pneumonia |
Coronavirus disease 19 infection, Viral pneumonia |
tocilizumab (intravenous), Roche/Chugai alone |
IL-6 receptor antagonist, IL-6 receptor modulator |
|
Chugai Pharmaceutical Co Ltd |
|
Japan |
|
|
|
Phase 3 Clinical |
Planned |
1 |
|
330 |
|
2020-04-21 |
| Bone Marrow-Derived Mesenchymal Stem Cell Treatment for Severe Patients With Coronavirus Disease 2019 (COVID-19) |
Coronavirus disease 19 infection |
bone marrow-derived mesenchymal stem cells alone, conventional treatment alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Guangzhou Institute Of Respiratory Disease |
Guangzhou 8th People's Hospital, Tongji Hospital, Huazhong University of Science and Technology |
China |
2020-04-30 |
2020-12-31 |
NCT04346368, SC-2020-01 |
Phase 1/Phase 2 Clinical |
Not yet recruiting |
1 |
8 Months |
20 |
Ming Liu, MD, ShiYue Li, Shiyue Li, MD |
2020-04-17 |
| Evaluation of Interleukine 6 (and Other Cytokines and Inflammatory Markers) in COVID-19 Patients With a Systemic Inflammatory Response Syndrome |
Coronavirus disease 19 infection, Systemic inflammatory response syndrome |
anti-IL-6-R antibody therapy alone, ventilation support alone |
|
|
Brugmann University Hospital |
|
Belgium |
2020-03-20 |
2020-12-31 |
CHUB-IL6-COVID-19, NCT04346017 |
Phase Not Applicable |
Recruiting |
1 |
9 Months |
200 |
Carole Nagant, MD, Carole Nagant, PhD, Francis Corazza, Francis Corazza, MD, Patrick Stordeur, PhD |
2020-04-20 |
| DHYSCO: Dexamethasone Treatment for Severe Acute Respiratory Distress Syndrome Induced by COVID-19 (DHYSCO) |
Coronavirus disease 19 infection, Respiratory distress syndrome |
standardized ventilatory management alone, dexamethasone plus hydroxychloroquine |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Association Marie Lannelongue |
|
France |
2020-04-30 |
2020-08-31 |
2037815010, DHYSCO, NCT04347980 |
Phase 3 Clinical |
Recruiting |
2 |
4 Months |
122 |
Francois STEPHAN, MD, PhD, Lilia Lamrani |
2020-04-20 |
| RegCOVID19: Observational Study of Follow-up of Hospitalized Patients Diagnosed With COVID-19 to Evaluate the Effectiveness of the Drug Treatment Used to Treat This Disease. COVID-19 Registry |
Coronavirus disease 19 infection |
|
|
Infants (6-23 months), Preschool Children (2-5 yrs), Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Fundacion Instituto de Investigacion Marques de Valdecilla, IDIVAL |
|
|
2020-04-15 |
2021-01-01 |
IDI-REM-2020-1, NCT04347278, RegCOVID19 |
Phase Not Applicable |
Not yet recruiting |
0 |
8 Months |
100 |
LUCIA LAVIN ALCONERO, Phd, MARIA DEL MAR GARCIA SAIZ, MDPhD |
2020-04-17 |
| Efficacy of Convalescent Plasma Therapy in Severely Sick COVID-19 Patients |
Coronavirus disease 19 infection |
convalescent plasma alone, supportive care alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Institute of Liver and Biliary Sciences, India |
|
India |
2020-04-14 |
2020-06-30 |
CTRI/2020/04/024706, F.No.X.11026/74/2020-BD, ILBS-COVID-02, NCT04346446 |
Phase 2 Clinical |
Recruiting |
2 |
2 Months |
20 |
Dr Meenu Bajpai, Dr Meenu Bajpai, MD, Dr Shiv Kumar Sarin, DM, Dr Suresh Kumar, Dr Suresh Kumar, MD |
2020-04-21 |
| COVID-HEP: Preventing COVID-19 Complications With Low and High-dose Anticoagulation |
Blood clotting disorder, Coronavirus disease 19 infection, Thrombosis |
enoxaparin sodium alone, unfractionated heparin alone |
Low molecular weight heparin |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Hopitaux Universitaires De Geneve |
|
Switzerland |
2020-04-14 |
2020-11-30 |
2020-00794, COVID-HEP, NCT04345848 |
Phase 3 Clinical |
Not yet recruiting |
1 |
7 Months |
200 |
Marc Blondon |
2020-04-22 |
| A phase I clinical study of 7HP-349 in healthy subjects for the potential treatment of COVID-19 infection |
Coronavirus disease 19 infection |
7HP-349 alone |
CD11a agonist, CD49d agonist, ICAM-1 stimulator, Integrin agonist, Vascular cell adhesion protein 1 agonist |
Healthy volunteers accepted |
7 Hills Pharma Llc |
|
US |
|
|
|
Phase 1 Clinical |
Not yet recruiting |
0 |
|
|
|
2020-04-17 |
| Effect of SARS-CoV-2 infection upon male reproductive system |
Coronavirus disease 19 infection |
|
|
Male, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Shandong Provincial Hospital |
|
China |
2020-04-09 |
2021-04-01 |
ChiCTR2000031779 |
Phase Not Applicable |
Not yet recruiting |
1 |
11 Months |
50 |
Liqiang Guo, Shengtian Zhao |
2020-04-20 |
| PEACE: Post-exposure Prophylaxis for Asymptomatic SARS-CoV-2 COVID-19 Patients With Choloroquine Compounds |
Coronavirus disease 19 infection |
hydroxychloroquine sulfate alone, standard of care alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) |
Specialized Healthcare and Medical Education Department |
Forman Christian College, Harvard TH Chan School of Public Health, Mayo Hospital, Pakistan Kidney and Liver Institute, SERVICES INSTITUTE OF MEDICAL SCIENCES |
US |
2020-04-14 |
2021-05-28 |
NBC-COVID19-02, NCT04346667, PEACE |
Phase 4 Clinical |
Not yet recruiting |
0 |
13 Months |
400 |
Ammar Sarwar, Ammar Sarwar, MD |
2020-04-17 |
| A Retrospective Study of Neural Network Model to Dynamically Quantificate the Severity in COVID-19 Disease |
Coronavirus disease 19 infection |
RT-PCR test alone, artificial intelligence technology deep learning method alone, computed tomography imaging alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Xinqiao Hospital of Chongqing |
|
China |
2020-01-17 |
2020-05-31 |
NCT04347369, XQONC-015 |
Phase Not Applicable |
Recruiting |
1 |
4 Months |
1000 |
Jianguo Sun, Sun JG |
2020-04-20 |
| Predict Adverse Events by Covid-19 Nephritis |
Coronavirus disease 19 infection, Nephritis |
urine analysis alone |
|
Healthy volunteers accepted |
University Hospital Goettingen |
Kliniken der Stadt Koeln gGmbH, University Hospital, Aachen, Universitätsklinikum Hamburg-Eppendorf |
Germany |
2020-04-13 |
2021-12-31 |
NCT04347824, UMG_CO19-NEPHRITIS |
Phase Not Applicable |
Not yet recruiting |
1 |
20 Months |
100 |
Oliver Gross, MD, Prof. Dr. O. Gross |
2020-04-22 |
| Chloroquine UN: Immune Monitoring of Prophylactic Effect of Hydroxychloroquine in Healthcare Providers Highly Exposed to COVID-19 |
Coronavirus disease 19 infection |
Hydroxychloroquine alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
National University of Colombia |
Fundacion Salud de los Andes |
Colombia |
2020-04-20 |
2020-10-01 |
Chloroquine UN, NCT04346329, UNAL-COVID-CP |
Phase 3 Clinical |
Not yet recruiting |
2 |
5 Months |
86 |
Calos A Parra-Lopez, MD PhD, Carlos A Parra-López, MD, PhD, Carlos A parra-Lopez, MD PhD, Carlos Alberto Parra Lopez, David A Bernal-Estevez, MD PhD, David A Bernal-Estévez, MD, PhDc |
2020-04-20 |
| Safety and Efficacy of Ruxolitinib for COVID-19 |
Coronavirus disease 19 infection, Viral pneumonia |
ruxolitinib (oral, myeloproliferative disorders), Incyte/Novartis alone |
Jak1 tyrosine kinase inhibitor, Jak2 tyrosine kinase inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University of Colorado, Denver, US |
|
US |
2020-04-30 |
2020-10-31 |
20-0869, NCT04348071 |
Phase 2/Phase 3 Clinical |
Not yet recruiting |
0 |
6 Months |
80 |
Angela Rachubinski, PhD, Joaquin Espinosa, PhD, Joaquin M Espinosa, PhD |
2020-04-18 |
| Preventing COVID-19 in Healthcare Workers With HCQ: A RCT |
Coronavirus disease 19 infection |
hydroxychloroquine alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Stony Brook University Hospital |
|
US |
2020-04-20 |
2020-12-30 |
IRB2020-00222, NCT04347889 |
Phase 2 Clinical |
Not yet recruiting |
0 |
8 Months |
1212 |
Adam Singer |
2020-04-21 |
| A clinical study of convalescent plasma therapy which involves a transfusion of blood from a patient who has recovered from COVID-19 into a critically ill patient |
Coronavirus disease 19 infection |
convalescent plasma therapy alone |
|
|
Houston Methodist |
|
US |
|
|
|
Phase Not Applicable |
Recruiting |
0 |
|
|
|
2020-04-20 |
| COVIDotheque: A Cohort of Patients With Possible or Confirmed SARS-CoV-2(COVID-19) |
Coronavirus disease 19 infection |
blood sampling alone |
|
Healthy volunteers accepted |
University Hospital, Montpellier |
|
France |
2020-02-01 |
2022-12-30 |
COVIDotheque, NCT04347850, RECHMPL20_0185 |
Phase Not Applicable |
Recruiting |
1 |
34 Months |
500 |
Edouard TUAILLON, MD, PhD |
2020-04-17 |
| A clinical trial of ADX-629 for the treatment of patients with COVID-19-associated respiratory disease |
Coronavirus disease 19 infection, Respiratory distress syndrome |
ADX-629 alone |
Acetaldehyde dehydrogenase inhibitor |
|
Aldeyra Therapeutics Inc |
|
|
|
|
|
Phase Not Applicable |
Planned |
0 |
|
|
|
2020-04-16 |
| Spironolactone in Covid-19 Induced ARDS |
Coronavirus disease 19 infection, Respiratory distress syndrome |
spironolactone alone |
Aldosterone antagonist |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Istanbul University-Cerrahpasa |
|
Turkey |
2020-04-21 |
2020-10-21 |
10042020, NCT04345887 |
Phase 4 Clinical |
Not yet recruiting |
1 |
6 Months |
60 |
Olcay Dilken, Yalim Dikmen |
2020-04-17 |
| CoVid-19 - Infection and Antibody Formation in the Viennese Population |
Coronavirus disease 19 infection |
serum blood and antibody measurement alone |
|
Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Ludwig Boltzmann Institute for Lung Vascular Research |
|
Austria |
2020-04-27 |
2020-09-30 |
LEAD COVID-19, NCT04346264 |
Phase Not Applicable |
Recruiting |
1 |
5 Months |
5500 |
Otto C Burghuber, Prof.MD |
2020-04-20 |
| Impact of the Double-Trunk Mask on Oxygenation Titration in COVID-19 |
Coronavirus disease 19 infection, Hypoxia |
double-trunk mask alone, standard nasal cannula alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Clinique Universitaires Saint-Luc, Universite Catholique de Louvain |
|
Belgium |
2020-04-09 |
2020-06-30 |
DTM-001, NCT04346420 |
Phase Not Applicable |
Recruiting |
1 |
2 Months |
15 |
Poncin, William Poncin, William Poncin, PT, PhD |
2020-04-17 |
| WUHAN: Efficacy of Nigella Sativa and Natural Honey Against COVID-19 |
Coronavirus disease 19 infection |
standard medical care alone, black cumin plus honey |
|
Preschool Children (2-5 yrs), Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Federal Postgraduate Medical Institute |
|
Pakistan |
2020-04-20 |
2020-05-30 |
1.6/M.EDU/141/2020, NCT04347382, WUHAN |
Phase 3 Clinical |
Recruiting |
1 |
1 Month |
30 |
Ahmad Imran, MBBS, Ayesha Hamayun, PhD, Muhammad Ahmad Imran, MBBS, Muhammad Ashraf, PhD, Shoaib Ashraf, PhD, Sohaib Ashraf, MBBS |
2020-04-22 |
| CALAVI: Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19. CALAVI (Calquence Against the Virus) |
Coronavirus disease 19 infection |
Best Supportive Care alone, acalabrutinib alone |
Btk tyrosine kinase inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
AstraZeneca plc |
Acerta Pharma BV |
Europe, US, Spain |
2020-04-24 |
2020-09-01 |
ACE-ID-201, CALAVI, D822FC00001, NCT04346199 |
Phase 2 Clinical |
Status not specified |
1 |
4 Months |
428 |
AstraZeneca Cancer Study Locator, AstraZeneca Clinical Study Information Center, Louis M. Staudt, Wyndham H. Wilson |
2020-04-22 |
| A Study to Assess the Virus RNA, and miRNA Levels Related to Viral Infection, and Inflammatory Response in Tears of Patients Affected by COVID-19 Disease |
Conjunctivitis, Coronavirus disease 19 infection, Inflammatory disease |
Schirmer Test I alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Universita Degli Studi G D`Annunzio Chieti |
|
Italy |
2020-04-14 |
2020-04-30 |
NCT04346160, UCHIETI03 |
Phase Not Applicable |
Not yet recruiting |
1 |
|
25 |
Leonardo Mastropasqua, Leonardo Mastropasqua, Professor, Manuela Lanzini, Doctor |
2020-04-21 |
| COVID-19: Investigation of Transmission and Immunisation Among Hospital Staff |
Coronavirus disease 19 infection |
Elisa-test for IgM and IgG alone, IgM and IgG diagnostic kits test alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Herlev Hospital Region Hovedstaden |
HS Hvidovre Hospital, Mental Health Services in the Capital Region of Denmark, Nordsjaellands Hospital, Rigshospitalet, Denmark, University Hospital Bispebjerg and Frederiksberg |
Denmark |
2020-04-15 |
2021-08-01 |
NCT04346186, REGHCOVIDSCREENING |
Phase 4 Clinical |
Not yet recruiting |
14 |
15 Months |
30000 |
Curt Sten, Fredrik Folke, Associate prof., Henning Bundgaard, Prof., Henrik Ullum, Prof., Ida Hageman, Jørgen Rungby, Jørgen Rungby, Prof., Kasper Iversen, Kasper Iversen, Prof., Ove Andersen, Prof., Rasmus Hasselbalch, Rasmus Hasselbalch, MD, Susanne Dam Poulsen, Prof., Thea Kølsen Fischer, Thomas Benfield, Prof. |
2020-04-20 |
| Oropharyngeal Dysphagia in Patients With COVID-19 |
Coronavirus disease 19 infection, Dysphagia |
EAT-10 and the volume-viscosity swallowing test (V-VST) alone, Swallowing evaluation alone |
|
|
Hospital de Mataro |
Centro De Investigación Biomédica En Red De Enfermedades Neurodegenerativas |
Spain |
2020-04-14 |
2020-08-31 |
COVID_OD, NCT04346212 |
Phase Not Applicable |
Recruiting |
1 |
4 Months |
100 |
Alberto Martín, Nurse, Alícia Costa, Nutritionist, Antonio Schindler, MD, PhD, Mireia Bolívar, Pharmacist, Omar Ortega, MSc, PhD, Pere Clavé, MD, PhD, Silvia Carrión, MD, PhD, Stephanie Riera, SLP, Viridiana Arreola, SLP, Weslania Nascimento, SLP, PhD |
2020-04-23 |
| SIMPLE: A global phase III trial to evaluate safety and efficacy of intravenous remdesivir in patients with moderate COVID-19 |
Coronavirus disease 19 infection |
remdesivir alone |
RNA polymerase modulator |
|
Gilead Sciences Inc |
|
|
2020-04-14 |
|
SIMPLE |
Phase 3 Clinical |
Recruiting |
0 |
|
|
|
2020-04-16 |
| SIMPLE: A global phase III trial to evaluate safety and efficacy of intravenous remdesivir in patients with severe COVID-19 |
Coronavirus disease 19 infection |
remdesivir alone |
RNA polymerase modulator |
|
Gilead Sciences Inc |
|
|
2020-04-14 |
|
SIMPLE |
Phase 3 Clinical |
Recruiting |
0 |
|
|
|
2020-04-16 |
| MACOVIA: A phase II/III, double-blinded, randomized, placebo-controlled, multicenter, pivotal study to assess the safety and efficacy of MultiStem therapy in subjects with moderate to severe acute respiratory distress syndrome (ARDS) induced by the novel coronavirus disease (COVID-19) |
Coronavirus disease 19 infection, Respiratory distress syndrome |
multipotent adult progenitor cell therapy (ischemia/ARDS/ocular diseases), Athersys/ Healios alone |
|
|
Athersys Inc |
|
US |
2020-06-30 |
|
MACOVIA |
Phase 2/Phase 3 Clinical |
Not yet recruiting |
0 |
|
400 |
|
2020-04-17 |
| A randomized-controlled, double-blind study to evaluate the effectiveness of the Kerecis Omega3 Viruxide system in COVID-19 patients |
Coronavirus disease 19 infection |
Kerecis Omega3 Viruxide system alone |
|
|
Kerecis Ehf |
|
|
|
|
|
Phase Not Applicable |
Status not specified |
0 |
|
|
|
2020-04-16 |
| Anti-Interleukin-8 (Anti-IL-8) for Cancer Patients With COVID-19 |
Advanced solid tumor, Coronavirus disease 19 infection, Respiratory disease, Viral pneumonia |
BMS-986253 alone |
IL-8 receptor antagonist |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Columbia University |
Bristol-Myers Squibb Co |
US |
2020-04-16 |
2022-09-30 |
AAAS9881, NCT04347226 |
Phase 2 Clinical |
Recruiting |
0 |
29 Months |
138 |
Lisa Olmos, RN, Matthew Dallos, MD |
2020-04-21 |
| ProCoV: Prospective molecular biological and serological examination for the detection of SARS-CoV-2 (COVID-19) in employees of a hospital of regular care in Germany |
Coronavirus disease 19 infection |
serological examination alone |
|
Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Krankenhaus Reinbek St. Adolf-Stift |
|
Germany |
2020-04-14 |
|
038/20 I, DRKS00021270, ProCoV |
Phase Not Applicable |
Not yet recruiting |
1 |
|
800 |
Jonas Herzberg, Tim Strate |
2020-04-17 |
| A randomized, placebo-controlled, phase II study to assess the effect of fenretinide in patients with Covid-19 |
Coronavirus disease 19 infection, Lung inflammation |
fenretinide (pulmonary Pseudomonas aeruginosa infections in cystic fibrosis), McGill University/Laurent Pharmaceuticals alone |
Nuclear factor kappa B gene modulator |
|
Laurent Pharmaceuticals |
|
Canada, US |
|
|
|
Phase 2 Clinical |
Planned |
1 |
|
200 |
|
2020-04-17 |
| A clinical trial of baricitinib for the potential treatment of hospitalized patients diagnosed with COVID-19 |
Coronavirus disease 19 infection |
baricitinib alone |
Jak1 tyrosine kinase inhibitor, Jak2 tyrosine kinase inhibitor |
|
Eli Lilly & Co |
National Institute of Allergy and Infectious Diseases |
|
|
|
|
Phase Not Applicable |
Planned |
0 |
|
|
|
2020-04-17 |
| A phase III trial of Ampligen prophylactic/early-onset therapeutic against COVID-19, the disease caused by SARS-CoV-2 |
Coronavirus disease 19 infection |
rintatolimod alone |
2,5-Oligoadenylate synthetase stimulator, Interferon type I receptor agonist, Ribonuclease stimulator, TLR-3 agonist |
|
AIM ImmunoTech Inc |
Shenzhen Smoore Technology Ltd |
US |
|
|
|
Phase 3 Clinical |
Status not specified |
0 |
|
|
|
2020-04-20 |
| A Study to Assess the Effect of SoftWaves in Patients with Covid-19 |
Coronavirus disease 19 infection |
SoftWaves alone |
|
|
Tissue Regeneration Technologies Llc |
|
|
|
|
|
Phase Not Applicable |
Recruiting |
0 |
|
|
|
2020-04-16 |
| A clinical trial to evaluate the effectiveness of different combinations of the anti-malarial drugs chloroquine and hydroxychloroquine and azithromycin in treating ill patients infected with the novel coronavirus |
Coronavirus disease 19 infection |
chloroquine alone, hydroxychloroquine alone, Variable regimens including azithromycin , chloroquine , hydroxychloroquine |
|
|
Washington University in St Louis |
Barnes-Jewish Hospital Foundation, National Center For Advancing Translational Sciences |
US |
|
|
|
Phase Not Applicable |
Status not specified |
0 |
|
500 |
Jane O’Halloran, Rachel M. Presti |
2020-04-16 |
| A phase I clinical trial of S-protein COVID antigen vaccine for the prevention of COVID-19 infection |
Coronavirus disease 19 infection |
protein subunit vaccine (COVID-19), Sanofi Pasteur alone |
|
|
GlaxoSmithKline plc, Sanofi Pasteur, Sanofi SA |
|
|
2020-12-31 |
|
|
Phase 1 Clinical |
Planned |
0 |
|
|
|
2020-04-16 |
| An questionnaire investigation of hydroxychloroquine for its potential protective effect against novel coronavirus infection (COVID-19) infection |
Coronavirus disease 19 infection, Respiratory distress syndrome, Viral pneumonia |
hydroxychloroquine alone |
|
|
The Second XiangYa Hospital of Central South University |
Hunan Provincial Department of Finance |
China |
2020-04-10 |
2020-06-30 |
ChiCTR2000031782 |
Phase Not Applicable |
Not yet recruiting |
1 |
2 Months |
1200 |
Hui Jin, Qianjin Lu |
2020-04-17 |
| Investigation for Prevention Awareness against COVID-19 |
Coronavirus disease 19 infection, Viral pneumonia |
|
|
Male, Adolescents (13-17 yrs), Young Adults (18-44 yrs) |
Universitad Major de S. Andres,, Wuhan University |
|
Bolivia |
2020-03-17 |
|
ChiCTR2000031783 |
Phase Not Applicable |
No longer recruiting |
1 |
|
883 |
DIANA MARIA CESPEDES ARCANI |
2020-04-20 |
| A medical records based retrospective study for analysis clinical characteristics and risk factors of death in patients with novel coronavirus pneumonia (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
The Central Hospital of Huanggang |
|
China |
2020-04-08 |
2020-05-08 |
ChiCTR2000031794 |
Phase Not Applicable |
Not yet recruiting |
1 |
1 Month |
130 |
Liping Jia, Quanshui Hao |
2020-04-17 |
| Evaluation of Hydroxychloroquine for prevention of hospitalization and respiratory complications in patients with confirmed diagnosis or suspected infection by (COVID-19) |
Coronavirus disease 19 infection, Respiratory disease |
hydroxychloroquine alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
EMS SA, Hospital Alemao Oswaldo Cruz |
|
Brazil |
2020-04-10 |
2020-07-10 |
A27736297878, RBR-3cbs3w |
Phase 3 Clinical |
Not yet recruiting |
1 |
3 Months |
1300 |
Dayane Correa Vila Nova, Priscila Kazue Kunitake, Álvaro Avezum |
2020-04-20 |
| Therapeutic Pulmonary Telerehabilitation Protocol in patients affected by COVID-19, confined in their homes |
Coronavirus disease 19 infection, Lung disease |
Non-specific Toning Exercise Program alone, Respiratory Exercise Program alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Universidad de Sevilla |
|
Spain |
2020-04-01 |
2020-04-15 |
ET-SEF-21/20, RBR-6m69fc |
Phase Not Applicable |
Recruiting |
1 |
|
99 |
Carlos Bernal Utrera |
2020-04-20 |
| A clinical study of GV-1001 to treat COVID-19 patients |
Coronavirus disease 19 infection |
tertomotide alone |
Telomerase modulator |
|
GemVax & Kael Co Ltd |
|
South Korea |
|
|
|
Phase Not Applicable |
Not yet recruiting |
1 |
|
2 |
|
2020-04-15 |
| A clinical study of Cellgram-AKI, a stem cell therapy, for the treatment of COVID-19 patients |
Coronavirus disease 19 infection |
Cellgram-AKI alone |
|
|
FCB-Pharmicell Co Ltd |
|
South Korea |
|
|
|
Phase Not Applicable |
Not yet recruiting |
1 |
|
24 |
|
2020-04-23 |
| CoVitTrial: Covid-19 and Vitamin D Supplementation: a Multicenter, Randomized, Controlled Trial of High-Dose Versus Standard Dose Vitamin D3 in High-risk COVID-19 Patients |
Coronavirus disease 19 infection, Viral pneumonia |
cholecalciferol (oral, COVID-19) University Hospital Angers/ Mylan Laboratories alone |
Vitamin D3 receptor agonist |
Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University Hospital, Angers |
Mylan Laboratories Ltd |
France |
2020-04-15 |
2020-07-31 |
2020-001602-34, CoVitTrial, NCT04344041 |
Phase 3 Clinical |
Recruiting |
10 |
3 Months |
260 |
Achille TCHALLA, Bertrand FOUGERE, Cedric ANNWEILER, Claire ROUBAUD BAUDRON, Cédric ANNWEILER, DCRI Angers, Frédéric SHOLASTIQUE, Guillaume CHAPELET, Jean Baptiste BEUSCART, Marjorie HOUVET, Olivier GUERIN, Thomas CELARIER |
2020-04-22 |
| Angiotensin Converting Enzyme Inhibitors in Treatment of COVID-19 |
Coronavirus disease 19 infection |
Variable regimens including captopril , chloroquine , enalapril |
ACE inhibitor |
|
Tanta University |
|
Egypt |
2020-04-15 |
2029-12-01 |
ACEIS COVID 19, NCT04345406 |
Phase 3 Clinical |
Not yet recruiting |
1 |
115 Months |
60 |
Sherief Abd-Elsalam, Sherief Abd-Elsalam, ass. prof. |
2020-04-16 |
| Impact of Covid-19 on Egyptian Health Care Workers and General Population Mental Health |
Coronavirus disease 19 infection |
|
|
Healthy volunteers accepted |
Assiut University |
|
Egypt |
2020-05-31 |
2020-10-31 |
COVID-19 MENTAL HEALTH, NCT04344834 |
Phase Not Applicable |
Not yet recruiting |
1 |
5 Months |
300 |
Haidi Karam |
2020-04-16 |
| CovidRegOUH: Prospective Quality Register of Patients With Confirmed COVID-19 at Oslo University Hospital |
Coronavirus disease 19 infection |
|
|
|
Oslo University Hospital |
|
Norway |
2020-03-15 |
2021-05-01 |
COVIDREGOUH, CovidRegOUH, NCT04345536 |
Phase Not Applicable |
Recruiting |
1 |
13 Months |
400 |
Aleksander Holten, MD, Aleksander Holten, PhD, Aleksander Rygh Holten, Kristian Tonby, MD |
2020-04-16 |
| CYTOCOV-19: Effect of CytoSorb Adsorber on Hemodynamical and Immunological Parameters in Critical Ill Patients With COVID-19 |
Coronavirus disease 19 infection |
CytoSorb adsorber alone, hemoadsorption alone, standard of care alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Universitätsklinikum Hamburg-Eppendorf |
|
Germany |
2020-04-01 |
2021-02-28 |
CYTOCOV-19, CYTOCOV-19, DRKS00021199, NCT04344080, U1111-1250-2078 |
Phase Not Applicable |
Recruiting |
1 |
11 Months |
24 |
Axel Nierhaus, MD, Dominik Jarczak, MD, Kevin Roedl, MD, Stefan Kluge, MD |
2020-04-17 |
| ChilblainCOVID: Assessment of Chilbains Occuring During Covid-19 Infection |
Coronavirus disease 19 infection, Dermatological disease |
|
|
Newborn Infants (up to 5 months), Infants (6-23 months), Preschool Children (2-5 yrs), Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Centre Hospitalier Universitaire De Nice |
|
France |
2020-04-09 |
2020-06-30 |
20DERMATOCOVID.02, ChilblainCOVID, NCT04344119 |
Phase Not Applicable |
Recruiting |
1 |
2 Months |
30 |
Cynthia CAILLON, Sylvie MALERBA, Thierry PASSERON |
2020-04-17 |
| PISCO: Pyridostigmine in Severe SARS-CoV-2 Infection |
Coronavirus disease 19 infection, Viral pneumonia |
Mestinon alone, medical care alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Instituto Nacional de Ciencias Medicas y Nutricion |
|
Mexico |
2020-04-04 |
2021-04-30 |
INF-3323, NCT04343963, PISCO |
Phase 2/Phase 3 Clinical |
Recruiting |
1 |
12 Months |
436 |
José C Crispín, MD, PhD, Juan Sierra-Madero, MD, Sergio I Valdés-Ferrer, MD, PhD |
2020-04-16 |
| Covid-19, Case-Cluster Study |
Coronavirus disease 19 infection |
|
|
Healthy volunteers accepted |
University of Bonn |
Ministerium für Arbeit, Gesundheit und Soziales NRW |
Germany |
2020-03-31 |
|
DRKS00021306, Lfd. Nr. 085/20 |
Phase Not Applicable |
Recruiting |
1 |
|
1400 |
Hendrik Streeck |
2020-04-20 |
| EVICT-CORONA-ALI: Early Infusion of Vitamin C for Treatment of Novel COVID-19 Acute Lung Injury |
Acute lung injury, Coronavirus disease 19 infection, Hypoxia |
vitamin C alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Virginia Commonwealth University |
|
US |
2020-04-22 |
2021-05-31 |
EVICT-CORONA-ALI, HM20018977, NCT04344184 |
Phase 2 Clinical |
Not yet recruiting |
0 |
13 Months |
200 |
Alpha (Berry) A Fowler, III, MD, Brian Davis, MD, Markos G Kashiouris, MD MPH |
2020-04-15 |
| Gargling and Nasal Rinses to Reduce Oro and Nasopharyngeal Viral Load in Patients With COVID-19 |
Coronavirus disease 19 infection |
chlorhexidine gluconate alone, povidone-iodine alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
NYU Langone Health |
|
US |
2020-04-09 |
2020-05-09 |
NCT04344236, S20-00444 |
Phase 2 Clinical |
Recruiting |
0 |
1 Month |
48 |
Lindsey Moses, MD, Scott Rickert, Scott Rickert, MD |
2020-04-15 |
| OHB10cov: Management by Hyperbaric Oxygen Therapy of Patients With Hypoxemic Pneumonia With SARS-CoV-2 (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
hyperbaric chamber alone, hyperbaric oxygen plus normobaric oxygen |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Direction Centrale du Service de Sante des Armees |
|
France |
2020-04-14 |
2021-05-31 |
2020PPRC03, NCT04344431, OHB10cov |
Phase 2/Phase 3 Clinical |
Recruiting |
1 |
13 Months |
100 |
Jean-Eric BLATTEAU, MD, PhD, Nicolas PALEIRON, MD |
2020-04-22 |
| APCOLIS STUDY: The Spectrum and Profile of COVID-19 Infection and Its Impact on Liver |
Coronavirus disease 19 infection, Hepatitis, Liver cirrhosis, Liver disease |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Institute of Liver and Biliary Sciences, India |
|
India |
2020-04-14 |
2020-06-30 |
APCOLIS STUDY, ILBS-COVID-01, NCT04345640 |
Phase Not Applicable |
Recruiting |
1 |
2 Months |
100 |
Dr Ashok Choudhary, DM, Dr Shiv Kumar Sarin, DM |
2020-04-16 |
| CORIMMUNO-COAG: Trial Evaluating Efficacy and Safety of Anticoagulation in Patients With COVID-19 Infection, Nested in the Corimmuno-19 Cohort |
Coronavirus disease 19 infection, Lung disease |
heparin sodium Choay alone, nadroparin calcium alone, tinzaparin sodium alone |
Antithrombin III, Factor Xa antagonist, Low molecular weight heparin |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Assistance Publique Hopitaux de Paris |
|
France |
2020-04-20 |
2020-09-30 |
APHP200389-6, CORIMMUNO-COAG, NCT04344756 |
Phase 2 Clinical |
Not yet recruiting |
3 |
5 Months |
808 |
Damien Roux, MD PhD, Frédéric Penne, MD PhD, Jean-Luc Diehl, Tristan Mirault |
2020-04-16 |
| Effect of Trifluoperazine in treatment of COVID-19 |
Coronavirus disease 19 infection |
Variable regimens including hydroxychloroquine , lopinavir + ritonavir , ribavirin , trifluoperazine |
HIV protease inhibitor |
Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Birjand University |
|
Iran |
2020-04-16 |
|
IR.BUMS.REC.1399.004, IRCT20200408046992N1 |
Phase 3 Clinical |
Recruiting |
1 |
|
70 |
Dr Masood Ziaee, Kazem Dastjerdi, Masood Ziaee, Motahareh Mahi-Birjand |
2020-04-20 |
| Prevention of Novel Coronavirus Disease by Hydroxychloroquine in cancer patients |
Coronavirus disease 19 infection |
hydroxychloroquine, Amin Pharmaceutical Company alone |
|
Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Mashhad University of Medical Sciences |
|
Iran |
2020-04-13 |
|
IR.MUMS.REC.1399.078, IRCT20200405046958N1 |
Phase 2/Phase 3 Clinical |
Recruiting |
1 |
|
60 |
Mohammad Moeini Nodeh |
2020-04-21 |
| RCT: Treatment in Patients With Suspected or Confirmed COVID-19 With Early Moderate or Severe Disease |
Coronavirus disease 19 infection |
hydroxychloroquine alone, azithromycin plus hydroxychloroquine |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
LCMC Health |
|
US |
2020-04-10 |
2021-12-10 |
COVID 2020-001, NCT04344444, RCT |
Phase 3 Clinical |
Recruiting |
0 |
20 Months |
600 |
Jeannine Ascani, Jeannine Ascani, MS, Meredith Clement, MD |
2020-04-16 |
| CovidDB: The Covid-19 Inpatient Database |
Coronavirus disease 19 infection |
|
|
|
ClarData |
|
Romania, Germany |
2020-03-30 |
2023-06-30 |
COVIDDB, CovidDB, NCT04344171 |
Phase Not Applicable |
Recruiting |
10 |
39 Months |
5000 |
Adi Kovacevic, Dr., Hans-Rudolf Tinneberg, Prof., Heribert Fröschl, Dr., Julia Ferencz, MD, Marius Ghidau, Dr., Ovidiu Bedreag, Prof., Sebastian Dieng, Stefan Budweiser, Prof., Thomas Seufferlein, Prof |
2020-04-22 |
| Efficacy and Safety of Ganovo (Danoprevir) Combined With Ritonavir in the Treatment of SARS-CoV-2 Infection |
Coronavirus disease 19 infection, Viral pneumonia |
danoprevir plus ritonavir |
Cytochrome P450 3A4 inhibitor, HIV protease inhibitor, HIV-1 protease inhibitor, Hepatitis C virus NS3 protease inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Wuhan Huoshenshan Hospital |
Ascletis Pharmaceutical Co Ltd |
China |
2020-03-18 |
2020-05-31 |
ASC-CTP-HS-01, ChiCTR2000031734, NCT04345276 |
Phase 4 Clinical |
Recruiting |
1 |
2 Months |
40 |
Bo Wei, MD, Junxue Wang, MD, Yahong Chen, MD |
2020-04-17 |
| Phase I/II Clinical Study of Immunotherapy Based on Adoptive Cell Transfer as a Therapeutic Alternative for Patients With COVID-19 in Colombia |
Coronavirus disease 19 infection |
natural killer cell alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
National University of Colombia |
Fundacion Salud de los Andes |
Colombia |
2020-04-13 |
2020-11-10 |
NCT04344548, UNAL FSA COVID |
Phase 1/Phase 2 Clinical |
Not yet recruiting |
2 |
6 Months |
10 |
Carlos A Parra-Lopez, MD PhS, Carlos Alberto Parra Lopez, David A Bernal E., MD PhD, David A Bernal-Estévez, MD PhD, Doris Mejía |
2020-04-17 |
| NIAID: COVID-19 Plasma Collection |
Coronavirus disease 19 infection |
plasma collection alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
National Institute of Allergy and Infectious Diseases |
National Institutes of Health Clinical Center |
US |
2020-04-15 |
2025-04-01 |
200081, NCT04344977, NIAID |
Phase Not Applicable |
Not yet recruiting |
0 |
59 Months |
1500 |
|
2020-04-22 |
| CORIMUNO-19-BEVA: Trial Evaluating Efficacy and Safety of Bevacizumab (Avastin/Zirabev) in Patients With COVID-19 Infection, Nested in the Corimmuno-19 Cohort |
Coronavirus disease 19 infection |
bevacizumab alone, bevacizumab biosimilar, Pfizer alone |
VEGF ligand inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Assistance Publique Hopitaux de Paris |
|
|
2020-04-15 |
2020-11-30 |
APHP200389-7, CORIMUNO-19-BEVA, NCT04344782 |
Phase 2 Clinical |
Not yet recruiting |
0 |
7 Months |
130 |
Jacques Cadranel, MD PhD |
2020-04-18 |
| A Study to Assess the Effect of Allocetra in Patients with COVID-19 |
Coronavirus disease 19 infection |
Allocetra alone |
|
|
Enlivex Therapeutics Ltd |
Israeli Government |
Israel |
|
|
|
Phase Not Applicable |
Not yet recruiting |
1 |
|
|
|
2020-04-15 |
| COVIDICUS: Dexamethasone and Oxygen Support Strategies in ICU Patients With Covid-19 Pneumonia |
Coronavirus disease 19 infection, Viral pneumonia |
Airvo-2, Fisher and Paykel Healthcare alone, continuous positive airway pressure (CPAP) alone, conventional oxygen therapy alone, dexamethasone alone, high-flow-nasal cannula alone, mechanical ventilation alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Assistance Publique Hopitaux de Paris |
|
France |
2020-04-10 |
2020-12-31 |
2020-001457-43, APHP200388, COVIDICUS, NCT04344730 |
Phase 2 Clinical |
Recruiting |
1 |
8 Months |
550 |
Jean François TIMSIT, Pr, Jean-François TIMSIT, Pr, LILA BOUADMA, Pr, Lila Bouadma, Pr |
2020-04-16 |
| A Study of CM-4620 Injectable Emulsion (IE) in Patients With Severe COVID-19 Pneumonia |
Coronavirus disease 19 infection, Viral pneumonia |
CM-4620 alone |
Ca2+ release activated Ca2+ channel 1 inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
CalciMedica Inc |
|
US |
2020-04-08 |
2020-09-30 |
CM4620-204, NCT04345614 |
Phase 2 Clinical |
Recruiting |
0 |
5 Months |
120 |
Charles Bruen, MD, Joseph Miller, MD, Kathleen Wilson, RN, Ken Stauderman, PhD, Marissa K. Peterson, Marissa Peterson, Michael Schnaus, MD, Sudarshan Hebbar, MD |
2020-04-25 |
| Hydroxychloroquine as Chemoprevention for COVID-19 for High Risk Healthcare Workers |
Coronavirus disease 19 infection |
hydroxychloroquine sulfate alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Hackensack Meridian Health |
|
US |
2020-04-14 |
2022-04-08 |
NCT04345653, PRO2020-0356 |
Phase 2 Clinical |
Recruiting |
0 |
23 Months |
45 |
Jawad Kirmani, MD |
2020-04-17 |
| Microbial Etiology of Ventilator-associated Pneumonia in SARS-CoV-2 Infected Patients |
Coronavirus disease 19 infection, Viral pneumonia |
bacterial species isolation alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Centre Hospitalier Universitaire De Poitiers Etablissement D’Hospitalisation |
|
France |
2020-04-30 |
2020-12-31 |
NCT04344509, PAVM COVID |
Phase Not Applicable |
Not yet recruiting |
1 |
8 Months |
10000 |
Christophe BURUCOA |
2020-04-16 |
| A clinical study for the effect of remote monitoring exercise rehabilitation on the discharged patients with novel coronavirus pneumonia (COVID-19) |
Coronavirus disease 19 infection, Dyspnea, Viral pneumonia |
exercise rehabilitation under remote monitoring alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Jiangsu Provincial People’s Hospital |
CF PharmTech Inc |
China |
2020-04-20 |
2020-10-20 |
ChiCTR2000031834 |
Phase Not Applicable |
Not yet recruiting |
2 |
6 Months |
120 |
Li Jianan, Wang Wenxia |
2020-04-16 |
| Exhaustion and Needs in Frontline COVID-19 Healthcare Workers: Cross-sectional Study in a Belgian Population |
Acute stress disorder, Anxiety disorder, Coronavirus disease 19 infection, Depression |
|
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Universite Libre de Bruxelles |
|
Belgium |
2020-04-16 |
2020-07-15 |
NCT04344145, PSY-ENCOVID19 |
Phase Not Applicable |
Recruiting |
2 |
3 Months |
200 |
Andrée Marcoen, Julien Tiete, PhD |
2020-04-21 |
| A Medical Records Based study for the Clinical Characteristics Of Hospitalized Novel Coronavirus Pneumonia (COVID-19) Patients With Acute Respiratory Distress Syndrome |
Coronavirus disease 19 infection, Respiratory distress syndrome, Viral pneumonia |
|
|
|
The First People's Hospital of Jingzhou |
National Natural Science Foundation of China |
China |
2020-02-01 |
2020-12-31 |
ChiCTR2000031836 |
Phase Not Applicable |
No longer recruiting |
1 |
11 Months |
45 |
Jinzhi Lu |
2020-04-16 |
| A Real-life Experience on Treatment of Patients With COVID 19 |
Coronavirus disease 19 infection |
Alexoquine alone, Yomesan alone, favipiravir alone, ivermectin alone, nitazoxanide alone, Alexoquine plus azithromycin |
Chloride channel modulator, RNA polymerase inhibitor |
|
Tanta University |
|
Egypt |
2020-04-15 |
2029-12-31 |
COVID 19 TREATMENT, NCT04345419 |
Phase 2/Phase 3 Clinical |
Not yet recruiting |
1 |
116 Months |
100 |
Eslam Saber, ass. lect, Mai Khalaf, ass. lect., Sherief Abd-Elsalam, Sherief Abd-Elsalam, ass. prof. |
2020-04-16 |
| Covid-19 Pandemic. Emerging Legal and Ethical Disputes Over Patient Confidentiality |
Coronavirus disease 19 infection |
questionnaire alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) |
Assiut University |
|
Egypt |
2020-04-30 |
2020-07-31 |
2020A10, NCT04344938 |
Phase Not Applicable |
Not yet recruiting |
1 |
3 Months |
874 |
Noha Esmael Ebrahem, |
2020-04-18 |
| Study for the exercise rehabilitation therapy for the dysfunction of cured discharged novel coronavirus pneumonia (COVID-19) patients |
Coronavirus disease 19 infection, Viral pneumonia |
rehabilitation exercise alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Beijing Sport Uninversity |
|
China |
2020-04-27 |
2020-09-16 |
ChiCTR2000031860 |
Phase 0 Clinical |
Not yet recruiting |
1 |
4 Months |
150 |
Jinghua Qian, Zicheng Gao |
2020-04-16 |
| COVI-GAPP: Can the Ava fertility tracker device detect early signs of COVID-19? |
Coronavirus disease 19 infection |
AVA bracelet alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) |
Lab Medical Center Dr. Risch AG |
Government of the Principality of Liechtenstein, HANELA-Stiftung, House of Liechtenstein |
Liechtenstein |
2020-03-20 |
2021-12-31 |
1.2, COVI-GAPP, ISRCTN51255782 |
Phase Not Applicable |
Recruiting |
1 |
21 Months |
7170 |
Dr Martin Risch, Dr Stefanie Aeschbacher, Mrs Kirsten Grossmann, Prof David Conen, Prof Risch |
2020-04-17 |
| Clinical study for natural killer (NK) cells from umbilical cord blood in the treatment of novel coronavirus pneumonia (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
natural killer (NK) cells from umbilical cord blood alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Huzhou Central Hospital |
Huzhou Science and Technology Bureau |
China |
2020-03-01 |
2021-02-28 |
ChiCTR2000031735 |
Phase 0 Clinical |
Not yet recruiting |
1 |
12 Months |
20 |
Enhai Cui, Feng Hua |
2020-04-16 |
| Anti COVID-19 Convalescent Plasma Therapy |
Coronavirus disease 19 infection |
anti-SARS-CoV-2 convalescent plasma alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
OrthoSera Korlátolt Felelősségű Társaság |
Humán Bioplazma Kft - Kedrion, Hungarian National Blood Service, Semmelweis University, University Of Pécs |
Hungary |
2020-04-14 |
2021-04-01 |
ANTICOVID19ORT, NCT04345679 |
Phase 0 Clinical |
Not yet recruiting |
1 |
11 Months |
20 |
Eszter Fodor, medical doctor, Veronika Müller, MD, PhD, Zsombor Lacza, MD, PhD |
2020-04-25 |
| Novel coronavirus pneumonia (COVID-2019) patients' prognosis and their influence on heart and lung function |
Coronavirus disease 19 infection, Viral pneumonia |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) |
Puai Hospital |
|
China |
2020-04-01 |
2022-04-01 |
ChiCTR2000031751 |
Phase Not Applicable |
Recruiting |
1 |
24 Months |
90 |
zhu pengfei |
2020-04-16 |